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Abstract
When a cell gets infected with a virus, the innate immune system swings into action 
within minutes. The rapid production of pro-inflammatory cytokines and antivirally 
active type-I Interferons (IFN-a/p) is the most significant mechanism to limit virus 
spread.
Two conceptually different pathogen recognition mechanisms are known that lead to 
antiviral responses through production of IFN-a/p: Specialised immune cells possess 
Toll-like receptors (TLRs), which sense incoming viruses in endosomes. Most other 
cells  rely  on  the  cytoplasmic  RNA-helicases  RIG-I  and  MDA5  that  sense  the 
presence  of  viruses  within  the  cell.  However,  although  proteins  and  signalling 
networks  involved  in  innate  recognition  of  viruses  are  well  known,  the  exact 
molecular details of their interactions with the virus are only marginally understood. 
During  my  PHD  thesis  I  dedicated  myself  to  aid  our  understanding  of  virus 
recognition.  I could show that recombinant lentiviruses are weak inducers of IFN- 
a/p  in murine immune  cells.  Standard preparations  of lentiviral  vectors,  however, 
are  strong  activators  of the  innate  immune  system.  This  activity  is  contained  in 
tubulo-vesicular  structures  that  are  present  within  standard  lentiviral  preparations 
and  have  the  ability  to  activate  TLR9.  Tubulo-vesicular  structures  can  serve  as 
adjuvant  to  facilitate  adaptive  immune  responses  and  may  therefore  be  important 
when considering lentiviral vectors for clinical applications.
In my second project I focused on cytoplasmic virus recognition.  Surprisingly, viral 
genomic  single-stranded  RNA  from  influenza  virus  can  activate  the  cytoplasmic 
virus recognition receptor RIG-I. Unlike most cellular RNA species, single-stranded 
RNA  from  influenza and other viruses bear a 5’  triphosphate  group,  which marks 
this  RNA  as  ‘foreign’  and  thereby  induces  interferon  responses.  Importantly, 
influenza virus codes for an interferon antagonist, the non-structural protein 1  (NS1), 
which  forms  a  complex  with  RIG-I,  suggesting  that  influenza  virus  specifically 
interferes with this pathway.
In conclusion, the innate immune system employs diverse mechanisms to sense the 
presence of a virus through recognising diverse forms of viral nucleic acid.
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CHAPTER 1:  Introduction  -  mechanisms  of virus
recognition
1.1.  The concept of viral defence
Viruses are obligate intracellular parasites that enjoy the supportive environment of 
the cell in order to proliferate and spread.  This process goes  at the expense of the 
host cell that very often dies as a result of virus infection (Benedict et al., 2002). For 
this  reason  it  is  essential  for  the  host  to  recognise  viruses  in  order  to  mount  an 
innate- and adaptive immune response (Haller et al., 2007; Hedrick, 2004; Pichlmair 
et al., 2004b).
Evolution  shaped  several  lines  of defence.  Unspecific  physical  barriers,  like  the 
stratum comeum of the skin and secretions containing antimicrobial elements are the 
first shields used to fend off pathogens. The interferon system constitutes one of the 
body’s main  initial  modulated responses to  viral  infections  (Samuel,  2001).  Alick 
Isaacs and Jean Lindenmann first described interferon (IFN) 50 years ago as a factor 
that is generated after virus infection and can confer resistance (‘virus interference’) 
to  infection  with  a  homologous  or  heterologous  virus  (Fig  1.1.1)  (Isaacs  and 
Lindenmann,  1957). Although the significance of this discovery was not appreciated 
initially (Vilcek, 2006), it is now clear that the early immune response to most viral 
infections  relies  on  a  functional  interferon  system  and  that  mutations  in  the 
interferon system in mice or men render individuals highly susceptible to a variety of 
microbial and viral pathogens (Casrouge  et al.,  2006;  Dupuis  et al.,  2003;  Stetson 
and  Medzhitov,  2006b).  To  date,  we  still  do  not  understand  all  of  the  diverse 
functions of IFN, which play important roles in innate- and adaptive immunity, cell 
differentiation, development, angiogenesis and apoptosis (Samuel, 2001; Stetson and 
Medzhitov, 2006b; Vilcek, 2006).
Patients receiving IFN as antiviral therapy very often suffer from flu-like symptoms, 
gastro-intestinal  side  effects,  and  neuropsychological-,  renal-,  dermatological-  and
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haematological disorders (Dusheiko,  1996; Theofilopoulos et al., 2005; Trask et al.,
2000).  Clearly,  IFN  has  wide-ranging  beneficial  and  detrimental  effects  and 
therefore its induction has to be controlled very tightly, i.e. cells produce no or very 
little IFN in a quiescent state but have to secrete vast amounts of this cytokine upon 
encountering a virus. Hence, it is of fundamental importance for the organism to be 
able  to  discriminate  an  invading  pathogen  from  cellular  components  and 
subsequently  trigger  the  IFN  system.  To  ensure  efficient  recognition  of pathogen 
infection,  the  organism  has  evolved  pathogen  recognition  receptors  that  can 
recognise  conserved  molecules  specific  to  a  given  pathogen  (Akira  et  al.,  2006; 
Creagh and O'Neill, 2006; Meylan et al., 2006).
This  ‘Innate recognition’  is not only important for innate resistance to viruses and 
other  pathogens,  but  also  the  basis  for  mounting  an  adaptive  immune  response. 
Charles  Janeway  originally  proposed  the  existence  of  ‘pathogen  associated 
molecular patterns’ (PAMPs) that are associated with, and are particular to any given 
immunity-inducing microorganism (Janeway,  1989).  To  induce  immunity,  PAMPs 
must be  recognised by  receptors  of the  innate  immune  system,  so-called  ‘pattern 
recognition receptors’ (PRRs), that have the ability to regulate the transcriptome and 
thereby activate innate- and adaptive immune responses, resulting in enhanced innate 
resistance  and  T-cell  priming  and  B-cell  activation  (Fig  1.1.2)  (Janeway,  1989). 
Meanwhile, the concept of innate recognition shaping adapive immune responses has 
been  proven  to  be  correct  (Iwasaki  and  Medzhitov,  2004;  Steinman  and  Hemmi, 
2006). Both, mice and men with genetic mutations in specific PRRs or in the PRR 
signalling  cascade  fail  to  mount  efficient  innate-  and  adaptive  immune  responses 
when encountering the corresponding pathogen (Lee and Iwasaki, 2007; Oganesyan 
et  al.,  2006;  Yang  et  al.,  2005;  Zhou  et  al.,  2007a).  Similarly,  viruses  that  have 
evolved  mechanisms  to  evade  the  innate  immune  recognition  system  are  poor 
inducers  of  innate-  and  adaptive  immunity  (Femandez-Sesma  et  al.,  2006). 
Consequently,  to  ensure  efficient  pathogen recognition,  our  organism  is  equipped 
with a vast array of diverse receptors that sense  a variety of different PAMPs and 
have  an  instructive  role  in  adaptive  immunity  (Akira  et  al.,  2006;  Creagh  and 
O'Neill, 2006; Meylan et al., 2006).
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Innate recognition of pathogens is evolutionary ancient and large parts of the innate 
sensing mechanisms are conserved in various species.  One of the best examples of 
this is the Toll-like receptor (TLR) system. Toll was initially discovered in the fruit 
fly {Drosophila melanogaster) where it serves as a signalling molecule during anti- 
fungal  responses.  Later,  close  homologues  of  Toll  were  found  in  many  other 
metazoan species, including vertebrates, in which a panel of Toll-like receptors serve 
as innate immune sensors for a variety of pathogens, including viruses (Takeda et al., 
2003).  More  recently  another  group  of  PRRs  that  belong  to  a  family  of  RNA- 
helicases was discovered and identified a major player in intracellular recognition of 
viral pathogens (Meylan et al., 2006; Yoneyama and Fujita, 2007).
The contribution of single pathways adding up to a complete picture of an immune 
response  is  complicated  as  pathogens  are  sometimes  very  complex  and  carry  a 
variety  of  PAMPs  which  may  stimulate  parallel  pathways.  Virus  particles,  for 
instance,  differ  greatly  in  their  structure:  some  but  not  all  viruses  contain  a 
membranous  envelope;  others  have  dense  core  proteins,  although  the  existence  of 
virus-like  particles  without  core-proteins  has  also  been  reported  (Harrison,  2001; 
Rolls  et  al.,  1994).  Interestingly,  the  innate  immune  system  appears  to be  able  to 
sense all of these distinct particles (Akira et al., 2006; Lechner et al., 2002). Specific 
interactions  between  receptors  of the  immune  system  and  viral  proteins  do  occur 
(Finberg et al., 2007); however, these might be exceptions and cannot be generalised 
for a diverse class of pathogens (see later). One common structural feature present in 
all virus particles is the virus genome consisting of nucleic acid. Virus particles can 
contain  DNA,  single  stranded  RNA  or  double  stranded  RNA  and,  indeed,  recent 
discoveries  suggest  that  antiviral  responses  are  mainly  orchestrated  through 
recognition  of virus  genomes  (Bowie  and  Haga,  2005)  or  via  recognition  of by­
products of virus replication (Kawai and Akira, 2006; Yoneyama and Fujita, 2007). 
My  interest lies  in  the  innate  recognition  of virus  infections.  I  will  introduce  and 
discuss  the  current  knowledge  on  virus  recognition,  the  interferon  system  and 
present  results  I  obtained  in  two  projects.  The  first  project  deals  with  Toll-like 
receptor-mediated  recognition  of  recombinant  lentiviruses  and  revealed  an 
unforeseen mechanism of cytokine  induction by gene therapy vectors.  The  second 
project  focuses  on  cytoplasmic  virus  recognition  and  describes  single-stranded
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(ss)RNA  as  an  activator  of  RIG-I,  which  is  a  cytoplasmic  PRR.  A  specific 
modification  present  on  genomic  RNA  of some  viruses  renders  ssRNA  a  potent 
interferon inducer and may constitute the mechanistic basis of the initial discovery of 
IFN 50 years ago.
1.2.  Interferon signalling and function
Since the original description of IFN as antiviral substance, it has become clear that 
the observed antiviral effect is orchestrated by a family of proteins that share high 
sequence homology and require similar proteins for downstream signalling. IFNs can 
be subdivided into three classes, type-I, -II and -III IFN (Pestka et al., 2004; Roberts 
et al.,  1998). Type-I IFNs (IFN-a/p) are encoded from intron-less genes and consist 
of one  IFN-P  protein  and  13-14  IFN-a  subtypes,  as  well  as  lesser  known  IFN-e, 
IFN-k, IFN-oo, IFN-6, IFN-t and IFN-£ (Pestka et al., 2004; van Pesch et al., 2004). 
IFN-y is the only known type-II IFN and is produced by NK cells and activated T- 
lymphocytes and acts on cells of the immune system. The recently discovered type- 
III IFN  consists  of IFN-X1,  -XI  and -X3  (also  termed  IL-28A,  IL-28B  and IL-29) 
(Kotenko  et al.,  2003).  Although binding  to  distinct receptors,  type-I  and type-III 
IFNs activate a similar downstream signalling cascade that results in a similar gene 
expression pattern (Ank et al., 2006;  Stark et al.,  1998; Zhou et al., 2007b). Type-I 
and -III IFN can be produced by all nucleated cells although the expression pattern 
of the different subtypes depends on upstream  signalling  and,  hence,  the  inducing 
stimulus (Ank et al., 2006; Pestka et al., 2004) (see later).
After secretion, type-I  IFNs bind with various affinities to  the two  subunits of the 
type-I  IFN  receptor  (IFNAR)  causing  heterodimerisation  and  a  conformational 
change of the intracellular signalling domain. It is believed that the affinities of the 
IFN-a/p subtypes explain differences in their functions (see later) (Jaks et al., 2007; 
van Boxel-Dezaire et al., 2006).
Activation of the IFNAR initiates intracellular signalling that involves Janus kinase 1  
(JAK1)  and  Tyrosine  kinase  2  (TYK2)  that  phosphorylate  signal  transducer  and 
activator  of transcription  (STAT)-l  and  -2  molecules  (van  Boxel-Dezaire  et  al.,
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2006).  Together  with  Interferon  regulatory  factor  (IRF)-9,  ST  ATI  and  -2  form  a 
trimeric  complex  named  Interferon  stimulated  Gene  factor  3  (ISGF3)  which 
translocates  into  the  nucleus  and binds  to  interferon  stimulated response  elements 
(ISREs) to drive transcription of interferon  stimulated genes  (ISGs).  Activation of 
the  Jak-STAT  pathway  initiates  transcription  of more  that  300  genes  (Der  et  al., 
1998), including enzymes, transcription factors, cell surface glycoproteins, cytokines 
and other factors that  still  await elucidation (Der et al.,  1998).  Functionally,  ISGs 
include proteins that display antiviral activity, are involved in interferon signalling or 
act  as  PRRs  (e.g.  RLRs  and  TLRs)  (Fig  1.2.1).  Furthermore,  IFNAR  signalling 
facilitates  DC  and  NK  cell  activation  and  therefore  is  involved  in  induction  of 
adaptive immunity (Le Bon and Tough, 2002;  Stetson and Medzhitov, 2006b) (Fig
1.2.1).
Gene  products  with  antiviral  activity  include  the  Fv  or  tripartite  motif  protein 
(TRIM)  5a,  both  of which  interfere  with  viral  proteins  (Bieniasz,  2004)  and  are 
thought to  sequester viral  proteins  and  thereby  inhibit virus  trafficking  within  the 
cell.  Similarly,  the  orthomyxovirus  resistance  (Mx)  proteins  appear  to  recognise 
virus  nuclecoproteins  or  ribonucleoprotein  complexes  and  sequester  them  into 
perinuclear complexes, thereby limiting virus assembly (Haller et al., 2007; Kochs et 
al.,  2002).  An  increase  in  expression  of the  eIF2a  kinases,  the  dsRNA  activated 
protein  kinase  R  (PKR)  and  general  control  nonrepressible-2  (GCN2),  leads  to 
increased apoptosis and a block in protein translation (Garcia et al., 2007;  Samuel,
2001).  Similarly,  2’5’  Oligoadenylate  synthetase  (2’5’OAS)  is  highly  upregulated 
after IFN-a/p treatment. RNAse L an endoribonuclease that is activated by 2’5’OAS 
and ISG20,  a 3’-5’  exoribonuclease,  can lead to induction of apoptosis and reduce 
the  amount  of viral  and cellular RNA  (Bisbal  and  Silverman,  2007;  Espert  et al., 
2003).  Importantly,  some of the  expressed genes  (e.g.  PKR,  GCN2  and 2’5’OAS) 
need to  be  activated by  viral  nucleic  acid before  they  can  execute  their  function, 
which  assures that possible  detrimental  effects  are  kept  in  check  (Berlanga  et  al., 
2006;  Williams,  1999).  The  orchestrated  expression  of  antiviral  and  cytostatic 
proteins  is  instrumental  in  reducing  virus  replication  and thereby preventing  virus 
spread. These mechanisms may even be effective enough to clear virus infections in 
a  non-cytolytic  manner  (Guidotti  and  Chisari,  2001).  Mice  or  humans  lacking
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functional  proteins  involved  in  IFNAR  signalling  are  highly  susceptible  to  virus 
infections (Dupuis et al., 2003; Durbin et al.,  1996; Muller et al., 1994).
The IFN response can be seen as a self-amplifying circuit, which explains reduced 
production of IFN-a/p in the absence of functional IFNAR signalling (Haller et al., 
2006) (Fig 1.2.1). However, PRRs are of central importance as they initiate IFN-a/p 
in the first place, thereby kick-starting the entire system.
1.3.  Toll like receptors are bona-fide PRRs
TLRs are evolutionary conserved PRRs that bind a variety of PAMPs (TABLE 1). 
Finding PRRs in mammals proved to be difficult, but was eventually boosted by the 
discovery  of Toll,  a  protein  in  the  fruit  fly,  Drosophila  melanogaster.  Toll  was 
initially  identified  as  a  product  involved  in  dorsoventral  polarity  in  the  fruit  fly’s 
development (Lemaitre et al.,  1995) and later found to have a pivotal role for anti- 
fungal responses in flies (Lemaitre et al.,  1996). Medzhitov and Janeway identified a 
gene  in  mammals  that  showed  high  sequence  homology  to  Drosophila  Toll  and 
encoded a transmembrane protein with an extracellular domain containing a leucine- 
rich repeat (LRR) and an intracellular signalling domain with high homology to the 
interleukin (IL)-l receptor (Medzhitov et al.,  1997). Furthermore, they showed that a 
constitutively  active protein  induces  pro-inflammatory  cytokines  such  as  IL1,  IL6 
and IL8  and therefore argued that human Toll (later called TLR4)  represented the 
first described PRR linking the innate-  and adaptive immune system in vertebrates 
(Medzhitov et al.,  1997).
To date 11 TLRs are known in humans (Table 1) (Akira et al., 2006) but many more 
exist in animals lacking an adaptive immune system,  such as the sea urchin, which 
possesses  222  TLRs  (Rast  et  al.,  2006).  TLRs  are  type-I  integral  membrane 
gycoproteins  characterized by  extracellular domains  carrying  a varying number of 
LRRs and a cytoplasmic signalling domain that is homologous with that of the IL1R, 
also called Toll/ILIR domain (TIR) (O'Neill and Bowie, 2007).
Most TLRs  are  localised  on the  plasma membrane  facing  the  extracellular milieu 
(Table 1) (Takeda et al., 2003). A subset (TLR3, -7, -8 and -9) however is located in 
the  endosomes  of  specialised  immune  cells  (Fig  1.3.4),  and  these  TLRs  screen
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incoming  material  for  pathogens.  This  subset  of  TLRs  seems  to  be  of  special 
importance for recognition of viruses and shares the ability to sense nucleic acid that 
can  lead  to  IFN-a/p  induction  (Bowie  and  Haga,  2005;  Wagner,  2004).  For this 
reason I will mainly concentrate on endosomal TLRs in this introduction.
Table 1: Toll-like receptors, their localisation, agonists and signalling molecules
localisation agonist adaptor
TLR1 cell surface bacteria: triacyl lipoproteins MyD88/MAL
TLR2 cell surface bacteria:  lipoproteins,  peptidoglycan,  lipoteichoic 
acids;  fungi:  zymosan,  mannans;  viruses: 
glycoprotein of Measles virus, HSV-1
MyD88/MAL
TLR3 endosome viruses: dsRNA in virally infected cells, poly-I:C, 
poly-I
TRIF
TLR4 cell surface bacteria: lipopolysacharide; fungi: mannans; 
viruses: glycoproteins of MMTV and RSV
MyD88/MAL
TRIF/TRAM
TLR5 cell surface bacteria: flagellin MyD88
TLR6 cell surface bacteria: diacyl lipoproteins MyD88/MAL
TLR7 endosome viruses: nucleotide analogs, ssRNA MyD88
TLR8 endosome viruses: nucleotide analogs, ssRNA MyD88
TLR9 endosome bacteria: unmethylated DNA motifs; viruses: DNA MyD88
TLR10 cell surface Unknown Unknown
TLR11 cell surface parasite: profilin-like molecule MyD88
1,3,1,  Activation  of endosomal  TLRs  by their ligands  and
consequences for the cell
The N-terminus of TLR3  is the only endosomal TLR ectodomain that has thus far 
been successfully crystallized (Choe et al., 2005). The LRRs form a horseshoe-like 
structure that was initially thought to provide a binding-pocket for the ligand at its 
concave  site  (Choe  et  al.,  2005).  Surprisingly,  extensive  mutagenesis  analysis 
suggest that dsRNA binds on the lateral  side of the TLR3  ectodomain (Bell et al.,
2006).  Binding  of  a  TLR3  agonist  results  in  receptor  clustering  and  induces  a 
conformational  change  that  brings  the  two  cytoplasmic  TIR  domains  in  close
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proximity,  thereby  initiating  downstream  signalling  events  via  TIR-domain 
containing adaptor molecules (Bell et al., 2006; O'Neill and Bowie, 2007). A recent 
report  shows  that  TLR9  may  work  in  a  similar  manner:  binding  of  its  ligand 
(unmethylated DNA) changes the conformation of latently forming homodimers and 
this unleashes signalling capacity (Latz et al., 2007). Interestingly, binding of DNA 
without  stimulatory  activity  does  not  result  in  a  conformational  change  in  TLR9, 
indicating that binding of a receptor cannot be equalised with its activation.
Cells prominently expressing endosomal TLRs include antigen-presenting cells, i.e. 
Dendritic cells (DC), macrophages and B-cells (Iwasaki and Medzhitov, 2004; Reis 
e  Sousa,  2004).  Stimulating  TLRs  on  these  cells  results  in  expression  of  co­
stimulatory  molecules  and  cytokines  that  ultimately  shape  the  adaptive  immune 
response  and  instruct  naive  CD4  T-cells  to  differentiate  into  effector T-cells  (Fig
1.1.2).
For  DC,  it  was  shown  that  TLR  activation  results  in  massive  cytoskeletal 
rearrangement. An initial boost of endosomal uptake, which can be understood as a 
‘sampling process’  of the  environment,  is  followed by  a phase  characterised by  a 
tremendous reduction in endocytosis and in maturation of the DC (West et al., 2004).
1.3.2.  Signalling events as a result of TLR activation
TLRs  activate  the  same  signalling  molecules  that  are  used  for  IL1R  signalling 
through a conserved Toll/ILl  Receptor (TIR) domain (Kawai and Akira, 2007)(Fig 
1.3.1).  Five  adaptor molecules  are  known  to  signal  downstream  of TLRs  (O'Neill 
and  Bowie,  2007).  These  are  Myeloid  differentiation  factor  88  (MyD88),  TIR- 
domain containing  adaptor molecule  inducing  IFN-(3  (TRIF),  MyD88  adaptor-like 
(MAL) protein (also called TIR adaptor like protein (TIRAP)), TRIF-adaptor related 
adaptor  molecule  (TRAM)  and  sterile  a-  and  armadillo-motif-containing  protein 
(SARM).  Usage  of  different  combinations  of  adaptor  proteins  partly  explains 
differences in cytokine production after TLR triggering (O'Neill and Bowie, 2007). 
Upon TLR stimulation, MyD88 interacts with the cytoplasmic portion of all TLRs, 
with the exception of TLR3. TLR3  and TLR4 can signal in MyD88 deficient cells, 
consistent with the fact that those receptors use an alternative pathway via TRIF (see 
below).  For TLR2  and TLR4,  MAL/TIRAP  is  necessary to bridge  the  association
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between  MyD88  and  the  TLR  (O'Neill  and  Bowie,  2007).  The  recruitment  of 
MyD88 results in formation of a complex with IL1R associated kinase-1   (IRAK-1) 
and IRAK-4 (Suzuki et al., 2002). Recently IRAK-2 was shown to be essential part 
of the  same  complex  (Keating  et  al.,  2007).  The MyD88-IRAK  complex  engages 
TNFR associated Factor 6 (TRAF6) (Kawai et al., 2004), which in turn activates the 
NF-kB and Janus kinase (JNK)  signalling cascade and Interferon regulatory  factor 
(IRF) 7 and/or IRF5 (Honda et al., 2005b; Takaoka et al., 2005) through additional 
signalling  molecules  (Chen,  2005).  These  events  eventually  result  in  binding  of 
activated  transcription  factors  to  the  corresponding  NF-kB,  API  and  IRF-binding 
sites and lead to the expression of IFN-a/p and pro-inflammatory cytokines such as 
IL12p40 and IL6. In most cell types a lack of IRF7 severely impairs IFN induction 
and mice lacking IRF3  and IRF7 do not produce any detectable IFN-a/p (Honda et 
al., 2005b). An exception are conventional DC (cDC) which rely on IRF1  (Negishi 
et al.,  2006;  Schmitz  et  al.,  2007).  The  production  of pro-inflammatory  cytokines 
appears to be a common feature of TLRs but only activation of few TLRs can elicit 
IFN-a/p (Uematsu and Akira, 2007).
TLR3  and  TLR4  use  a  MyD88  independent  TRIF-  or  TRAM-mediated  pathway 
whereas for TLR7,  -8 and -9 MyD88  is required (O'Neill and Bowie,  2007).  After 
activation,  TLR3  directly  recruits  TRIF  to  its  TIR  domain  (Hoebe  et  al.,  2003; 
Yamamoto et al., 2003) whereas TLR4 requires a bridging molecule, namely TRAM 
(Fitzgerald  et  al.,  2003b).  However,  in  both  cases  TRIF  eventually  interacts  with 
receptor-interacting protein  1   (RIP1),  which activates the NF-kB pathway (Meylan 
et  al.,  2004).  TRIF  can  also  recruit  TRAF-family-member-associated  NF-kB 
activator (TANK) binding  kinase  1   (TBK1)  via TRAF3  (Oganesyan  et  al.,  2006). 
This recruitment results in the phosphorylation of IRF3  and -7,  which form hetero- 
or  homodimers  and  translocate  into  the  nucleus  to  bind  and  activate  the  IFN- 
promoter (Honda and Taniguchi, 2006).
TLR7 and -9 mediated IFN-a production is restricted to plasmacytoid dendritic cells 
(pDC)  (Uematsu and Akira,  2007).  This  subset of DC  has  also  been  described  as 
interferon producing cells (IPC) due to the vast amounts of IFN-a/p produced after 
virus  infection  (Liu,  2005).  The  exact  mechanism  for the  restricted  expression  of
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IFN-a is not entirely understood as cDC  also express TLRs and can produce high 
amounts  of pro-inflammatory  cytokines  and  IFN-P  in  response  to  TLR9  agonists 
(Negishi  et  al.,  2006;  Schmitz  et  al,  2007).  Furthermore,  pDC  and  cDC  use  a 
MyD88 dependent signalling pathway, which, in pDC, suggests either a bifurcation 
of  signalling  events  downstream  of  this  molecule  or  engagement  of  additional 
molecules  beside  MyD88  (Negishi  et  al.,  2006;  Schmitz  et  al.,  2007).  In  case  of 
pDC,  TLR7/9  triggering  leads  to  formation  of a  complex  consisting  of MyD88, 
IRAK-1, IRAK-4, TRAF-3 and -6, TBK1 and IRF7 (Uematsu and Akira, 2007). 
Recently,  IkB  kinase-a  (IKKa)  has  been  identified  as  a  key  player  for  IFN-a 
production  by  pDC  after  TLR7  and  -9  stimulation  (Hoshino  et  al.,  2006).  IKKa 
seems to be a unique requirement for TLR-mediated IFN-a production  in pDC,  as 
this  protein  is  not  required  for  secretion  of other  cytokines  expressed  after  TLR 
stimulation or for IFN-a/p production elicited by the cytoplasmic virus recognition 
pathway in other cell types (Hoshino et al., 2006). As IKKa is not unique for pDC 
and cDC contain both TLRs and IKKa, the unique requirement of IKKa for IFN-a 
production  in  pDC  does  not  elucidate  why  it  is  that  pDC  can  and  cDC  cannot 
produce  this  cytokine.  IFN-a  induction  also  relies  on  osteopontin  (Opn),  a 
phosphoprotein that is necessary for TH1 immune responses. pDC lacking Opn show 
a  defect  in  expressing  IFN-a  but  produce  normal  amounts  of  other  cytokines 
(Shinohara et al., 2006).
Although cDC do  not produce IFN-a  when  stimulated with a TLR9  agoinst,  they 
have  recently  been  found  to  secrete  substantial  amounts  of  IFN-p  upon  TLR9 
stimulation.  Surprisingly, IFN-P production  in this cell  type depends on IRF1  but 
not on IRF3 or -7 (Negishi et al., 2006; Schmitz et al., 2007).
The  discrepancy between  pDC  and  cDC  in  terms  of IFN-a  induction  has  fuelled 
speculation  on  the  nature  of  the  underlying  mechanism.  The  most  widespread 
explanation  for the  superiority  of pDC  is based on the  fact that pDC  have  higher 
basal levels of IRF7 and therefore may be able to promote IFN-a induction earlier 
than any other cell type (Izaguirre et al., 2003; Liu, 2005). However, this notion may 
not  be  entirely  correct  as  IFN-a/p  treatment  of cDC  induces  IRF7  to  similar  or 
higher levels than those observed in resting pDC, yet IFN-a/p pre-treatment of cDC
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does  not  promote  IFN-a  production  after  TLR7  or  -9  stimulation  (personal 
communication Oliver Schulz). Furthermore, pDC stimulated by TLR activation and 
cDC stimulated via cytoplasmic PRRs can, in principle, produce similar amounts of 
IFN-a (Diebold et al., 2003) suggesting that signalling molecules necessary for both 
recognition pathways are not limiting.
It may be that cell biological aspects like differences in endocytosis are the basis for 
the  special  ability  of pDC  to  translate  TLR9  activation  to  intracellular  signalling 
leading to IFN-a production (see below).
1.3.3.  TLR2 and TLR4 stimulation by viral proteins leads to
pro-inflammatory cytokines
Some TLRs can be activated by viral proteins. One example for this is the activation 
of TLR4  by the  RSV-F  protein  (Kurt-Jones  et  al.,  2000).  Compared  to  wild-type 
animals,  infection  of  TLR4-deficient  animals  showed  lower  numbers  of  tissue- 
infiltrating mononuclear cells and decreased IL12  levels and eventually resulted in 
reduced virus clearance (Kurt-Jones et al., 2000). However, another publication has 
suggetsted that there is no involvement of TLR4 in the clearance of this virus (Ehl et 
al., 2004). Therefore the contribution of TLR4 to an immune response against RSV 
remains controversial.
TLR2-dependent  immune  responses  have  been  reported  for other viruses,  such  as 
measles,  human  cytomegalovirus,  murine  cytomegalovirus  (MCMV),  Herpes 
Simplex Virus  1   (HSV-1), coxsackie virus and Vaccinia virus (W ) (Aravalli et al., 
2005; Bieback et al., 2002; Compton et al., 2003; Kurt-Jones et al., 2004; Richer et 
al., 2006; Szomolanyi-Tsuda et al., 2006). However, there is considerable difference 
in terms of the relation between TLR2 and these viruses: TLR2 activation seems to 
be  critical  to  mount  an  efficient  immune  response  against  VV,  whereas  TLR2 
recognition  of HSV-1  triggers  a  vast  cytokine  response,  which  is  responsible  for 
HSV-1  induced immunopathology linked to morbidity and mortality (Aravalli et al., 
2005;  Kurt-Jones et al.,  2004).  Similar to HSV-1,  Coxsackie virus activates TLR4 
and  the  resulting  pro-inflammatory  cytokine  burst  is  linked  to  cell  damage  and 
disease  (Richer  et  al.,  2006).  Thus,  the  interaction  between  a  virus  and 
plasmamembrane-bound TLRs  does not necessarily  result  in  an  advantage  for the
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host. On the contrary, some reports suggest that TLR -  virus interactions can be of 
benefit for the pathogen: mouse mammary tumour virus (MMTV) envelope protein, 
for instance,  stimulates TLR4 on B-cells or DC  (Burzyn et al.,  2004;  Rassa et al.,
2002)  and  thereby  activates  B-cell  divisions  and  expression  of the  MMTV  entry 
receptor  CD71,  both  essential  factors  for  MMTV  infection  (Otten  et  al.,  2002). 
Clearly, some viruses hijack cellular ‘anti-viral’ mechanisms for their own purposes, 
which  make  predictions  of  the  benefits  of  TLR2  and  -4  activation  by  viruses 
difficult. Therefore, TLR2 and -4 mediated immune responses have to be evaluated 
separately for any given virus. This may be even more complicated as many in vivo 
experiments can vary considerably depending on the exact experimental procedure 
used,  i.e.  virus clearance depends on the mouse strain and age, the  infection route, 
the exact virus isolate and the amount of virus used (Pichlmair et al., 2004a; Zhou et 
al., 2007a).
1.3.4.  Endosomal TLRs mediate IFN-a/p production upon
virus infection
Treatment of pDC with a variety of viruses results in production of high amounts of 
IFN-a/p,  a  feature  that  designated pDC  as  interferon  producing  cells  (Liu,  2005; 
Siegal et al.,  1999). The fundamental basis for this was not known but it appears that 
pDC have  a  special ability to  link TLR7,  -8  and -9  activation  in the  endosome to 
IFN-a production and that this is the main reason for their superiority (Kato et al.,
2005).  TLR3  present  in  cDC  and  TLR7,  -8  and  -9  in  pDC  are  are  able  to  sense 
nucleic  acid  that  gains  access  into  endosomes  (Fig  1.3.4)  (Uematsu  and  Akira,
2007).  During  their  life  cycle  most  viruses  enter  the  endocytic  compartment  and 
thereby are believed to  deliver TLR ligands,  which  results  in  TLR activation  and 
production of IFN-a/p.
Poly-I:C, poly-I and viral dsRNA activate TLR3
It is well established that dsRNA  is produced after viral  infection.  In  1964  David 
Baltimore  showed that the  ssRNA containing poliovirus produces vast amounts  of 
dsRNA during virus replication (Baltimore et al.,  1964). As dsRNA is uncommon in 
cells it was soon recognised to be a PAMP for cytosolic virus recognition and was
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considered to be the major or even only structure being sensed after virus infection 
(Field et al.,  1967a; Lampson et al.,  1967; Merigan,  1970; Tytell et al.,  1967).  The 
discovery that the synthetic dsRNA analogue polyinosinic-polycytidylic acid (poly- 
I:C) induces IFN-a/p supported the notion that long dsRNA serves as determinant 
for virus infection (Field et al.,  1967b).
One protein that recognises dsRNA is TLR3, which is expressed on many cell types 
although predominantly on cDC (Iwasaki and Medzhitov, 2004; Reis e Sousa, 2004). 
dsRNA derived from reovirus particles and poly-I:C activate the NF-kB pathway via 
TLR3  in  vitro  (Alexopoulou et al.,  2001)  and TLR3  on  CD8  positive  cDC  (CD8+  
DC)  can recognise dsRNA  in virus-infected cells (Fig  1.3.4)  (Schulz  et al.,  2005). 
Cells infected with  EMCV and SFV or loaded with the  dsRNA  homolog poly-I:C 
can be phagocytosed by CD8+ DC and stimulate this cell type to produce IFN-p and 
pro-inflammatory  cytokines  like  IL6  and results  in  increased  ability  of the  DC  to 
cross  prime  T-cells  (Schulz  et  al.,  2005).  Influenza  virus,  that  does  not  generate 
detectable amounts of dsRNA (Weber et al., 2006) is a weak inducer of this pathway 
(Pichlmair et  al.,  2006)  emphasising  the  notion  that  TLR3  can  recognise  dsRNA. 
More  recently  it  was  proposed  that  mRNA  and  poly-inosinic  acid  (poly-I)  were 
sufficient  to  activate  TLR3,  suggesting  that  special  forms  of ssRNA  can  contain 
stimulatory activity (Kariko et al., 2004; Marshall-Clarke et al., 2007).
Several in vivo studies have demonstrated that TLR3 is dispensable for the outcome 
of a virus infection. TLR3-deficient animals show almost unchanged susceptibility to 
viruses  such  as  vesicular  stomatitis  virus  (VSV)  lymphochoriomeningitis  virus 
(LCMV) and reovirus (ReoV) when experimentally infected (Edelmann et al., 2004; 
Johansson et al., 2007). Interestingly, some DNA viruses appear to activate antiviral 
responses  through  TLR3,  which  is  consistent  with  the  notion  that  DNA  viruses 
commonly produce dsRNA during replication (Colby and Duesberg,  1969; Jurale et 
al.,  1970;  Weber et al.,  2006).  Macrophages  lacking a functional  TLR3  signalling 
cascade were compromised in their ability to suppress vaccinia virus replication in 
vitro and infection of TLR3 deficient mice with MCMV resulted in increased viral 
titres in the spleen,  slightly increased mortality, decreased serum levels of IFN-a/p 
and other cytokines and decreased activation of natural killer (NK) cells (Edelmann 
et al., 2004; Tabeta et al., 2004). A recent paper by Jean-Laurent Casanova’s group
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describes  TLR3  as  an  important  receptor  to  prevent  encephalitis  after  HSV-1 
infection  in  human  patients,  suggesting  that  TLR3  is  mainly  involved  to  control 
neurotropic viruses (Zhang et al., 2007).
Surprisingly,  pathogenesis  of some  virus  infections  is  reduced  in  mice  that  lack 
TLR3. For instance, TLR3-deficient mice are more resistant to infection with lethal 
doses of West Nile Fever virus (WNV) (Wang et al., 2004b). This phenomenon was 
explained  by  a  TLR3-mediated  peripheral  inflammatory  response  that  results  in 
leakiness of the blood-brain barrier, thereby promoting virus  infection of the brain 
(Wang et al., 2004b). Likewise, infection of mice with Influenza A virus that causes 
a  highly  contagious,  acute  pulmonary  disease  resulted  in  pneumonia,  which  was 
linked to  inflammatory mediators (Le  Gofflc  et  al.,  2006;  Le  Goffic  et  al.,  2007). 
Finally,  tlr3'/'  mice  are  also  more  resistant  to  infection  with  Punta  Toro  virus, 
perhaps  because  TLR3-deficiency  restricts  production  of  proinflammatory 
mediators, such as IL6, which contribute to immunopathology (Gowen et al., 2006). 
It has to be noted, however, that experimental infection of mice does not necessarily 
reflect  the  situation  in  vivo  where  limited  amounts  of  virus  may  not  result  in 
exacerbated TLR3  stimulation (Gowen et al.,  2006).  Moreover,  mice used in most 
experiments are  inbred and lack interferon stimulated response  genes  such  as  Mx- 
proteins  that  are  essential  to  control  pathogenicity  caused  by  orthomyxo-  and 
rhabdoviruses (Haller et al., 2007; Pichlmair et al., 2004a).
TLR9 is a receptor for DNA
TLR9 can be activated by unmethylated 2’deoxyribo(cytidine-phosphate-guanosine) 
(CpG)  DNA  motifs  that  are  present  in  bacterial  and  viral  DNA  whereas  in 
mammalian  genomes  such  motifs  are  mainly  methylated  (Hemmi  et  al.,  2000). 
Nontheless, cellular DNA can activate TLR9 if the DNA is experimentally delivered 
into endosomes or if present in immune complexes that can be internalised by Fc- 
receptor mediated uptake (Barrat et al., 2005; Leadbetter et al., 2002). Although first 
discussed as a means to recognise bacteria it became clear that TLR9 is important for 
recognition of DNA  viruses  such as  herpes  simplex virus  2  (HSV-2),  HSV-1  and 
MCMV (Hochrein et al., 2004; Iacobelli-Martinez and Nemerow, 2007; Krug et al., 
2004a; Krug et al., 2004b; Lund et al., 2003). pDC are the main cell type producing
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IFN-a after stimulation with CpG DNA and viruses but other cell types can produce 
pro-inflammatory cytokines like IL6 (Akira et al., 2006).
Endosomal localisation apparently serves as a mechanism to guarantee specificity of 
TLR9 activation:  extracellular DNA, for instance, is quickly degraded and does not 
allow  activation  of TLR9.  The  endosomal  localisation  of TLR9  can  be  seen  as 
mechanism  to  minimise  responses  to  self-DNA  that  can  be  released  from  cells 
during  necrotic  cell  death.  A  chimeric  TLR  (TLRN9C4)  consisting  of  the 
ectodomain of TLR9 and the intracellular tail and transmembrane domain of TLR4 
can be found at the plasma membrane, facing the extracellular milieu (Barton et al., 
2006).  Unlike  cells  expressing  wild-type  TLR9,  cells  expressing  TLRN9C4 
responded  to  naked  DNA  added  into  the  culture  medium.  TLRN9C4  was  less 
effective  in  recognising  HSV-1  and  the  authors  therefore  speculated  that  the 
endosomal  localisation  of TLR9  is of importance  for both  sensing  viral  pathogens 
and preventing recognition of self-DNA, which could be produced by bursting cells 
(Barton et al., 2006).
The exact molecular mechanism of TLR9 recognition was only recently uncovered 
(Latz et al., 2007). Latz and colleagues could show that binding of agonistic DNA to 
TLR9 in vitro results in a conformational change that initiates downstream signalling 
(Latz et al., 2007). However, it is still not entirely clear how this works in vivo and 
whether cell type specific TLR9-dependent cytokine expression patterns can solely 
be explained by conformational change of the receptor. A lot of work has been done 
with two types of synthetic CpG oligonucleotides that differ in their sequence: CpG- 
A (also called D-type CpG) with a 3’  poly-C  sequence and CpG-B (also called K- 
type  CpG)  (Klinman,  2004;  Krieg,  2002)  can  both  stimulate  TLR9,  but  lead  to 
different  cytokine  production  in  pDC.  CpG-A  elicits  IFN-a  from  pDC,  whereas 
CpG-B promotes lower levels of IFN-a but initiates large amounts of IL6 and TNF- 
a. Interestingly, pDC retain CpG-A in early endosomes for a longer time than CpG- 
B, which is transported into lysosomal compartments quickly after uptake (Guiducci 
et al., 2006; Honda et al., 2005a). Similarly to CpG-B in pDC, CpG-A is transported 
into  lysosomal  compartments  in  cDC.  CpG-A  complexed with  cationic  lipids  (i.e. 
DOTAP) is retained in early endosomal compartments of cDC and can elicit a TLR9 
dependent IFN-a response (Guiducci et al., 2006; Honda et al., 2005a). This shows
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that TLR9 activation can lead to expression of different cytokine patterns depending 
on the agonist and the cell type used. However, more work is required to understand 
the  mechanistic  basis  for  this  and  whether  this  is  also  the  case  during  a  viral 
infection.
Anti-nucleic acid antibodies, that are present in systemic lupus erythematosus (SLE) 
patients,  can  deliver  nucleic  acid  into  endosomes  through  Fc-receptor  mediated 
uptake  (Leadbetter  et  al.,  2002).  In  case  of  SLE,  the  constant  stimulation  of 
endosomal TLRs (TLR7 and -9) exacerbates this autoimmune disease (Christensen 
et  al.,  2005).  It  remains  to  be  shown,  however,  whether  this  is  the  cause  or  a 
consequence of SLE.
In vitro evidence of TLR9 activation and its importance for cytokine production after 
stimulation with  DNA  ligands and viruses  is  clear but  its  role  in  vivo  is  less well 
understood.  Human  patients  with  mutations  in  UNC93B  that  is  involved  in 
recognition via endosomal TLRs are highly susceptible to HSV-1  infection and often 
die  from  virus-induced  encephalitis,  demonstrating  a  role  of the  TLR  pathway  in 
controlling HSV-1  during a natural infection in humans (Casrouge et al., 2006; Yang 
et al., 2005). However, IRAK4 that is involved in the TLR7, -8, -9 pathway seems to 
be  redundant  to  control  HSV-1  and  other  viruses  in  humans  (Yang  et  al.,  2005). 
Consistent  with  its  function  in  vitro,  the  adjuvant  effect  of  CpG-containing 
oligonucleotides to mount an immune response against a co-injected antigen clearly 
depends  on  the  presence  of TLR9  (Klinman,  2004).  Furthermore,  in  an  in  vivo 
mouse model TLR9 is important in controlling HSV-2  in an intravaginal  infection 
model and mice depleted of pDC are more susceptible to HSV-2 challenge (Lund et 
al.,  2006),  in  agreement  with  the  notion  that  pDC  recognise  HSV-2  via  TLR9 
leading to production of antiviral cytokines. However, when HSV-1  was injected in 
the  footpad,  wild  type  and  TLR9'A  mice  mounted  a  similar  adaptive  immune 
response and were similarly resistant to the virus (Krug et al., 2004b) consistent with 
the  notion  that  DNA  viruses  can  be  detected  by  TLR9  independent  mechanisms 
(Hochrein et al., 2004).  Further, plasmid DNA clearly activates TLR9  in vitro, but 
when  plasmids  are  used  for  DNA  immunisation  TLR9  deficient  mice  mount  an 
immune response  that  is  indistinguishable  from that  of control  mice  (Spies  et al.,
2003). Clearly, TLR9 dependent immune responses in vivo can be seen in some but
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not  in  other  experimental  models  and  alternative  DNA-  and  DNA-virus  sensing 
mechanisms are in place.
In  conclusion,  endosomal  recognition  of DNA  by  TLR9  is  the  current  working 
model  that  explains  how  TLR9  expressing  cells  can  sense  viral  nucleic  acid  (Fig 
1.3.4).
TLR7 and TLR8 are activated by ssRNA
TLR7 and TLR8 show a high degree of similarity to TLR9 and are both located on 
the  X-chromosome.  When  expressed,  both  receptors  are  mainly  localized  at  the 
endoplasmatic  reticulum  and  at  endosomes.  The  murine  version  of  TLR8  was 
previously believed  to  be  non-functional  or  have  a  non-immune  role  (Jurk  et  al., 
2002;  Ma  et  al.,  2006),  although  recent  evidence  from  Gorden  and  colleagues 
suggests that overexpresion  of murine TLR8  in  HEK  cells  and  stimulation  with  a 
selective TLR8 agonist can lead to activation of an NF-kB promoter (Gorden et al.,
2006).  Initially,  murine  TLR7  and  human  TLR7/8  were  found  to  recognise 
imidazoquinolins (e.g. R848, Imiquimod, etc) and some guanine nucleotide analogs 
(e.g. Loxoribine) (Hemmi et al., 2002; Jurk et al., 2002). The discovery that ssRNA 
of viral and cellular origin can activate TLR7 when experimentally delivered into the 
endosome led to the supposition that this receptor may have evolved to sense RNA- 
viruses  (Diebold  et  al.,  2004;  Heil  et  al.,  2004).  Indeed,  TLR7  and  human  TLR8 
recognise ssRNA-virus particles such as influenza, VSV or Hepatitis C (Diebold et 
al., 2004;  Heil  et al.,  2004;  Lee et al.,  2006;  Lund et al.,  2004;  Triantafilou et al., 
2005a; Triantafilou et al., 2005b), and mice lacking the signalling molecule MyD88 
are highly susceptible to intranasal infection with the ssRNA virus VSV (Zhou et al., 
2007a).  In  murine  pDC,  the  IFN-a/p  response  to  VSV  expressing  a  glycoprotein 
mediating fusion  at the plasma membrane is reduced,  which  is  consistent with the 
notion  that  TLR7  senses  viruses  in  endosomes  (Lund  et  al.,  2004).  Interestingly, 
some viruses of the paramyxo-  and retrovirus family (e.g.  Sendai virus  (SeV)  and 
HIV-I) infect cells by fusion at the plasma membrane and one could speculate that 
this  infection  route  serves  as  a  means  to  evade  innate  recognition  by  TLR 
recognition.  Surprisingly,  however,  sensing  of  SeV  by  murine  pDC  requires 
endosomal acidification and TLR7  (Lee et al.,  2007;  Lund et al.,  2004)(see  later).
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Similarly, it was proposed that IFN-a/p production by pDC treated with HIV-1  was 
due to TLR7/8 activation (Beignon et al., 2005).
TLR7  recognises  RNA that  is  delivered into  endosomes but  the  molecular  details 
leading  to  TLR7  activation  are  only  marginally  understood.  Various  studies  have 
proposed the existence of sequence-dependent “immunostimulatory motifs” leading 
to  TLR7  activation  (Heil  et  al.,  2004;  Judge  et  al.,  2005;  Sioud,  2005)  but  more 
recently  it  was  demonstrated  that  three  or  more  uridine  molecules  on  a  ribose 
backbone are necessary and sufficient for TLR7  stimulation (Diebold et al.,  2006). 
However, total RNA or tRNA isolated from mammalian cells only induce minimal 
amounts of cytokines in DC derived from human monocytes, whereas RNA isolated 
from E.  Coli  appears  to  be  a very potent  TNFa  inducer  (Kariko  et  al.,  2005).  A 
possible  explanation  for this reduction  of stimulatory  potential  is  that  mammalian 
RNA may be  subject to posttranscriptional  RNA  modifications that are  commonly 
found  in  mammalian  cells.  RNA  consisting  of  methylated  adenine,  cytidine  or 
uridine or thiolated uridine is  less potent in activating TLRs  (Kariko  et al.,  2005), 
which suggests that RNA modifications that evolved in mammalian cells can  alter 
the stimulatory potential of cellular RNA.
As  for  TLR9,  activation  of  TLR7  can  lead  to  differential  cytokine  responses 
depending on the stimulus used. In murine pDC, a RNA homopolymer consisting of 
uridine nucleotides (poly-U) induces high amounts of IFN-a but little IL6 whereas 
R848 and Loxoribine elicit much less IFN-a/p but potent IL6 responses (Diebold et 
al.,  2006).  Currently  it  is  unknown  how  this  differential  cytokine  production  is 
mediated but one  could  speculate that clustering  of the receptor or engagement of 
additional  receptors  could be  involved.  In  addition,  Imidazoquinolins  and guanine 
nucleotide  analogs  may  be  engulfed  differently  than  RNA  and  therefore  lead  to 
different responses. Whether similar differences can be found after treatment of pDC 
with viruses belonging to varying classes is currently not clear.
7.5.5.  Cells involved in TLR recognition
Although at first glance it may seem obvious that a cell should posses every means 
possible to recognise and respond to viral infections, it is not beneficial in vivo to be
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over-sensitive.  Autoreactive  B-cell  responses  resulting  in  autoimmunity,  for 
instance, are fuelled by the presence of two copies of TLR7 (Pisitkun et al., 2006). 
TLR activation differs greatly depending on the cell type being stimulated.  Murine 
CD8+  DC  and  Langerhans  cells,  for  instance  do  not  express  TLR7  and therefore 
cannot respond to TLR7 ligands. As CD8+ DC are involved in phagocytic clearance 
of dying  cells  the  lack  of TLR7  may  constitute  a  mechanism  not  to  respond  to 
cellular RNA present in apoptotic bodies.  The converse argument applies to TLR3 
expressed  on the  same  cell  types:  some  virally  infected cells  contain  dsRNA  and 
their uptake activates TLR3 on CD8+ DC (Schulz et al., 2005). Similarly, TLR2 and 
TLR4 are highly expressed in human macrophages whereas only small amounts of 
TLR7 and TLR9 are present. In humans, TLR9 is exclusively expressed on pDC and 
B-cells (Iwasaki and Medzhitov, 2004).
TLR agonists can elicit differential cytokine responses depending on the cell type. 
As mentioned above, TLR9 agonistic CpG-A mainly elicits IFN-a in pDC, whereas 
cDC  exposed to  the  same  agonist  secrete  IFN-|3,  IL6  and  other pro-inflammatory 
cytokines.  In cDC this relies on a  signalling pathway  strongly depending  on  IRF1 
but not on IRF7,  whereas pDC need IRF7 but do not require IRF1  (Negishi  et al., 
2006; Schmitz et al., 2007), suggesting that activation of PRRs is coupled differently 
to downstream signalling molecules in a cell-type specific manner.
Clearly, the cells of the immune system are specialised to  serve the  specific needs 
they are designed for and share the challenge to fight a diverse range of pathogens.
1.4.  Cytoplasmic recognition of viruses
The  very  first description  of IFN  in  1957  was  carried out  in  chicken  egg  chorio­
allantoic  membrane  and,  as  we  now  know,  most  likely  based  on  intracellular 
recognition  of a  virus:  supernatant  from  chicken  egg  chorio-allantoic  membrane 
cultures infected with influenza virus contained a factor (interferon)  that conferred 
resistance to infection with a heterologous or homologous virus (Fig  1.1.1)  (Isaacs 
and  Lindenmann,  1957).  Only  very  recently,  almost  50  years  after  the  original 
discovery  of IFN,  was  the  receptor  responsible  for  IFN  induction  after  influenza 
virus infection finally identified (see later) (Kato et al., 2006).
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One  of  the  central  issues  following  the  discovery  of  IFN  was  to  identify  the 
component the cell recognises during a viral infection. It was hypothesised that such 
a component differs from cellular components, and is related to the viral infection. 
Alick Isaacs proposed that nucleic  acid that  is  not  self,  for  instance  RNA  from  a 
different cell type, can elicit IFN when added to cells (Isaacs et al.,  1963). This idea 
was questioned however (Lampson et al.,  1967), as the experiments appeared to be 
of little reproducibility (Isaacs,  1965). In  1964 David Balitmore described that cells 
infected with poliovirus, a ssRNA virus, contained large amounts of dsRNA and this 
depended on virus replication (Baltimore et al.,  1964). This phenomenon appeared to 
be  true  for  a variety  of other  ssRNA  viruses  like  Tobacco  mosaic  virus,  EMCV, 
Semliki forest virus (SFV) and Sindbis virus as well as for the dsRNA viruses ReoV 
and a dsRNA bacteriophage (Friedman and Sonnabend,  1965;  Horton et al.,  1964; 
Kaemer  and  Hoffmann-Berling,  1964;  Shipp  and  Haselkom,  1964;  Stollar  and 
Stollar,  1970) Even DNA viruses like Vaccinia virus and T4 bacteriophage (Colby 
and Duesberg,  1969; Jurale et al.,  1970) generate dsRNA in infected cells.  DsRNA 
fulfilled all the criteria necessary for being a virus specific marker:  it has  apparent 
different  structural  features  compared  with  cellular  RNA  and  is  only  present  in 
virally infected cells.  Furthermore, the IFN-a/(3 inducing activity was contained in 
the  RNA  fraction  of virally  infected  cells  and  it  was  resistant  to  digestion  with 
RNAses  specific  for ssRNA (Merigan,  1970).  After early publications could show 
that highly purified dsRNA isolated from penicillium funiculosum or virally infected 
cells  had  the  potential  to  induce  IFN-a/p  in  vitro  and  in  vivo,  dsRNA  was  soon 
established as the predominant or even the only IFN-a/p inducer (Field et al.,  1967a; 
Field et al.,  1967b;  Lampson et al.,  1967; Merigan,  1970; Tytell et al.,  1967).  This 
notion was  further underlined by the  fact  that dominant  interfering particles  from 
VSV contained dsRNA  and were very  strong IFN-a/p  inducers whereas  a ssRNA 
wild-type virus did not induce IFN-a/p (Marcus and Sekellick,  1977). Following the 
original description of dsRNA being an interferon inducer, research on this molecule 
soared and it soon consolidated its central position in the field of interferon research. 
A protein responsible for recognising cytoplasmic dsRNA and linking this IFN-a/p 
induction, however, has not yet been found.
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1.4.1.  Receptors  involved  in  cytoplasmic  recognition  of 
viruses
Unlike  the  expression  of  TLRs  that  is  restricted  to  specific  cells,  cytoplasmic 
receptors  that recognise  viruses  appear  to  be  expressed  in  most  cell  types.  Many 
cellular proteins  can  sense  viral  nucleic  acid or  viral  proteins  and thereby  restrict 
virus growth. Examples for these are adenine deaminases (ADAR proteins), GCN2, 
ISG20, Fv- and Mx-proteins (Haller et al., 2007; Samuel, 2001). However, only few 
proteins have the ability to regulate interferon production and I will concentrate on 
these within this introduction.
DsRNA dependent protein kinase R (PKR)
As described above, dsRNA was defined as the bona-fide inducer of IFN-a/p after 
viral  infection,  and  therefore  the  search  for  receptors  mainly  focused  on  dsRNA- 
binding  proteins.  PKR  was  identified  as  a  protein  that  is  activated  by  dsRNA 
(Williams,  1999).  This  process  requires  binding  of two  dsRNA-binding  domains, 
which  explains  the  minimal  length  requirement  of around  60  nucleotide  dsRNA 
(Garcia  et  al.,  2007).  Activation results  in  PKR  dimerisation,  autophosphorylation 
and signal transduction to downstream molecules.
Mice with deletions in the dsRNA binding domains of PKR are more susceptible to 
virus infection (Bergmann et al., 2000;  Streitenfeld et al.,  2003; Zhou et al.,  1999), 
which  is  believed  to  be  due  to  the  ability  of  activated  PKR  to  constitutively 
phosphorylate the eukaryotic initiation factor 2a (eIF2a) and, leading to a block of 
protein  synthesis  (Garcia  et  al.,  2007).  In  vitro  PKR  has  been  shown  to  be  pro- 
apoptotic,  probably  through  activation  of the  Fas-Associated  protein  with  Death 
Domain (FADD) pathway and it may be that virus clearance  in  vivo  requires pro- 
apoptotic signals through the activation of PKR (Balachandran et al., 1998).
Cells  lacking  functional  PKR  appear  to  produce  less  IFN-a/p  when  treated  with 
poly-I:C (Der and Lau,  1995; Diebold et al., 2003). PKR has been shown to interact 
with IKKp and JNK2, both of which are essential for IFN-a/p induction (Chu et al., 
1999;  Zamanian-Daryoush  et  al.,  2000).  PKR  can  be  found  in  a  complex  with 
TRAF3  that  is  also  implicated  in  IFN-a/p  induction  (Oganesyan  et  al.,  2006).
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Surprisingly, pkrf~   cells  produce  normal  amounts  of IFN-a/p  when  infected  with 
some viruses like Newcastle disease virus (NDV),  SeV and Influenza virus (Gilfoy 
and Mason, 2007; Smith et al., 2001)and personal communication, Sandra Diebold). 
Interestingly,  a  recent  report  shows  that  PKR  is  required  for  potent  IFN-a/p 
production in West-Nile virus infected cells and mice, which could suggest that PKR 
may only sense a specific group of viruses (Gilfoy and Mason, 2007).
DAI and other receptors sense intracellular DNA
DNA  is  a  fundamental  entity present  in  all  living  organisms  and  normally  tightly 
packaged either in the nucleus, in mitochondria, in bacteria or within viral structural 
components.  However,  any  failure of DNA removal  e.g.  by the  lack of DNAse-II 
results in TLR9 independent activation of innate and adaptive immune responses and 
can eventually climax in an autoimmune disease (Ishii and Akira, 2006; Okabe et al.,
2005),  suggesting  the  existence  of  additional  DNA-sensing  mechanisms  beside 
TLR9. The notion that transfected DNA can induce innate immune responses is not 
new;  in  1999,  Suzuki and colleagues reported that transfection of DNA  into target 
cells  can  lead  to  upregulation  of co-stimulatory  molecules  and  expression  of low 
amounts  of  IFN-P  (Suzuki  et  al.,  1999).  More  recent  evidence  suggest  that 
cytoplasmic delivery of DNA results in a TLR9  independent induction of IFN-a/p 
(Martin  and  Elkon,  2006;  Shirota  et  al.,  2006;  Yasuda  et  al.,  2005)  through  the 
canonical  IFN  induction  pathway  involving  IRF3  (Ishii  et  al.,  2006;  Stetson  and 
Medzhitov,  2006a).  B-form  DNA,  which  constitutes  the  DNA  most  commonly 
found in the nucleus,  is better recognised than the Z-form DNA that appears to be 
more common in pathogens. Therefore, cytoplasmic DNA recognition in mammalian 
cells does not require a specific signature on DNA and a tight spatial separation of 
the nuclear from the cytoplasmic compartment guarantees unresponsiveness to self- 
DNA.
One candidate involved in cytoplasmic DNA recognition is Z-DNA binding protein 
1   (Takaoka et al.,  2007).  Exogenous  expression  of this  protein  enhances  IFN-a/p 
production in response to B-DNA transfection and HSV-1  infection. In addition, Z- 
DNA binding protein 1  can form a complex with IRF3. For both reasons this protein 
was  re-named  DNA  activator  of  interferon  regulatory  factors  (DAI).  siRNA
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knockdown  of DAI  reduces  IFN-a/p  mRNA  in  response  to  B-DNA  3-5  fold  as 
compared to control cells receiving unspecific siRNA. Cells lacking IRF3, however, 
show a  1000-fold reduction in their response to DNA transfection (Takaoka et al.,
2007). Although this may be attributable to insufficient knockdown, it may suggest 
the  presence  of other  proteins  sensing  cytoplasmic  DNA,  and  studies  with  mice 
lacking DAI will probably clarify this point in the future.
Chu and colleagues reported that immunostimulatory DNA activates bone-marrow- 
derived macrophages (BMMs) to produce  IL6 and IL12  and that this depended on 
DNA-protein kinase (DNA-PK) (Aderem and Hume, 2000; Chu et al., 2000). DNA- 
PK  is  implicated  in  the  DNA  damage  response  pathway  and  is  known  to 
phosphorylate p53,  leading to transcriptional activation of proteins  involved in cell 
cycle  arrest.  Importantly,  CpG-dependent  activation  of  BMMs  is  independent  of 
TLR9,  as activation of DNA-PK dependent signalling can also be found in BMMs 
and  MEFs  lacking  TLR9  (Dragoi  et  al.,  2005).  DNA-PK  forms  a  complex  with 
IKKp and thereby activates NF-kB  and AKT  signalling.  However,  whether  DNA- 
PK  is  involved  in  cytoplasmic  sensing  of DNA  was  questioned  by  other  groups 
(Hemmi et al., 2003; Shirota et al., 2006).
DNA  viruses  commonly  produce  high  amounts  of dsRNA  during  replication  and 
therefore  would  possibly  activate  both  cytoplasmic  DNA  receptors  like  DAI  and 
receptors sensing viral dsRNA.
Rig-like Helicases
In 2004,  Takashi  Fujita’s group  identified an ATP  dependent  DExD/H box  RNA- 
helicase,  Retinoic  acid  inducible  gene-I  (RIG-I),  as  a  protein  that  is  able  to  bind 
poly-I:C and induce IFN responses (Yoneyama et al., 2004). RIG-I expression itself 
is  enhanced  when  cells  are  treated  with  IFN-a/p  and  reducing  RIG-I  levels  by 
siRNA diminishes the IFN response elicited by NDV. The protein has a very unusual 
structure as it contains a helicase domain, which has the ability to bind dsRNA, and 
two caspase activation and recruitment domains (CARDs) (Fig  1.4.1) (Yoneyama et 
al.,  2004).  CARDs  are  known  players  in  signal  transduction  and  are  generally 
composed of six antiparallel a  helices that serve as docking platform for homotypic 
interactions with other CARD bearing proteins  (see  RLR signalling)  (Werts et al.,
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2006).  Expression  of the  RIG-I  CARD  constitutively  activates  IRF3  and  IFN-P 
expression. The helicase domain has ATP-binding capacity believed to be important 
in unwinding dsRNA and an amino acid substitution at position Lys-270 (K270A) 
abrogates this activity and results  in a dominant inhibitor.  Likewise,  RIG-I lacking 
the  CARD or bearing a mutated CARD  (T55I),  leaving  only a  functional  helicase 
domain, also acts as a dominant negative protein and suppresses IFN-a/p induction 
in response to NDV (Yoneyama et al., 2004). More recently it has been shown that a 
C-terminal repression domain can act as an inhibitor of activation and keeps RIG-I 
silent in the absence of virus infection (Saito et al., 2007).  Binding of an agonist to 
RIG-I  induces  protein  dimerisation  and  a  conformational  change  that  exposes  the 
CARD (Yoneyama et al., 2004). The identification of RIG-I as a cytoplasmic sensor 
for viral infection has defined a new family of PRRs that are therefore known as Rig­
like receptors (RLRs) (Creagh and O'Neill, 2006).
Two other proteins belong to this family: Melanoma differentiation factor-5 (MDA5) 
and Laboratory of genetics and physiology-2 (LGP2)  are both DExD/H box RNA- 
Helicases involved in virus recognition (Kato et al., 2006; Rothenfusser et al., 2005; 
Yoneyama  et  al.,  2005).  Like  RIG-I,  MDA5  bears  a  RNA-helicase  and  a  CARD 
(Kato et al.,  2006).  MDA5  was first implicated  in virus  recognition  as  it interacts 
with  the  interferon  antagonist  of Parainfluenza  virus-5  (PIV-5)  (Andrejeva  et  al., 
2004).  It  was  therefore  hypothesised  that  MDA5  may  be  involved  in  PIV-5 
recognition.  Interestingly,  despite  the  striking  similarity  to  RIG-I,  MDA5  has  a 
distinct virus specificity (see below). MDA5 is the only RLR that lacks a C-terminal 
repression  domain  and  overexpression  of MDA5  results  in  production  of IFN-a/p 
(Andrejeva et al., 2004; Saito et al., 2007).
LGP2  shares  high  homology  with  RIG-I  but  lacks  a  CARD  (Rothenfusser  et  al., 
2005;  Yoneyama  et  al.,  2005).  Consequently,  LGP2  cannot  transmit  signals  to 
downstream  molecules  and  was  thought  to  act  as  a  down-regulator  of IFN-a/p 
production.  In  agreement  with  this  hypothesis  expression  of LGP2  in  HEK  cells 
reduced  IFN-a/p  responses  to  RIG-I  and  MDA5  dependent  stimuli,  as  seen  for 
dominant  negative  RIG-I.  Therefore  LGP2  was  proposed  to  have  regulatory 
properties,  which  it  may  accomplish  through  sequestering  agonists  for  RIG-I  and 
MDA5  and/or  through  interfering  with  components  of  the  IFN-a/p  signal
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transduction pathway (Rothenfusser et al, 2005; Yoneyama et al., 2005). Consistent 
with this, mice lacking LGP2 show enhanced production of IFN-P when stimulated 
with  poly-I:C  (Venkataraman  et  al.,  2007).  However,  in  vitro  IFN-a/p  levels 
declined similarly  in wt  MEFs  and MEFs  lacking LGP2,  suggesting that LGP2  is 
dispensable  for  down-regulation  of IFN-a/p.  LGP2-deficient  mice  produce  more 
pro-inflammatory  cytokines  in  response  to  VSV  infection  and  appear  to  be  more 
resistant  to  this  virus.  Surprisingly,  however,  cytokine  expression  after  EMCV 
infection is impaired in these mice, which manifests itself in enhanced susceptibility 
to  EMCV.  Therefore,  it  is  believed  that  LGP2  plays  important  roles  in  the 
recognition  of  EMCV,  but  may  not  be  mandatory  for  modulating  IFN-a/p 
expression after infection (Venkataraman et al., 2007).
1.4.2.  Interaction of  RLRs and their ligands
As  described  above,  dsRNA  is  thought  to  be  the  major  agonist  for  IFN-a/p 
induction. All RLRs have the ability to bind the dsRNA homolog poly-I:C or dsRNA 
forming poly-A:U (Rothenfusser et al., 2005; Yoneyama et al., 2005; Yoneyama et 
al., 2004).
Shizuo Akira’s group generated mice lacking RIG-I and MDA5  (Kato et al., 2005; 
Kato et al., 2006). Surprisingly, these mice showed remarkable virus specificity (Fig 
1.4.2):  in  vitro,  RIG-I  is  required  for  IFN  induction  in  response  to  viruses  like 
Japanese encephalitis- (JEV), SeV and influenza virus, whereas MDA5 appears to be 
a  specific  receptor  for  picomaviruses,  i.e.  EMCV  and  mengovirus  (Kato  et  al.,
2006).  Furthermore,  IFN  induction  from  in  vitro transcribed  dsRNA  depended on 
RIG-I,  whereas  poly-I:C  responses  were  mediated  by  MDA5.  Similarly  to  the  in 
vitro data,  RIG-I deficient mice were highly susceptible to infection with JEV and 
MDA5 deficient mice succumbed to EMCV as early as mice that cannot respond to 
IFN-a/p  (ifnar'A   mice)  (Kato  et  al.,  2006).  The  mechanism  underlying  this 
discrepancy was unknown.
As for activation of TLR9 by DNA, the above results clearly show that binding of a 
ligand is not necessarily sufficient to activate a given PRR.  Binding of poly-I:C is 
not sufficient to activate RIG-I responses and an unknown specificity associated with 
in  vitro  transcribed  dsRNA  is  required  for  RIG-I  activation.  Similarly,  MDA5
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responses are not simply elicited by dsRNA, as in vitro transcribed dsRNA does not 
activate  MDA5.  Therefore,  PRR  binding  of a  ligand  and  PRR  activation  by  an 
agonist need to be considered separately.
1.4.3.  Signalling downstream of  RLRs
The  discovery  of  RIG-I  and  MDA5  resulted  in  unravelling  of  an  entirely  new 
signalling cascade downstream of these proteins. Both PRRs seem to funnel through 
Interferon-p promoter stimulator-1   (IPS-1),  also called MAVS,  CARDIF or VISA, 
which contains a N-terminal CARD that links to  the CARDs of RIG-I and MDA5 
(Kawai  et  al.,  2005;  Meylan  et  al.,  2005;  Seth  et  al.,  2005;  Xu  et  al.,  2005). 
Interestingly,  IPS-1  appears to  attach  to  mitochondria through  its  C-terminus;  this 
localisation is important as disruption of this association through mutation analysis 
or  proteolytic  cleavage  by  the  NS3  protein  of  Hepatitis  C  virus  can  abrogate 
signalling (Meylan et al., 2005).  Overexpression of IPS-1  results in activation of an 
IFN-P-promoter and NF-KB-promoter and siRNA mediated knock down or a genetic 
knockout diminishes virus and poly-I:C induced IFN responses (Kawai et al., 2005). 
Binding  of RIG-I  to  IPS-1  results  in  the  recruitment  of molecules  that  mediate 
downstream  signalling  (simplified  depicted  in  Fig  1.4.2).  A  C-terminal  catalytic 
domain  associates  with  the  adaptor  FADD  and  the  kinase  receptor  interacting 
protein-I (RIP1), transforming growth factor-  p- activated kinase  1   (TAK1),  IKKa 
and IKKp that mediate activation of NF-kB (Balachandran et al., 2004; Kawai et al., 
2005;  Meylan  et  al.,  2006;  Xu  et  al.,  2005).  TBK1  and  IKKe,  both  kinases  that 
mediate  IRF3  phosphorylation  and  activation  of  IFN  responses,  co- 
immunoprecipitated with  IPS-1  (Meylan  et  al.,  2006;  Xu  et  al.,  2005).  Additional 
proteins like TRAF6 or NAK associated protein 1  (NAP1) are also found in the same 
complex  (Seth  et  al.,  2005;  Xu  et  al.,  2005)  and  may  be  necessary  for  this 
interaction. Taking together, IPS-1  activation appears to initiate the formation of an 
intracellular  signalling  complex  that  mediates  activation  of promoters  containing 
NF-kB and IRF3 and -7 binding sites.
The association with mitochondria and the signalling through FADD, both of which 
are  involved  in  apoptosis,  supports  the  supposition  that  there  are  intervening 
pathways of IFN induction and cell death (Balachandran et al., 2004; Takahashi et
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al., 2006).  Although FADD and RIP1  deficient cells are highly susceptible to VSV 
infection  (Balachandran  et  al.,  2004),  the  role  of  FADD  and  RIP1  in  IFN-a/p 
induction is not entirely clear (Kawai et al., 2005).
IFN-a/p  induction  critically  requires  Interferon  regulatory  factor  (IRF)  7  and  -3 
(Honda  et  al.,  2005b;  Sato  et  al.,  2000)  that  are  activated  by  TBK1  and  IKKs 
(Fitzgerald  et  al.,  2003a;  Sharma  et  al.,  2003).  Loss  of IRF7  abolished  IFN-a/p 
induction from both, the TLR and the RLR pathway and therefore IRF7 appears to 
be  a  merger  of these  two  pathways  (Honda  et  al.,  2005b).  IRF3  and  -7  are  first 
phosphorylated,  then  they  dimerise,  translocate  into  the  nucleus  and  bind  to  IRF- 
binding sites present in IFN promoters (Honda et al., 2006).  In addition to the IRF 
binding site, the IFN-p promoter contains binding sites  for ATF-2/cJun (API) and 
NF-kB  and  the  best  activation  is  achieved when  all  sites  are  activated  in  parallel 
(Honda and Taniguchi, 2006).
1.5.  Battle of existence -  viruses vs. interferon system
Viruses  have  to  multiply  extensively  in  infected  hosts  to  ensure  successful 
transmission.  This is a challenging task,  especially in the presence of the powerful 
innate-  and  adaptive  immune  system  (see  paragraph  1.2.1).  The  IFN  system  in 
particular seems to be a major target of virus anti-immunity mechanisms (Haller et 
al.,  2006;  Weber  et  al.,  2004).  Viruses  can  inhibit  IFN-a/p  synthesis,  inactivate 
secreted  IFN  molecules,  interfere  with  IFN-a/p  signalling  or  specifically  block 
activation of IFN stimulated antiviral response proteins. Viruses that have lost their 
ability  to  block  IFN-a/p  are  mainly  non-pathogenic  and  are  sometimes  used  as 
vaccine  strains (Haller et al.,  2006;  Weber et al.,  2004).  Interferon is necessary to 
prevent mice being infected with Myxoma virus, which may  suggest that IFN-a/p 
contributes to confine virus spread in certain species (Wang et al., 2004a). In vitro 
studies suggest that some interferon antagonists may act in a species-specific manner 
and  thereby  contribute  to  restricted  host-range  of viral  pathogens  (Bossert  et  al., 
2002;  Hagmaier et al.,  2007;  Hayman  et al.,  2007;  Park et al.,  2003; Wang et al., 
2004a). Of particular interest is the activity of the V-proteins of Simian virus 5 and
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Parainfluenza virus 5 that can degrade ST AT proteins in a species specific manner 
(Parisien  et  al.,  2002).  In  the  light  of recurrent  epidemics  it  may  seem  as  if the 
body’s  immune  system  is  insufficiently  prepared  to  resist  attacks  from  viral 
pathogens,  but  one  has  to  be  aware  that  only  the  most  sophisticated  viruses  can 
successfully  battle  the  immune  system.  Despite  the  action  of  IFN  antagonistic 
mechanisms  during  most viral  infections,  IFN  suppression  is  never  as  severe  as  a 
genetic  knockout  for IFNAR or  STAT-proteins,  illustrating  the  remarkably potent 
ability  of the  IFN  system  (Dupuis  et  al.,  2003;  Durbin  et  al.,  1996;  Muller  et  al., 
1994).  Therefore,  anti-interferon  mechanisms  only  modify  antiviral  responses  to 
allow the virus to spread sufficiently.
A  summary  of anti-IFN  mechanisms  has  been  discussed  in  depth  in  some  recent 
reviews (Garcia-Sastre and Biron, 2006; Goodboum et al., 2000; Haller et al., 2006; 
Hengel et al., 2005; Pichlmair et al., 2004b; Weber et al., 2004), and therefore I will 
only touch on a few mechanistic details of interferon antagonists.
As mentioned above, viral IFN antagonists can inhibit different levels of the innate 
immune  system.  Unspecific  mechanisms  include  a  broad  shutdown  of  cellular 
transcription and translation. The NSs protein of Rift valley fever virus, for instance, 
can interact with the TFIIH transcription factor, thereby preventing proper assembly 
of the cellular polymerase II (Le May et al., 2004). This results in diminished mRNA 
expression including mRNA of IFN-a/p genes.  Intriguingly, the virus expresses its 
own polymerase and therefore does not require the cellular transcription machinery 
to generate progeny virus.  The Matrix (M) protein of VSV also  interferes with the 
transcription factor (TFIID) but in addition blocks mRNA export into the cytoplasm 
and can inhibit the translation machinery (Hengel et al., 2005). Likewise, subversion 
of the  IFN  system  is  put  forward  as  the  major  reason  for  the  transcriptional  and 
translational shut off seen in picomavirus- and HSV-I  infected cells (Weber et al.,
2004).  Interestingly,  Sindbis  virus  seems  to  block  the  cellular  machinery  through 
using the cell’s own weapon: the activation of PKR and other eIF2a-kinases blocks 
protein translation but the viral RNA possesses a 5’ hairpin that facilitates initiation 
of translation through stalling of ribosomes, despite the presence of phosphorylated 
eIF2a (Ventoso et al., 2006).
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Inhibiting cellular protein synthesis cannot be sustained without severely impacting 
on  cellular  viability  and  therefore  eventually  affecting  virus  replication.  For  that 
reason  some  viruses  may  have  evolved  mechanisms  tailored  to  suppress  the  IFN 
system  more  specifically.  dsRNA  binding  proteins,  for  instance,  are  thought  to 
sequester dsRNA and thereby have an anti-IFN  function (Garcia-Sastre  and Biron,
2006).  The  Vaccinia  virus  E3L  protein  blocks  IFN  induction  and  it  has  been 
suggested  that  this  is  due  to  the  capacity  to  bind  dsRNA  through  a  C-terminal 
dsRNA-binding  site.  More recent evidence  suggesting that cytosolic  DNA  induces 
IFN-a/p may explain the presence of a Z-DNA binding site on the N-terminus of the 
same protein (Kim et al., 2003). In vivo pathogenicity of the Vaccinia virus requires 
both  the  N-  and the  C-terminus  of the  E3L  protein  and  it would be  interesting to 
know  whether  the  DNA  binding  motif  is  responsible  for  interfering  with  innate 
recognition of cytoplasmic DNA (Kim et al., 2003).
Signalling molecules downstream of PRRs are another attractive target to block IFN- 
a/p induction. The NS3-4A protein of Hepatitis C virus, for instance, can cleave the 
RIG-I adaptor protein IPS-1 and TRIF that acts downstream of TLR3 (Meylan et al.,
2005).  Similarly,  a  variety  of  viruses  belonging  to  different  classes  have  been 
reported to interfere with activation of IRF3, suggesting either direct interaction with 
IRFs or inhibition of upstream kinases.  Vaccinia virus expresses  B18R,  a IFNAR- 
like  molecule  that  neutralizes  secreted  IFN-a/p (Symons  et  al.,  1995).  More 
specifically,  V  proteins  of paramyxoviruses  can  lead  to  degradation  of JAK  and 
STAT  proteins  thereby  alleviating  the  antiviral  action  of type-I,  -II  and  -III  IFN 
(Goodboum et al., 2000).
Another efficient way to block the action of IFN-a/p is to specifically interact with 
antiviral proteins. As mentioned above, many of these proteins need to be activated 
by viral  RNA  and viral  antagonists  capable  of binding  dsRNA  often  inhibit  their 
activation. The E3L protein of Vaccinia and the non-structural protein 1  (NS1) of the 
influenza  virus,  for  instance,  block  activation  of 2’5’OAS  (Xiang  et  al.,  2002). 
EMCV and HIV induce expression of a cellular RNAse L inhibitor (RLI) (Martinand 
et al.,  1999). HSV-1  and HSV-2 express 2’5’ oligoadenylate derivates that bind and 
de-activate RNAse L (Weber et al., 2004).
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PKR  is  one  of the  best-studied  targets  of viruses  (Garcia  et  al.,  2007).  Poxviral 
proteins  can  directly  bind  and  inactivate  PKR,  and  poliovirus  leads  to  PKR 
degradation. The VAI RNAs of Adenoviruses are believed to inhibit dimerisation of 
PKR  and  therefore  its  activation  also.  Hepatitis  C  virus  and  HIV  express 
pseudosubstrates  that  inhibit  activation  of cellular  targets  of PKR  and  the  Herpes 
Simplex virus y34.5 protein dephosphorylates eIF2a (Garcia et al.,  2006;  Weber et 
al., 2004). The efforts made by viruses to inhibit PKR suggest that this protein plays 
a  central  role  in  cellular  IFN-a/p  responses.  In  fact,  PKR  has  multiple  functions 
beside blocking cellular translation,  including induction of apoptosis and activation 
of cytokine transcription through the NF-kB pathway.
Viruses have co-evolved under the selective pressure of the innate immune system, 
and  therefore  understanding  their  countermeasures  can  give  further  insight  into 
cellular  processes  involved  in  virus  recognition  (Hengel  et  al.,  2005).  Recent 
discoveries  highlighting  divergent  recognition  processes  in  virus  innate  immunity 
may suggest that viruses have evolved similarly divergent multipotent mechanisms 
to escape this cellular surveillance. Indeed, some viral proteins interact with the IFN 
pathway  at  various  points.  One  such  protein  is  NS1  of  influenza  virus,  a 
pathogenicity factor that is active in a wide variety of species (Hayman et al., 2006). 
A genetic or natural deletion of the NS1  protein results in virus attenuation in vitro 
and in  vivo  (Garcia-Sastre et al.,  1998).  This attenuation is due to the IFN  system, 
because  wt  and NS1-deleted Influenza  viruses  (strain  A/WSN/33)  can  replicate  to 
similar  levels  in  IFN-deficient  systems  (Garcia-Sastre  et  al.,  1998).  Garcia-Sastre 
and colleagues  speculated that the NS1  protein has the ability to  sequester dsRNA 
and  thereby  blocks  IFN-a/p  induction  (Talon  et  al.,  2000).  However,  the  dsRNA 
binding capacity could serve multiple purposes as the sequestration of dsRNA could 
explain the NS1-mediated inhibition of dsRNA binding proteins  such as PKR and 
2’5’OAS (Bergmann et al., 2000; Hatada et al.,  1999; Lu et al.,  1995; Min and Krug,
2006).  Two  point  mutations  in  the  dsRNA  binding  site  in  the  NS1  protein  of 
Influenza A/WSN/33 (NS1  R38A, K41A) result in greater cytokine production than 
with the wild-type virus (Donelan et al., 2003). A revertant NS1 protein (NS1 R38A, 
K41A, G42S) that lacks dsRNA binding activity inhibits IFN-a/p induction, which 
indicates  that  dsRNA  binding  is  only  one  feature  that  modifies  innate  immune
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responses.  Recent  work  from  Robert  Krug’s  laboratory  suggests  that  the  same 
amino-acid  residues  mutated  in  Influenza  A/Udom/72  inhibit  the  nuclear 
accumulation of NS1, and the authors speculated that this altered cellular distribution 
is the real reason why NS1(R38A, K41A) is inactive (Min and Krug, 2006).
The C-terminus of some NS1  strains impair the post-transcriptional processing and 
nuclear export of cellular pre-mRNAs (Fortes et al.,  1994; Li et al.,  2001) through 
direct  interaction  with the  cleavage  and polyadenylation  specificity  factor  (CPSF) 
(Chen et al.,  1999; Nemeroff et al.,  1998). Un-processed pre-mRNA is not exported 
into the cytoplasm, resulting in diminished IFN-a/p expression (Noah et al., 2003). 
Clearly,  the  NS1  protein  may  serve  different  functions  and  may  be  remarkably 
flexible in its mode of action. However, this activity depends on the influenza virus 
strain the NS1 protein derives from as is highlighted in recent reports (Hayman et al., 
2007; Kochs et al., 2007). Kochs et al.  for instance directly compared NS1  proteins 
of different  virus  strains  and  could  show  that  NSl(A/PR8/34)  is  more  potent  in 
blocking activation of IRF3 than NSl(A/TX/36/91), and that NSl(A/TX/36/91) but 
not NSl(A/PR8/34) has the ability to interfere with mRNA processing (Kochs et al.,
2007).
1.6.  Aim of this thesis
IFN-a/p  clearly  plays  a  major  role  in  antiviral  immunity,  yet  the  mode  of  its 
induction  is  ill  understood.  I  therefore  dedicated myself to  work on  the  following 
two questions, both designed to deepen our understanding of virus sensing:
•  TLR  recognition  takes  place  in  endosomes  and  therefore  I  wanted  to 
understand what role the infection route of a virus has on TLR activation. To 
address  this  I  used  recombinant  lentiviruses  that  were  pseudotyped  with 
glycoproteins that mediate infection via endosomes or fusion  at the plasma 
membrane. Although I did not succeed in answering the original question, I 
found that preparations of lentiviruses pseudotyped with vesicular stomatitis 
virus  glycoprotein  (VSV-G)  are  strong  activators  of  the  innate  immune 
system.  Surprisingly, this does not depend on vims particles but on tubulo- 
vesicular structures that are produced through VSV-G expression. VSV-G on
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the surface of those tubulo-vesicular structures mediates uptake and delivery 
of a TLR agonist into the endosome.
•  dsRNA  is  the  proposed  activator  for  cytoplasmic  PRRs.  However,  ssRNA 
can  induce  IFN-a/p  (Baron  et al.,  1969),  and  some  viruses  do  not  express 
detectable  amounts  of dsRNA.  I  wanted  to  understand  whether  there  are 
cytoplasmic recognition mechanisms that go beyond dsRNA sensing. I found 
that  RIG-I  can be  activated by  single-stranded viral  genomic  RNA bearing 
5’phosphates.  The  NS1  protein  of  influenza-A  virus  counteracts  this 
activation and forms a complex with RIG-I.
1.7.  Figures 
Figure  1.1.1
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Figure 1.1.1:  Innate virus recognition results in IFN production and 
antiviral resistance
Upon virus infection, pattern recognition receptors (PRRs) alert the cell that a virus 
is present and this results in the production of pro-inflammatory cytokines including 
type-I interferon (IFN-a/p). IFN-a/p acts on adjacent cells where it activates the so- 
called  JAK/STAT  pathway  which  increases  expression  of  antiviral  proteins  that 
reduce virus proliferation and virus spread.
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Figure 1.1.2
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Figure 1.1.2: Innate immune recognition controls adaptive 
immunity
An antigen presenting cell (APC), e.g. dendritic cell or B-cell, senses the presence of 
a virus through pattern recognition receptors (PRRs).  This  leads to  APC  activation 
and activated APCs present peptides on MHC-I (green,  1), costimulatory molecules 
(purple, 2) and produce pro-inflammatory cytokines (green dots, 3).  Signals  1, 2 and 
3 are necessary for activation of resting T-cells to gain effector function.
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Figure  1.2.1
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Figure  1.2.1:  IFN-a/p  increases  expression  of  PRRs,  signalling 
molecules and effector molecules
PRRs are activated by viral pathogens and initiate production of IFN-a/p.  IFN-a/p 
increases expression of antiviral proteins like FV/TRIM5a and Mx proteins as well 
as the  signalling molecules  PKR and 2’5’OAS  that modulate the  activity  of eIF2a 
and  RNAse  L,  respectively.  The  latter  proteins  have  the  ability  to  regulate 
translation,  apoptosis  and  RNA  degradation,  as  indicated.  Furthermore,  IFN-a/p 
positively regulates expression of PRRs and signalling molecules thereby increasing 
sensitivity  by  providing  a  positive  feedback  loop.  IFN-a/p  contributes  to  shape 
adaptive immune responses.
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Figure 1.3.4
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Figure 1.3.4: Endosomal TLRs recognise nucleic acid
Viral infection or engulfment for virally infected cells delivers the indicated nucleic 
acid  into  the  endosomal  compartment.  In  pDC  TLR7,  -8  and  -9  recognise  ssRNA 
and  DNA,  respectively,  and  activate  a  MyD88  and  IKKa dependent  signalling 
cascade. This leads to phosphorylation of IRF7 that translocates into the nucleus and 
stimulates  expression  of IFN-a.  In  cDC  TLR9  activation  results  in  signalling  via 
IRF1  and this leads to IFN-|3. TLR3 activation occurs in cDC and signalling goes via 
TRIF  and  involves  TBK1  and  IKKe  which  activate  IRF3  to  induce  IFN-p.  LRR: 
Lecuine rich repeat; TIR: Toll/ILIR domain
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Figure 1.4.1
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Figure 1.4.1: Schematic drawing of RIG-I Helicases
RIG-I  consists  of N-terminal  tandem  caspase  activation  and  recruitment  domains 
(CARD), a helicase domain and a repressor domain (RD). When inactive, the RD is 
believed to bind to the  CARD  and  prevent downstream  signalling.  Binding  of the 
RIG-I agonist results in a conformational change that allows homodimerisation and 
exposes the CARD. MDA5 also has tandem CARDs and a helicase domain but lacks 
the RD. LGP2 only consists of the helicase domain and a RD and lacks a CARD.
H elicase
Page 50Chapter 1 Introduction
Figure 1.4.2
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Figure 1.4.2: RIG-I and MDA5 have different virus specificity
MDA5  is  activated  by  encephalomyocarditis  virus  (EMCV)  whereas  RIG-I  is 
activated by viruses such as influenza (Flu) or Sendai virus (SeV). It is believed that 
virus  replication  is  an  essential  step  to  activate  MDA5  and  RIG-I.  Signalling 
downstream of both RNA helicases funnels through a common signalling molecule 
IPS-1   that  activates  TBK1  and  IKKe.  This  results  in  phosphorylation  and 
translocation  of  IRF3  and  -7,  which  then  stimulate  the  IFN-p  and/or  IFN-a 
promoters, respectively.
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CHAPTER 2:  Material and Methods
2.1.  Reagents
2.1,1.  Common Buffers
PBS-TC: (GIBCO-BRL, Gaithersburg, MD) for Tissue culture 
PBS-EDTA-Trypsin:  PBS-TC  containing  2mM  EDTA  (Sigma,  Poole,  UK)  and 
0.2% (w/v) Trypsin (GIBCO-BRL)
RPMI1640 medium: (GIBCO-BRL)
RIO:  RPMI  1640 medium supplemented with  10% (v/v)  FCS,  Penicillin  lOOU/ml, 
Streptomycin  lOOU/ml,  L-Glutamine  0.3pg/ml  (GIBCO-BRL),  50|xM  (3-
mercaptoethanol (GIBCO-BRL)
DMEM: (Dulbeccos Modified Eagle Medium): (GIBCO-BRL)
DIO:  DMEM  (GIBCO-BRL)  supplemented  with  10%  (v/v)  FCS,  Penicillin 
lOOU/ml, Streptomycin lOOU/ml, L-Glutamine 0.3pg/ml (GIBCO-BRL)
D5:  DMEM (GIBCO-BRL)  supplemented with 5% (v/v)  FCS, Penicillin  lOOU/ml, 
Streptomycin lOOU/ml, L-Glutamine 0.3pg/ml (GIBCO-BRL)
OptiMEM: (GIBCO-BRL)
VP-SFM:  Virus production serum  free medium  (GIBCO-BRL)  was  supplemented 
with L-Glutamine 0.6pg/ml (GIBCO-BRL)
TC-grade agarose:  (Sigma,  Poole,  UK)  solved in TC-grade water (Sigma,  Poole, 
UK) to give a final concentration of 4% (w/v), autoclaved
Red  blood  cell  (RBC)  lysis  buffer:  155mM  NH4CI  (Sigma,  Poole,  UK),  lOmM 
KHCO3  (Sigma,  Poole,  UK),  O.lmM EDTA  (Sigma,  Poole,  UK),  MilliQ  H2O,  pH 
7.0-7.2, sterile filtered
PBS  (For  analytical  assays  only):  8g  NaCl,  0.25g  KC1,  1.43g  Na  2 HPO4,  0.25g 
KH2PO4,  (all  from  Sigma)  dissolved  in  11  H2O,  pH  7.2.  Solution  is  prepared  by 
Cancer Research UK and autoclaved before use
MACS-Buffer: PBS-TC containing 2mM EDTA (Sigma, Poole, UK) and  1% (v/v) 
FCS
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FACS buffer: PBS, 5mM EDTA (Sigma, Poole, UK),  1% (v/v) FCS, 0.02% (w/v) 
NaN3 (Sigma, Poole, UK)
PFA: 8% (w/v) PFA stock solution, pH7
ELISA  buffer:  PBS,  2.5%  (v/v)  FCS  (Autogen  Bioclear),  0.02%  (w/v)  NaN3  
(Sigma, Poole, UK)
ELISA coating buffer: 0.1M NaHC03  (Sigma, Poole, UK) in H20, pH 8.2
PBS-tween: 0.05% (v/v) Tween-20 (Sigma, Poole, UK) in PBS
ELISA wash: 0.05% (v/v) Tween-20 (Sigma, Poole, UK) in PBS
TAE buffer: 0.04M Tris-acetate (Sigma, Poole, UK), 0.002M EDTA (Sigma, Poole,
UK)
ELISA block: PBS, 2.5% (v/v) FCS, 0.02% (w/v) NaN3 (Sigma, Poole, UK)
ELISA coating buffer: 0.1M NaHC03  (Sigma, Poole, UK) in H20, pH 8.2
ELISA wash: 0.05% (v/v) Tween-20 (Sigma, Poole, UK) in PBS
TAE  buffer:  0.04M  Tris-Base  (Sigma,  Poole,  UK),  2mM  EDTA  (Sigma,  Poole,
UK)
2x Laemmli buffer: 20% (v/v) Glycerine, 0.125M Tris-HCl pH 6.8, 2% (v/v) SDS, 
0.02% (w/v) Bromphenol blue
2x western blot sample buffer: Laemmli buffer + 2% (v/v) (3-mercaptoethanol 
Western blot running buffer: 25mM Tris-Base, 250mM Glycine, 0.1% (w/v) SDS, 
pH 8.3
Western blot transfer buffer:  15,15g Tris-Base, 42,75g Glycine H20  ad 4 litre, pH 
8.3, add 20% (v/v) methanol were added before use
DNA  extraction  buffer:  lOOmM  Tris-HCl,  pH  8.5,  200mM  NaCl,  5mM  EDTA, 
0.2% (w/v) SDS and Proteinase K lOOpg/ml (Qiagen, Crawley, UK)
2.2.2.  Tissue culture stimuli
CpG  1668  was  synthesised  by  Sigma:  TCCATGACGTTCCTGATGCT  -   all 
phosphorothioate linked and HPLC-purified.  Loxoribine and R848 were purchased 
from InvivoGen (San Diego, CA). poly-I:C was from Amersham (Uppsala, Sweden). 
Spleen mRNA, Flu vRNA, and in vitro transcribed GFP RNA (transcribed by T7 or 
T3  polymerase, respectively) were a kind gift from  Sandra Diebold.  7SK-as RNA 
(SP6 polymerase) was a kind gift of Choon-Ping Tan. Genomic RNA from VSV was
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a kind gift of Andreas Bergthaler (University of Zurich, Switzerland). poly-U, total 
bovine RNA, bovine t-RNA and E. coli t-RNA were from Sigma. Genomic RNA of 
EMCV was isolated from concentrated virus particles.  Briefly, 4ml of EMCV virus 
stock was ultracentrifuged through 1ml of a 20% (w/v) sucrose cushion in a MLS50 
rotor (Becton Dickinson, Mountain View, CA) at 33.000 rpm for 2h and resuspended 
in  200pl  PBS.  vRNA  was  isolated using  the  Qiagen  RNeasy  RNA  extraction  kit 
according  to  the  protocol  provided  by  the  manufacturer.  siRNAs  for  reducing 
endogenous  levels  of human  and  murine  RIG-I  were  bought  from  Qiagen,  target 
sequences  were  ACGGATTAGCGACAAATTTAA  for  human  RIG-I  and 
CCGGACTTCGAACACGTTTAA for murine RIG-I.
2.1.3.  Plasmids
name features source
pUC19 Plasmid from invitrogen Invitrogen
pCDNA3 Cloning Vector, CMV-MCS-Neo Invitrogen
pEGFP-Cl
Cloning vector, eGFP under control of the CMV 
promoter
Clontech
pCAGGS
Cloning Vector, Chicken (3-actin promoter upfront a 
multiple cloning site
Urs Schneider
pLL3.0
Lentiviral vector, siRNA expression from U6 
promoter, eGFP from CMV
Luc van Paris
pLLCG pLL3.0 without U6 promoter self cloned
pSIN-OVA
Ovalbumin expressed from SFFV promoter in 
lentiviral vector
Mary Collins
pLentiLox 3.7 Lentiviral vector designed for siRNA knockdowns Luc van Paris
pRSV-REV REV expression vector Luc van Paris
pRREg/pMDL HIV-gag-pol expression vector Luc van Paris
pVSV-G
VSV glycoprotein (Indiana strain) expression 
plasmid. CMV-intron-VSV-G
Invitrogen
pCAAGS-LCMV.GP
(ARM)
LCMV glycoprotein (Armstrong strain) in pCAAGS
Daniel
Pinschewer
pCAAGS-THOV.GP
Thogotovirus glycoprotein  (Strain: SiAR129) in 
pCAAGS
Georg Kochs
pMLV-AMPHO Amphotropic murine leukaemia virus envelope Mary Collins
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protein in pFB
pMSCVeGFP Retroviral vector Clontech
pLeGFP-N 1
Retroviral vector expressing GFP from a CMV 
promoter
Clontech
pLNC-VSV-G VSV-G replacing eGFP in pLeGFP-N 1 self cloned
pCAAGS-PR8 NS1  SAM NS1 from Influenza virus (strain PR8) in pCAAGS
Adolpho
Garcia-Sastre
pCAAGS-mutNS 1  
(R38A, K41A)
NS1 with indicated mutations in the dsRNA binding 
domain in pCAAGS, no dsRNA binding
Adolpho
Garcia-Sastre
peGFP-RIG-I huRIG-I-eGFP fusion protein in peGFP-Cl
Friedemann
Weber
peGFP-Helicase
huRIG-I-helicase domain-eGFP fusion protein in 
peGFP-Cl
Friedemann
Weber
pCDNA-MDA5 MDA5 in pCDNA3
Friedemann
Weber
pCDNA-HA-MDA5 HA-tagged hu MDA5 in pCDNA3 self cloned
pl25-luc
Reporter plasmid: IFN-{5 promoter driving firefly 
luciferase
Friedemann
Weber
pRL-TK
Renilla-luciferase driven by Thymidin-kinase 
promoter
Promega
pCMVAR8.91 2nd Generation HIV-gag-pol packaging construct Mary Collins
I  am grateful to those who provided constructs:  Luc van Parijs  (MIT,  Cambridge, 
MA,  USA),  Mary  Collins  (University  College  London,  UK),  Daniel  Pinschewer 
(University  of  Zurich,  Switzerland),  Adolpho  Garcia-Sastre  (Mount  Sinai,  New 
York, USA) and Urs Schneider, Georg Kochs, Friedemann Weber (all University of 
Freiburg, Germany).
2.1.4.  DNA oligos (Primers)
All primers listed below were purchased from Sigma.
primer name sequence
5’ VSV-G GAAGTGCCTTTTGTACTTAG
3’ VSV-G GATCGGATGGAATGTGTTAT
5’ eGFP(APl) GGCCACAAGTTCAGCGTGTC
3’ eGFP(APl) TTGCCGTCCTCCTTGAAGTC
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5’ HIV 1-gag GCAGTTAATCCTGGCCTGTT
3’ HIV 1-gag GTGGCTCCTTCTGATAATGC
5’ HIVl-pol TCAGAAGCAGGAGCCGATAG
3’ HIVl-pol TGCAGCCAATCTGAGTCAAC
5’ integrated LV GGAGCT  AGAACGATTCGC  AGTT A
3’ integrated LV GGTTGTAGCTGTCCCAGTATTTGTC
5’ p-actin GTTTGAGACCTTCAACACCCC
3’ P-actin GTGGCCATCTCCTGCTCGAAGTC
5’ HA-huRIG-I GACAATGTATCCTTATGATGTTCCTGATTATGCTACCACCGA
GCAGCGACGCAGCCT
3’ SI-huRIG-I GACAGTCGACTCATTTGGACATTTCTGCTGGATCAAA
T7 seq primer TAATACGACTCACTATAGGG
5’ huRIG-I 1222-ds CTGACTGCCTCGGTTGGTGT
5’ huRIG-I 1839-ds CCTCTGCTTCATCTTACAAG
5’ HA-huMDA5 GACAATGTATCCTTATGATGTTCCTGATTATGCTTCGAATGG 
GT  ATTCCACAG  ACGAGA  ATTT
3’ MDA5 GACACTAATCCTCATCACTAAATAAACAGCATTCTGAAT
2.1.5.  Antibodies for western blot
Primary antibodies
antibody (clone) isotype source dilution
anti-VSV-G (P5D4) msIgGl Cancer Research UK 1:1000
anti-GFP (3E1) msIgGl Cancer Research UK 1:2000
anti-P-actin (AC-15) ms Sigma 1:1000
bt anti-HIVp24 (BC1071- 
BIOT)
ms AALTO Bio Reagents LTD 1:1000
anti-NSl (1A7) msIgG2a Jon Yewdell IP
btanti-NSl (1A7) msIgG2a Cancer Research UK 1:1000
anti-Tubulin (TAT-1) ms Cancer Research UK
HRP anti-HA (HA7) ms Sigma 1:5000
anti-influenza A (H1N 1) 
virus
gt Europa Bioproducts Ltd. 1:1000
Secondary antibodies and reagents
HRP anti-ms gt Santa Cruz Biotechnology 1:5000
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HRP anti-rb gt Southern Biotech 1:5000
HRP-Streptavidin Sigma 1:2500
anti-gt ms Jackson ImmunoResearch 1:1000
2.1.6.  Antibodies and protein standards for ELISA
Step antibody (clone) Isotype source dilution
IFN-a ELISA
Coating
anti-mIFN-a 
(clone FI8)
rtlgGl
Hycult
Biotechnologies
1:200
Detection
ABs
anti-IFN-a rb polyclonal PBL 1:5000
anti-rabbit biotin ms mAB
Jackson
ImmunoResearch
1:1000
IL6 ELISA
Coating
anti-IL6
(MP5-20F3)
rtlgGl BD Pharmingen 4pg/m
Detection
AB
biotin anti-IL6 
(MP5-32C11)
rt mAB BD Pharmingen 1  pg/ml
HIV p24 ELISA
Coating
anti-HIV-l-p24 
(D7320)
sheep
polyclonal
AALTO BIO 
REAGENTS LTD
5pg/ml
Detection
AB
biotin anti-HIVp24 
(BC1071-BIOT)
ms mAB
AALTO BIO 
REAGENTS LTD
1:1000
anti-OVA serum antibodies
Coating Ovalbumin protein Calbiochem 5pg/ml
Detection
AB*
biotin anti-msIgG rt mAB
Jackson
ImmunoResearch
1:1000
anti-FCS serum antibodies
Coating ELISA buffer protein
2% (v/v) 
FCS
Detection
AB*
biotin anti-msIgG rt mAB
Jackson
ImmunoResearch
1:1000
* reagents diluted In 1% (w/v) fish skin gelatine (FSG) in PBS
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The following protein standards were used for ELISA
protein Source top concentration
recombinant mIFN-a Hycult Biotechnologies 10.000 Units/ml
recombinant mIL6 5ng/ml
recombinant HIVp24 AALTO BIO REAGENTS LTD lOOng/ml
2.1.7.  Antibodies and reagents used  for Flow cytometry
antibody (clone) isotype source dilution
anti-CD llc-PE (HL3) Hamster IgGl
anti-CD llc-APC (HL3) Hamster IgGl
anti-CD 1  lb-APC (Ml/70) rat IgG2b
anti-B220 (CD45R)-TC rat IgG2a
Pharmingen 
(Becton-Dickinson, 
Oxford, UK)
anti-Ly6C (GRl)-FITC rat IgM
1:100
anti-CD8-TC rat IgG2b
anti-IFN-y-PE rat IgGl
anti-CD45.1-PE ms IgG2a
anti-CD4-FITC
(RM4-5)
rat IgG2a
anti-VSV-G (P5D4) mouse IgGl Cancer Research UK 1:100
anti-mlFNa  (RMMA-1) rat polyclonal
PBL Biomedical 
Therapeutics
1:50
anti-mlFNa (FI8) rat IgGl HyCult Biotechnology 1:10
unspecific rat IgG
Jackson
ImmunoResearch
anti-ms-IgG-Alexa546 gt polyclonal Molecular probes 1:200
YOYO-1 Nucleic acid stain Molecular Probes 1:1000
Streptavidin-APC Conjugate Pharmingen 1:200
OVA/H2-Kb-PE
SIINFEKL-tetramer 
PE conjugated
2.1.8.  Antibodies used  for virus neutralisation
antibody (clone) isotype source dilution
anti-VSV-G (VA-7) rt IgG Andreas Bergthaler 1:25
unspecific rt IgG Jackson ImmunoResearch 1:25
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2.1.9.  Antibody used  for confocal microscopy
antibody (clone) isotype source dilution
anti-NSl-Cy3 (1A7) ms IgG2a Oliver Schulz 1:100
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2.2.  Cells and mice
2.2.7.  Cell lines
293FT were from Invitrogen (Invitrogen,  Paisley,  UK),  293T and STAR-HV cells 
(Ikeda et al., 2003) were a kind gift from Mary Collins (University College London, 
UK).  GP293  (retroviral  packaging  cells)  were  from  Clontech  (Clontech,  Becton- 
Dickinson, Oxford, UK). 293-HV cells were generated through infection with VSV- 
G LV produced in STAR-HV cells and subsequent FACS  sorting for GFP positive 
cells.  NIH3T3  fibroblasts  were  kindly  provided  from  Richard  Treisman  (Cancer 
Research  UK,  London,  UK).  All  cell  lines  were  grown  in  DIO  medium,  were 
maintained at 37°C, 5% CO2 and split regularly to constantly grow in a logarithmic 
phase.
2.2.2.  Mice
C57BL/6 were purchased from Charles River.  tlr9'A, tlrTf' mice (a kind gift
from  S.  Akira,  Osaka,  Japan) RAG2~/~   and  B6.SJL  CD45.1  mice  were bred at the 
Biological  resources  facility  of Cancer  Research  UK  (Clare  Hall,  South  Mimms, 
UK). All mice were used at an age of 6-10 weeks.
2.2.2.  Isolation of  splenocytes
Spleens  were  removed  under  aseptic  conditions  and  collected  in  RPMI  1640 
medium.  Thereafter  individual  spleens  were  injected  with  1ml  of  RPMI  1640 
medium  containing  Liberase  (1.67  WiinschU/ml,  Boehringer  Mannheim)  and 
DNAse  I  (0.2mg/ml,  Boehringer  Mannheim)  and  incubated  at  37°C  for  20-30 
minutes.  The  digested  spleens  were  passed  through  a  70pm  cell  strainer  (Becton 
Dickinson,  Oxford, UK),  if necessary cells were released through extrusion with a 
syringe  plunger  followed  by  several  washes  with  PBS-EDTA.  Splenocytes  were 
collected by  spinning  at  1500  rpm  in  a  Beckman  Allegra  6R  centrifuge  at  room 
temperature for 5min and re-suspension in an appropriate buffer or growth medium. 
One spleen yields approx 108 cells
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2.2.4.  Bone Marrow isolation
Mice femurs and tibias were removed under sterile conditions and bone marrow was 
flushed  out  with  RIO  medium  using  a  23G  needle  syringe.  The  resulting  cell 
suspension was strained through a 70pm cell sieve, subjected to red blood cell lysis 
and used at a concentration of 5*106/ml if not indicated otherwise.
2.2.5.  Red blood cell lysis (RBC-lysis)
Splenocytes or BM cells were pelleted, resuspended in  10ml RBC-lysis buffer and
incubated  for  lmin.  After  adding  10ml  RIO  cells  were  again  pelleted  and 
resuspended in an appropriate volume of the medium used for further experiments 
(RIO if not indicated otherwise).
2.2.6.  Production of GM-CSFDC
BM cells that underwent RBC-lysis were resuspended in 10ml RIO, plated in a 10cm 
TC  plate  (Falcon,  BectonDickinson,  Oxford,  UK)  and  incubated  at  37°C  for  30 
minutes.  Non-adherent  cells  were  recovered  into  30ml  R10  supplemented  with 
granulocyte and monocyte colony stimulating factor (GM-CSF) (dilution  1:20.000) 
(made by the Cancer Research UK protein purification service, batches were tested 
to be endotoxin free and titrated to give optimal growth conditions for BM-DCs) and 
equally  distributed  in  one  sixwell  plate  (Falcon,  BectonDickinson,  Oxford,  UK). 
After 48hrs incubation at 37°C, 5% CO2, 2.5ml of medium was removed from each 
well and replaced with fresh R10 supplemented with GM-CSF. Cells were incubated 
over  night  at  37°C,  5%  CO2.  The  next  day  90%  of  the  medium,  containing 
nonadherent  and  loosely  adherent  cells,  was  removed  and  the  remaining  cells, 
consisting  of  an  adherent  macrophage-like  population  and  small  round  DC 
progenitors,  supplemented with  5ml  of R10  containing  GM-CSF.  DC  were  either 
used at day 4 (evening) or at day 5.
2.2.7.  Production of Flt-3L DC
BM  cells  that  underwent  RBC-lysis  were  resuspended  in  R10  to  give  a  final 
concentration of 1.5*106 cells/ml. This cell suspension was supplemented with Flt- 
3L (R&D, Minneapolis) at a final concentration of 0.5pg/ml and seeded in six wells
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(5ml/ sixwell cavity). Cells were maintained at 37°C,  5% CO2. 90% of the medium 
was changed  at day  5  and day  8.  The purity  of the  culture was tested at  day  10: 
cultures  contained  about  30%  of  pDC  (bearing  surface  markers  CD llcpositlve, 
B220positlve and CD1 lblow ) and were used for further experiments.
2.2.8.  MACS enrichment of B22(fosU ive cells
BM  cells  from  RAG2  deficient  mice  were  MACS  separated  into  B220positlve  and 
B220negatlve fractions to enrich for pDC.  Briefly,  BM cells were labelled with anti- 
CD45R  (B220)  magnetic  MicroBeads  (Miltenyi  Biotech,  Bergisch  Gladbach, 
Germany) according to the protocol of the manufacturer (30pl beads per  107 cells, 
incubated  15min  at  room  temperature,  washed  twice  in  5ml  MACS  buffer)  and 
enriched  using  an  AutoMACS  (Miltenyi  Biotech,  Bergisch  Gladbach,  Germany) 
(Possel program) according to the manufacturer’s instructions.  Enriched cells were 
resuspended in RIO medium and enrichment evaluated by FACS for CD 11c,  B220 
and CD lib.  Importantly, the B220  antibody used for FACS recognises  a different 
epitope than the one used for MACS enrichment.
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2.3.  Viruses
2.3.1.  Production of recombinant lend- and retroviruses:
LVs were produced as follows:  6*106 293FT or 293T cells were seeded in a  10cm 
dish and, at the next day, transfected using Lipofectamine 2000 (Invitrogen, Paisley, 
UK)  as  per  manufacturer’s  instructions  with  pMDLg/pRRE  (5pg),  pRSV-REV 
(5pg),  pLLCG  or pSIN-OVA  (lOpg)  and  the  plasmid  encoding  desired  envelope 
protein  (5pg;  pVSV-G  unless  stated  otherwise).  For  LVs  lacking  the  envelope 
protein  (LVAenv)  the  Env  plasmid  was  omitted.  For  LVs  without  viral  RNA 
(LVAvRNA) pLLCG was omitted.  For control supernatant (SN), all plasmids were 
omitted.
When LV produced by retrovirus infection was compared with LV produced through 
transient  transfection,  SRAR-HV  cells,  that  stably  express  GFP  encoding  LV 
particles without envelope proteins (Ikeda et al.,  2003), were infected with VSV-G 
encoding retrovirus (see below) or transfected with pVSV-G (5pg).
16  to  24h  after  transfection  or  retroviral  infection,  cells  were  washed  and  fresh 
medium  was  added.  Supernatant  was  collected  at  48,  60  and  72  hours  after 
transfection,  filtered  through  a  0.45pm  Millex-HV  filter  (Millipore,  Carrigwohill, 
Ireland) and stored at -80°C.
Before use, supernatants were pooled and concentrated through a 20% (w/v) sucrose 
cushion using an ultracentrifuge (Becton Dickinson, Oxford, UK) (85.000 g,  1.5h in 
a SW28 rotor).
To produce retrovirus-encoding VSV-G three  10cm dishes containing 6x106 GP293 
cells were used. Each plate was transfected with pLNC-VSV-G (lOpg) and pVSV-G 
(5pg).  Supernatant  was  harvested,  filtered  through  a  0.45pm  Millex-HV  filter 
(Millipore,  Carrigwohill,  Ireland),  concentrated  10-fold  by  ultracentrifugation  and 
used to infect one 10cm plate containing 6xl06 STAR-HV cells.
For  LV  fractionation,  a  20  -   60%  (w/v)  sucrose  gradient  was  used.  Briefly,  a 
gradient mixer was installed at a stirring plate (8000rpm/min) and the outlet tubing 
connected to a gradient maker. Thereafter the mixer was filled with 6.5ml 20% (v/v)
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sucrose  at  the  outlet  side  and  6.5ml  60%  (v/v)  sucrose  at  the  non-outlet  side, 
respectively. The gradient maker slowly (approx lml/min) poured the mixed sucrose 
into  a  15ml  ultracentrifugation  tube  (Ultraclear,  Becton  Dickinson,  Oxford,  UK). 
Supernatant containing 4xl08  infectious viruses  was loaded on top  of the gradient 
and centrifuged in a SW40 Ti rotor (Becton Dickinson,  Oxford,  UK)  at  85.000 g, 
4°C  for  16  h.  1.5ml  fractions  were  collected,  diluted  in  PBS  and  centrifuged  for 
another  1.5h (SW40 Ti, 4°C,  85.000 g).  Pellets were resuspended in R10 and used 
for further analysis
2.3.2.  Virus isolates
EMCV,  SFV and phage dsRNA (BRL  5907) were a kind gift of Ian Kerr (Cancer 
Research UK, London, UK).  Influenza virus (strain influenza A/PR/8/34) and delta 
NS1  influenza  virus  (FluANSl)  were  a  gift  from  Thomas  Muster  (University  of 
Vienna, Vienna, Austria). SeV was purchased from LGC Promochem/ATCC.  Cells 
infected  with  VSV  (New  Jersey  strain)  were  a  kind  gift  of  Yasu  Takeuchi 
(University College London, UK).
2.3.3.  Infections with viruses and blocking with
neutralising antibody
Viruses were diluted to infect cells at the MOI indicated in the figure legends. With 
the exception for plaque assays on Vero cells the medium was not changed before or 
after infection as this commonly resulted in detachment of cells.
The  neutralizing  anti-VSV-G  antibody  (clone  VA7)  (Bachmann  et  al.,  1997)  was 
incubated  with  TVS  preparations  or  CpG  and  used  in  a  final  titre  of  1:32000  as 
assessed in  a VSV inhibition assay.  After 30min treatment,  viruses were added to 
BM and accumulation IFN-a was tested after over night incubation.
2.3.4.  Blocking infection of  LV with weak bases
293FT  cells  were  seeded  at  a  density  of 5*105  cells/sixwell  and  pre-treated  with 
OmM,  lOmM  and  25mM  ammonium  chloride  (NH4CI)  for  lh.  Cells  were  then 
washed with PBS and infected for lh with the indicated viruses. Medium containing
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ammonium chloride was again added for over night incubation.  At 24h cells were 
analysed by flow cytometry.
2.3.5.  Titration of lentiviruses
Lentivirus titre was determined by transduction of 293FT cells. Briefly, 5*105  cells 
were  seeded into  a  sixwell plate,  left over night to  adhere  and then  infected with 
dilutions of the desired virus. 48h later cells were analysed by FACS and the number 
of GFP positive cells determined. One infectious virus can transduce one 293T cell. 
For  GFP  expressing  LV  the  virus  titre  was  measured  and  is  depicted  as  green 
fluorescent units/ml (gfu/ml). To determine the vims titre the following formula has 
been used:
% GFP pos cells * number of cells infected
Vims titre/ml (gfu/ml) =  --------------------------------------------------------
100 * dilution of vims used for infection
Non-infectious vims (LVAenv and LVAvRNA) was quantified by ELISA for HIV 
p24 according to the protocol provided by the manufacturer (AALTO Bio Reagents 
LTD, Dublin, Ireland). Infectious vims of known gfu was used as a standard.
2.3.6.  Titration of cytopathic viruses 
Plaque assay
EMCV and SFV were titrated by plaque-assay on Vero cells as follows: Vero cells 
were seeded at a density of 2.5  to 5*105  per sixwell  cavity and infected  for  lh at 
37°C with 500pl of 10 fold dilutions of the vims stock. Thereafter the vims soup was 
removed and cells covered with a mixture of hot 2.5ml TC-grade agarose (Sigma, 
Poole, UK),  10ml pre-warmed D5 and 15ml pre-warmed DMEM medium. Agarose 
was  allowed to polyermerise at room temperature  for  15  minutes  and plates were 
incubated until clearly visible plaques appeared (24h for EMCV and 48h for SFV). 
Plaques  were  counted  and  virus  titre  was  determined  as  plaque-forming  units/ml 
(pfu/ml) follows:
number of plaques * 2
Vims titre/ml (pfu/ml) =  -------------------------------------------------
dilution of vims used for infection
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TCID50
Influenza virus was titrated by TCID50.  Vero cells were resuspended in VP-SFM 
and seeded at a density of 104 cells per cavity 96-well plate. 24h later the virus stock 
of interest  was  serially  10-fold  diluted  in  VP-SFM  containing  1  jig/ml  TC-grade 
trypsin.  Addition  of trypsin  is  necessary  in  tissue  culture  to  cleave  and  thereby 
activate the hemagglutinin protein of Influenza virus.  lOOpl of virus dilutions were 
used  to  infect  Vero  cells.  Infections  were  done  in  quadruplets  if  not  indicated 
otherwise. 3-4 days later, when cytopathic effects were clearly visible, the cells were 
or were not stained with giemsa stain (Cancer Research UK) and the virus titre was 
determined using the following formula:
1
Virus titre/ml (TCID50/ml)=10*10y  y = -log (X0) - 0.5 + ( --------* J  X * 1)
n
n = number of wells infected per dilution
Xo = last dilution causing cytopathic effect (cpe) in all wells
X ^ 1  = Sum of wells with cpe after Xo
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2.4.  Tissue culture techniques
2.4.1.  Transfection
Lipofection was commonly used to deliver nucleic acids into cells. Fibroblasts were 
seeded the day before transfection to allow attachment. To prepare the transfection 
reaction,  5ml  polystyrene  tubes  (Becton  Dickinson,  Oxford,  UK)  were  used.  The 
indicated  amount  of  Lipofectamine  2000  (see  table  below)  was  incubated  with 
OptiMEM at room temperature for 5 minutes and then pooled with nucleic acids pre­
diluted in OptiMEM. The following table shows the amount of reagents and nucleic 
acids used:
Tissue culture vessel/ 
number of cells
OptiMEM + 
LF2000
OptiMEM + 
DNA
OptiMEM + 
RNA
96 well cavity 
104- 2 x 105
50 + 0.5pl not done 50 + 
0.004 -  0.5pg
24 well cavity 
5 x 104- 1  x 106
100+ 1  pi 100 + 
0.25 -  0.8pg
100 + 
0.004 -  lpg
6 well cavity 
5 x 105- 2 x 106
500 + 5 pi 500 + 
0.5-lp g
not done
10cm dish 
6 x 106- 1  x 107
1500 + 30pl 1500 + 
6 -  25pg
not done
The  combined mixture was  incubated for another  5-15  minutes  and then  added 
dropwise to cells.  16-72h later transfected cells were used for experiments.
2.4.2.  Electroporation
Electroporation was used to introduce poly-I:C into BM cells.
BM cells were washed 2 times in  lx electroporation buffer (120mM KC1; 0.15mM 
CaCl2;  lOmM K2HP04, pH 7.6; 25mM Hepes, pH 7.6; 2mM EGTA, pH 7.6; 5mM 
MgCl2;  pH adjusted with KOH).  Cells were resuspended in 200pl  lx intracellular 
buffer containing 2mM ATP (stock  solution  50mM ATP, pH  7.6,  sterile  filtered),
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glutathione  (final  concentration  1.6mg/ml)  and  lOpg/ml  poly-I:C.  2*107  cells  per 
sample  were  transferred  into  an  electroporation  curette  (Equibio  ECU-104)  and 
pulsed with  300V /  150pF  using  a  BioRad  electroporator.  Cells  were  transferred 
immediately into a 96-well plate containing growth medium. The final concentration 
of cells was 106 cells/well.
2.4.3.  Reporter assays
A dual luciferase reporter assay was used to measure activity of the IFN-(3 promoter. 
The  assay  is  based  on  expression  of two  enzymes  that  have  different  substrate 
specificity and can be measured separately. One enzyme (firefly luciferase) is under 
control  of the  promoter  of interest  (IFN-(3  promoter)  whereas  the  other  enzyme 
(renilla  luciferase)  is  controlled  by  a  constitutively  active  promoter  (Thymidine 
kinase promoter). The ratio of both activities gives clues on the activation status of 
the promoter of interest.
Briefly,  2*105  293HEK  cells  or  5*104  3T3  cells  were  seeded  per  cavity  24-well 
plate.  After over night  incubation,  cells  were  transfected  as  described  above  with 
250ng of the reporter plasmid pl25-luc (IFN-|3 promoter driving firefly luciferase) 
and 25ng the control plasmid pRL-TK (Thymidine kinase promoter driving renilla 
luciferase).  Where  necessary,  siRNAs  for  RIG-I  (final  concentration  lOOnM)  or 
500ng of pCAAGS-NSl  and pCAAGS-mutNSl, respectively, or plasmids encoding 
dominant negative RIG-I or empty vector were co-transfected. Cells were incubated 
for  16-72h and were mock treated, infected with viruses or transfected with RNAs 
using Lipofectamine 2000. Luciferase activity was measured  14-16h later using the 
Dual-luciferase Reporter assay system (Promega, Southampton, UK). For that, cells 
were  lysed  in  lOOpl  lx  Passive  lysis  buffer  (Promega,  Southampton,  UK)  and 
incubated at room temperature for 15min. 20pl of cell lysate was pipetted into a 96- 
well  plate  and  analysed  in  an  Envision  96-welll  plate  Luminometer  (Promega, 
Southampton, UK). First, 50pl of firefly luciferase substrate was added to measure 
the activity of firefly luciferase (equivalent to IFN-p reporter activity), then renilla 
values were determined by adding 50pl stop and glow substrate. Results are shown 
as fold induction of the ratio between firefly activity and renilla activity as compared 
to mock-treated control samples
Page 68Chapter 2 Material and Methods
2.5.  Molecular Biology
2.5.1.  RNA extraction and reverse transcription
RNA  extraction  using  the  RNeasy  mini  kit  (Qiagen,  Crawley,  UK)  and  an  on- 
column DNAse-I (Qiagen, Crawley, UK) digestion was performed according to the 
instructions  given  by  the  manufacturer.  Where  necessary  RNA  was  reverse 
transcribed  using  Superscript  II  reverse  transcriptase  (Invitrogen,  Paisley,  UK) 
according  to  the  manufacturer’s  protocol.  Briefly,  20pl  extracted  RNA  was 
incubated with lOpM random hexamer primers (Invitrogen, Paisley, UK) at 65°C for 
5 minutes. The mixture was put on ice for 2min and 18 pi of a master-mix containing 
2pl  lOmM dNTP (Promega,  Southampton, UK),  8pl  5x first strand buffer (part of 
Superscript II kit, Invitrogen, Paisley, UK), 4pl of 0.1 M DTT (part of Superscript II 
kit,  Invitrogen,  Paisley,  UK),  3.5pi of H2O and 0.5pi  Superscript II  was added to 
each tube. The mixture was incubated in a PCR machine at 42°C for lh followed by 
a denaturation step at 70°C for 15 minutes.
2.5.2.  Dephosphorylation of  RNA
For  some  experiments  purified  RNAs  were  subjected  to  mock  or  5’- 
dephosphorylation  using  calf intestinal  phosphatase  (CIP)(New  England  Biolabs, 
Ipswich,  UK).  2-10pg  of  RNA  was  incubated  in  a  total  volume  of  lOOpl  of 
NEBuffer 3 (lx) in the absence (NoCIP treated) or presence (CIP treated) of 20 units 
of CIP. The incubation was carried out at 37°C for 3-6h. Thereafter the enzyme was 
removed  by  phenol/chloroform  extraction  followed  by  RNA  precipitation  with 
sodium acetate/ethanol or by using the RNeasy RNA extraction kit.
2.5.3.  DNA extraction from cells and virus preparations
LV preparations (35pl) and cells pelleted by centrifugation (106 cells), respectively, 
were  resuspended  in  500pl  DNA  extraction  buffer  and  incubated  at  55°C  in  a 
shaking heating block for 2h (LV preparations) or  16h (cells). 500pl of Isopropanol 
was added and the mixture incubated for 30min on dry ice.  DNA was pelleted by 
centrifugation for 30min at 13.000rpm, 4°C, in an eppendorf benchtop centrifuge and
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washed once with 500pl 70% (v/v) EtOH.  The resulting DNA pellet was air-dried 
and resuspended in 20pl (LV) or lOOpl (cells) TE-buffer.
2.5.4.  Polymerase chain reaction (PCR)
PCR reactions were performed using Taq polymerase (Cancer Research UK) or, for 
cloning  purposes,  PWO  polymerase  (Roche,  Mannheim).  lOx  PCR  buffer  (PWO 
polymerase kit, Roche, Mannheim) and dNTPs (Promega,  Southampton, UK) were 
used as follows:
PCR cloning-PCR
dNTPs (lOmM) 0.75 pi 1.25 pi
FW-primer (1 OpM) 0.3pl 0.5pl
RV-primer (lOpM) 0.3pl 0.5pl
Buffer lOx 3pl 5pl
Polymerase Taq 0.2pl PWO 0.5pl
Template ~ 200ng ~ 200ng
h 2o ad 30pl ad 50pl
DNA and cDNA were amplified using the following program:
Step nr Description Temperature Duration
1 Denaturing 96°C 2min
2 Denaturing 96°C 30s
3 Annealing 55°C 30s
4 Extension 60°C 2min
5 Return to step 2, 29 times
6 Cool 4°C Forever
PCR reactions were analysed on a 1% (w/v) agarose gel.
2.5.5.  Sequencing of  plasmids
DNA  sequencing  was  done  at  the  Cancer  Research  UK  sequencing  facility.  The 
sequencing reaction mix contained 8 pi of BigDye Terminator mix v3.1  (provided by
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Cancer Research UK), the sequencing primer (equivalent of 3.2pmol),  150-300ng of 
plasmid and H2O ad 20pl.
Following program was used for the PCR reaction:
Step nr Description Temperature Duration
1 Denaturing 96°C lmin
2 Denaturing 96°C 30s
3 Annealing 50°C 15s
4 Extension 60°C 4min
5 Return to step 2, 24 times
6 Cool 4°C Forever
DNA was precipitated by adding 2pl  125mM EDTA, 2pl 3M NaAC and 50pl EtOH 
(100%)  and spinning at 2500 rpm in an eppendorf benchtop  centrifuge  for 20min. 
After washing once with  lOOpl  70%  (v/v)  EtOH the pellet was  dried and handed 
over to the sequencing facility.
2.5.6.  Cloning of  plasmids
To  generate  a  lentiviral  vector  coding  for  eGFP  under  the  control  of  a  CMV 
promoter (pLLCG), the Xbal -  Xhol fragment of pLentiLox 3.7, containing the U6 
promoter,  was  excised  and  circularised  using  the  quick  ligation  kit  (Qiagen, 
Crawley, UK).
pLNC-VSV-G,  a retroviral vector expressing VSV-G,  was generated by  replacing 
the eGFP gene in pLeGFP-N 1   with VSV-G. Briefly, pLeGFP-N 1   was cut with Clal 
and Hindlll.  The backbone fragment was circularised after blunting the overhangs 
using Klenow fill-in. The resulting plasmid was cut by Bgl-II, dephosphorylated and 
ligated to the VSV-G encoding BamHI fragment of pVSV-G.
HA-MDA5  and  HA-RIG-I  were  cloned  from  cDNA  of human  293T  cells  (HA- 
MDA5)  or  peGFP-RIG-I  (HA-RIG-I)  and  ligated  into  pCDNA3  using  TOPO- 
cloning.
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2.5.7.  Restriction Enzyme digests
For  cloning purposes  or  to  test  the  integrity  of plasmids,  restriction  digests  were 
performed.  Restriction  enzymes  and  buffers  were  purchased  from  New  England 
Biolabs (NEB, Ipswich, UK) and used according to the manufacturer’s instructions. 
Briefly, 0.5-3 pg of plasmid was added to a mix containing 2-10 Units of enzyme in 
the appropriate buffer. The restriction reaction commonly had a final volume of 20pl 
(0.5pg DNA) for test digestions or 80pl (3pg DNA) for cloning purposes and was 
incubated at 37°C for 3h.
2.5.8.  Gel Electrophoresis
TAE-Buffer was supplemented with  1% (w/v)  agarose  and melted by heating in a 
microwave oven.  1  pg/ml ethidium bromide (Sigma, Poole, UK) was added and the 
solution  was  poured  into  a  gel  tray  equipped  with  an  appropriate  comb.  After 
polymerisation of the gel, the tray was transferred into a running chamber (BioRad, 
Hemel Hempstead, UK) containing TAE buffer and DNA, supplemented with DNA 
loading Buffer (Sigma, Poole, UK) to a final  lx concentration, was loaded into the 
slots. Gels were commonly run with a current of 100-120 for lh.
When  staining  agarose  gels  with  acridine  orange  1%  (w/v)  agarose  gels  (without 
ethidium  bromide)  were  run  as  described  above.  Staining  of  nucleic  acid  was 
accomplished using 30pg/ml Acridine orange in a final volume of 150ml  1% (w/v) 
NaHCC>3 for 15 min. Thereafter the gel was de-stained by rinsing in hot tap water for 
2h. Nucleic acid was visualised on a UV transilluminator and a picture taken using a 
Dimage Xt digital camera (Minolta, Tokyo, Japan). The blue channel, showing the 
UV  bulbs  of  the  transilluminator,  was  removed  electronically  using  Adobe 
Photoshop.
2.5.9.  Extraction of  DNA from agarose-gels
After size-separation of the DNA by agarose-gel electrophoresis, the DNA fragment 
of the appropriate size was excised using a sterile scalpel. DNA was purified from 
the gel slice using the Qiagen gel extraction kit (Qiagen, Crawley, UK) according to 
the manufacturer’s instructions. DNA was eluted from the column in 20pl TE buffer.
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2.5.10.  Klenow fill-in
Overhangs after restriction digests were filled up by using the large subunit of DNA 
polymerase-I  (Klenow)  (NEB,  Ipswich,  UK).  For  that,  DNA  fragments  were 
resuspended in a buffer containing a final concentration of lx NEBuffer 2 and 33pM 
dNTPs (Promega, Southampton, UK). 5 units of DNA polymerase-I were added and 
the mixture incubated for 15min at 25°C, followed by a denaturation step at 72°C for 
20min.
2.5.11.  Dephosphorylation of  DNA
In order to remove phosphates on the 5’  terminus,  lpg DNA was diluted in a total 
volume of 18pl of lx shrimp alkaline phosphatase buffer and incubated with 2pl of 
shrimp alkaline phosphatase (NEB, Ipswich, UK) for  lh at 37°C. To inactivate the 
enzyme the mixture was heated to 65°C for  15min and the DNA was directly used 
for further cloning applications.
2.5.12.  Ligation of  DNA fragments
DNA fragments were ligated using the QuiaQuick ligation kit (NEB, Ipswich, UK) 
according to the protocol of the manufacturer.
2.5.13.  TOPO-cloning
TOPO-cloning was performed using the pcDNA3.1/V5-His©TOPO®TA cloning kit 
(Invitrogen,  Paisley,  UK)  according  to  instructions  provided  by  the  manufacturer. 
Briefly,  PCR reactions  or  blunted  DNA  fragments  were  separated  by  size  on  an 
agarose gel and the DNA fragment corresponding to the size of the gene of interest 
was excised from the agarose gel with a sterile scalpel. DNA was released from the 
gel  slice  using  the  Gel  extraction  kit  (Qiagen,  Crawley,  UK)  according  to  the 
instructions of the manufacturer. Appropriate amounts of 10 x PCR Buffer, dATP (to 
a final concentration of 0.2nM) and 0.5pl Taq polymerase (Cancer Research UK) 
were added and the mixture incubated at 72°C for 15min. 2pl of the resulting PCR- 
ffagment containing adenine overhangs was added to 3pl of the T/A cloning buffer, 
incubated  with  0.5pl  of the  T/A  cloning  vector  for  5min  and  transformed  into 
competent bacteria.
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2.5.14.  Transformation of competent E. Coli
l-10pl of plasmid DNA  solution was  added to  20-50pl  of ice-cold DH5a (Top 10 
one shot) competent cells (Invitrogen, Paisley,  UK)  in a  1.5ml eppendorf tube and 
incubated on ice for 30-60min.  The bacteria were heat-shocked by transferring the 
tube into a 42°C heating block for 60s and then put on ice for an additional 2min. 
200pl  SOC  medium  (Invitrogen,  Paisley,  UK)  was  added  and  the  suspension 
incubated in a heating block at 37°C for 30-60 minutes under constant shaking (500 
rpm). Bacteria were plated on LB-agar plates containing an appropriate antibiotic for 
selection  (Ampicillin  or  Kanamycin,  both  50pg/ml).  Plates  were  incubated  over 
night at 37°C.
2.5.15.  Plasmid isolation from bacteria
Single  resistant clones were  isolated from LB-agar plates using  sterile  pipette-tips 
and  incubated  in  2ml  LB  containing  appropriate  antibiotics  (Ampicillin  or 
Kanamycin at 50pg/ml) over night at 37°C on a shaker.  The cells were pelleted by 
spinning 5min at 13000rpm in an eppendorf benchtop centrifuge and plasmids were 
isolated  from  the  resulting  bacteria  pellet  using  the  Qiagen  plasmid  mini-kit 
(Qiagen, Crawley, UK), according to the protocol provided by the manufacturer.
For large-scale plasmid isolation 500pl of the over night culture was added to  150ml 
of LB containing appropriate antibiotics (Ampicillin or Kanamycin at 50pg/ml) and 
incubated over night at 37°C  on a shaker.  Over night cultures were centrifuged at 
3500rpm  for  30min  (Allegra  6R centrifuge,  Beckman-Coulter),  supernatants  were 
discarded  and  plasmids  were  isolated  using  the  PureLink™  HiPure  Plasmid 
Maxiprep  Kit  (Invitrogen,  Paisley,  UK)  following  the  instructions  given  by  the 
manufacturer.
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2.6.  Protein biochemistry
2.6.1.  Western Blot
A western blot is a method to detect a specific protein in a given sample. It uses gel 
electrophoresis to  separate proteins by  size.  The proteins are then  transferred to  a 
membrane, where they can be detected using antibodies specific to the target protein. 
For  western  blotting,  cells  were  lysed  in  lx  passive  lysis  buffer  (Promega, 
Southampton,  UK)  for a minimum of 10 minutes on  ice.  Lysates were  spun in an 
eppendorf benchtop centrifuge at full speed for 5 min.
Concentrated  LV  preparations,  cell  lysates  or  immunoprecipitated  proteins  were 
mixed  1:1  with western blot sample buffer and denatured at 94°C  for 5min.  In the 
meantime  a  10%  Tris-glycine  pre-cast  mini-gel  (Novex,  Invitrogen,  Paisley,  UK) 
was  assembled  in  a  NOVEX  running  chamber  filled  with  western  blot  running 
buffer.  20pl  per  sample  were  loaded  in  each  gel  slot  and  proteins  separated  at  a 
currency of 125 volts for  l-1.5h. Proteins were blotted onto an Immobilon P PVDF 
membrane (Millipore, Carrigwohill, Ireland) using a wet transfer method.  For that, 
the gel was transferred into a gel holder cassette (BioRad, Hemel Hempstead, UK) 
and fitted with a methanol  activated Immobilon P  PVDF membrane and whatman 
filter paper (Millipore, Carrigwohill, Ireland) according to the protocol provided by 
BioRad. The cassette was then assembled in a Mini Trans-Blot cell (BioRad, Hemel 
Hempstead, UK) filled with western blot transfer buffer and a Bio-Ice cooling unit 
(BioRad, Hemel Hempstead, UK). Proteins were blotted for 2-3h at a maximum of 
0.35 ampere.
The  membrane was blocked  in  5%  (w/v)  BSA  or  5%  (w/v)  dried  skimmed  milk 
powder in PBS-tween for 0.5 to 16h at 4°C.
Primary antibodies were diluted in  1% (w/v)  dried skimmed milk powder in PBS- 
tween and incubated with the membrane for l-16h on a shaker. The membrane was 
washed 3-5 times in PBS-tween (5 minutes each wash). Then the secondary reagent, 
diluted  in  1%  (w/v)  dried  skimmed  milk  powder  in  PBS-tween,  was  added  for 
another hour. 3-5 thorough washes in PBS-tween removed unbound antibodies and
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the  streptavidin-conjugate,  respectively.  HRP  was  detected  using  the  Supersignal 
WestPico  Chemiluminsecent  Substrate  (Pierce,  Perbio,  Rockford,  IL).  The 
membrane was wrapped in cling film and used to expose X-ray films  (Amersham, 
Uppsala, Sweden) for 5s to over night. X-ray films were developed in an X-ray film 
developer.
2.6.2.  Immunoprecipitation
For immunoprecipitation,  1-6* 106 293T cells were lysed in PBS containing 1% (v/v) 
Triton,  complete®  protease  inhibitor  cocktail  (Roche,  Mannheim,  Germany), 
orthovanadate  ImM,  NaF  5mM  and  sodium  orthophosphate  ImM  (all  Sigma). 
Lysates were spun in an eppendorf benchtop centrifuge at full  speed  for 5min and 
the  supernatant  incubated  with  GammaBind  streptavidin  sepharose  (Amersham, 
Uppsala,  Sweden)  (50pl  beads  per  sample)  at  4°C  for  1   hour  to  precipitate 
unspecifically  binding  proteins.  Meanwhile,  GammaBind  streptavidin  sepharose 
(50pl beads per sample) was coated with antiNSl  antibody (lOpg/sample) for  lh at 
room temperature on an inverting wheel. Lysates were spun at low speed (1000 rpm) 
for  5min  and  incubated  with  NS1-loaded  GammaBind  sepharose  on  an  inverting 
wheel for 3  hours at 4°C.  Samples were washed five times in ice cold lysis buffer 
diluted  1:5 in PBS. Proteins attached to the beads were extracted using 20pl sample 
buffer and denaturation at 94°C and samples were subjected to western blotting.
2.6.3.  Biotinylation ofNSl antibodies
Purified  NS1  AB  was  incubated  with  biotin  (final  concentration:  1  mg/ml,  final 
volume  500pl)  for  3min,  thereafter  injected  into  a  pierce  dialysis  chamber 
(molecular cut off: 30.000 Dalton) and dialysed against 3 litres of PBS for 2 days at 
4°C. During this period PBS was exchanged twice.
2.6.4.  Enzyme-Linked Immuno Sorbent Assay (ELISA)
ELISA is a method to quantify the concentration of a protein of interest in solution. 
All  ELISAs  were  carried  out  in  MAXISORP  96-well  immunoplates  (Nunc, 
Roskilde,  Denmark)  and all  incubation  steps were  done  in  a humidified chamber. 
Capture  antibodies  or  capture  proteins  were  diluted  in  ELISA  coating  buffer  and
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50pl  added  to  each  well.  Plates  were  covered  with  flexi-lids  (Falcon, 
BectonDickinson, Oxford, UK) and incubated over night at 4°C. Coated plates were 
then  washed  3  times  with  ELISA  wash  buffer  and  blocked  at  4°C  for  1-16h  by 
addition of 200pl ELISA buffer (for cytokine ELIS  As) or 200pl  1% (w/v) fish skin 
gelatine  (FSG,  for detection  of serum  antibodies).  This  step  is  essential  to  reduce 
unspecific  binding  of  proteins  during  the  procedure.  To  detect  FCS-specific 
antibodies,  ELISA  buffer  was  used  for  coating.  Coated  ELISA  plates  were  either 
used directly or stored at minus 80°C until use. The ELISA buffer was discarded and 
50pl  of  serial  dilutions  of  a  protein  standard  and  experimental  samples  (cell 
supernatants or diluted mouse serum) were added per well. Plates were covered with 
flexi-lids and incubated for 2h at RT on a shaker or over night at 4°C. After 4 washes 
with ELISA wash buffer,  50pl per well of the detection antibody (diluent:  ELISA- 
buffer  for  cytokines  and  proteins,  1%  (w/v)  fish  skin  gelatine  in  PBS  for  serum- 
antibodies) was added to the ELISA plate. This step (4 washes,  lh incubation with 
antibody) was repeated for all staining steps during the ELISA procedure.
For detection of biotinlyated antibodies, streptavidin-alkaline phosphatase conjugate 
(ExtrAvidin-AP, Sigma) was used at a dilution of 1:5000 in ELISA buffer (detection 
of cytokines and HIVp24) or 1% (w/v) FSG in PBS (detection of serum-antibodies). 
After streptavidin-alkaline phosphatase incubation for  lh, the plates were washed 6 
times  with  ELISA  wash  buffer  and  lOOpl  of  ELISA  substrate  (Sigma-fast  p- 
Nitrophenyl  Phosphate,  Sigma)  was  added  per  well.  A  SpectraMax  190  ELISA 
reader  (Molecular Devices,  Wokingham,  UK)  was used to  read the  absorbance  at 
405nm after appropriate developing time (lOmin to over night). To analyse the data, 
SoftMax®  Pro  software  (Molecular  Devices,  Wokingham,  UK)  and  Excel 
(Microsoft)  were  used.  Graphs  show  the  average  of  measurements  ±  standard 
deviation  of triplicate  samples.  Only  data  within  the  range  of  the  experimental 
standard curve were used.  The IFN-a/p  ELISA used  in this thesis has a detection 
limit of 30U IFN-a/ml.
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2.7.  Flow cytometry and FACS
Flow  cytometry  is  a  powerful  technique  for  examining  and  sorting  microscopic 
particles suspended in a stream of fluid. It allows analysis of single cells on multiple 
physical  parameters  (defined  by  size  and  granularity)  and  chemical  parameters 
(defined  by  fluorescent  markers).  Fluorescent  activated  cell  sorting  (FACS)  is  a 
specialised type of flow cytometry that allows isolation of homogenous cells from a 
heterogeneous population.
2.7.1.  Surface staining of  DC
To prepare cell suspensions for flow cytometry, cells were washed twice with pre­
cooled FACS buffer.  The antibody or antibody-combination of interest was diluted 
in  50pl/sample  FACS  buffer  and  used  to  stain  the  cells  on  ice  for  30min.  This 
procedure (2 washes and incubation on ice for 30min) was repeated when secondary 
reagents were used.  After the  last staining step  cells were washed  in  FACS buffer 
and data acquired using  a  FACS  Calibur cytometer  (Becton  Dickinson,  Mountain 
View, CA). Data was analysed using FlowJo software (Treestar, San Carlos, CA).
2.7.2.  Intracellular stain for IFN-a in BM
BM cells were left untreated or treated with LV preparations at an MOI of 0.2. After 
3h incubation at 37°C,  10% CO2,  Brefeldin A (Sigma,  Poole,  UK) was added at a 
final  concentration  of 5pg/ml  and  cells  incubated  for  another  3h.  Thereafter  cells 
were harvested, washed once  in PBS and fixed in 4%  (w/v)  PFA for  15min.  After 
fixation, the cells were washed twice in PBS and left in ELISA buffer over night at 
4°C. All following steps were performed using FACS buffer containing 0.1 % (w/v) 
saponin  (Sigma,  Poole,  UK).  Cells  were  washed  once  and  resuspended  in  the 
primary antibody solution containing a mixture of rat anti-IFN-a antibodies (clone 
FI8 (1:10) and RMMA-1  (1:50)). After lh incubation on ice, the primary antibodies 
were washed away thoroughly (2 washes), the secondary antibody (biotinylated ms 
anti-rat-IgG  1:100)  added  and  incubated  for  another  hour.  The  last  staining  step 
consisted of CD1 lc, Ly6C, B220 antibodies and Streptavidin-PE conjugate. After lh
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staining on ice, the cells were washed twice in FACS buffer and analysed in a FACS 
Calibur cytometer.
2.7.3.  Intracellular stain for IFN-y in restimulated CD4 T- 
cells
Splenocytes  were  restimulated  over  night  with  or  without  10%  (v/v)  FCS  and 
Brefeldin A (5pg/ml) was added for another three hours. This was followed by two 
washes in PBS and a fixation step with 4% (w/v) PFA for  15min. After three more 
washes with PBS, cells were resuspended in ELISA buffer for over night incubation 
at 4°C.  Cells were then  washed with  FACS  buffer containing  0.1%  (w/v)  saponin 
and  incubated  for  lh  with  a  FITC  conjugated  CD4  and  a  PE  conjugated  IFN-y 
antibody  (each  1:100  diluted).  Cells were  washed twice  in  FACS  buffer and data 
acquired with a FACS Calibur cytometer.
2.7.4.  Flow cytometric analysis of TVS
TVS could be detected as population with distinct forward- and sideward scatter blot 
properties.  To  analyse TVS,  forward-  and sideward scatter axes had to be  set to a 
logarithmic scale and data needed to be collected with low acquisition speed.
For  staining  TVS  with  antibodies  and  subsequent  FACS,  TVS  preparations  were 
stained with  anti-VSV-G  (clone  P5D4)  or a control  ms  IgGl  (each  lOpg/ml)  and 
then with an Alexa546 conjugated anti-mouse-IgG antibody (1:200).  Each staining 
step (30 min, 4°C, dark) was followed by a wash with 5ml PBS in a MLS50 rotor in 
a benchtop  ultracentrifuge  (Becton  Dickinson,  Oxford,  UK),  33.000  rpm,  4°C,  30 
min. Pellets were resuspended in PBS and analysed using a FACS calibur cytometer. 
To  stain nucleic acid for flow cytometric  analysis LV and TVS  preparations were 
fixed  in  4%  (w/v)  PFA  and  stained  with  YOYO-1  (dilution  1:1000)  for  5min  to 
visualise  nucleic  acid.  YOYO-1  is  a  dimeric  cyanine  nucleic  acid  stain  that 
intercalates into the backbone of nucleic acid and only then gains fluorescent activity 
and emits light at 509nm when excited at 491nm (Molecular probes, Poort Gebouw, 
The Netherlands) (Rye et al.,  1992). Intercalated YOYO-1  can be detected in FL1  of 
the FACS calibur cytometer.
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2.7.5.  FA CS sorting of cells
To  generate  a  homogenous  population  of cells  expressing  the  lentiviral  genome 
(293-HV cells), 293T cells were infected with LV produced in STAR-HV cells and 
GFP  positive  cells  sorted  3  days  later.  Briefly,  infected  cells  were  trypsinised, 
washed twice  in PBS-TC  containing 2%  (v/v)  FCS  and filtered through a 0,45pm 
cell strainer. Cells were then sorted for GFP expression using a FACS Aria (Becton 
Dickinson, Mountain View, CA) by the Cancer Research UK FACS facility.
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2.8.  Confocal and electron microscopy imaging
2.8.1.  Confocal microscopy
HEK293  cells  were  seeded  on  13mm  diameter  coverslips  at  a  density  of 4xl05  
cells/sixwell plate and transfected with GFP-RIG-I the next day. 24h later cells were 
infected with  wild type  influenza  virus.  After another  16h  cells  were  fixed in  4% 
(w/v)  PFA,  permeabilised with  0.1%  (v/v)  Triton X-100 and stained  with a  1:100 
diluted  Cy3-conjugated  anti-NSl  antibody  (clone  1A7,  kindly provided  by  Oliver 
Schulz).  After three  washes  in  PBS,  cover slips  were  mounted  with  Fluoromount 
(Southern  Biotech,  Birmingham,  AL,  USA)  and  images  were  taken  using  a  laser 
scanning confocal microscope (LSM 510, Zeiss, Jena, Germany).
2.8.2.  Electron microscopy
Electron microscopy was carried out with a lot of help from Steven Gschmeissner, 
Cancer Research UK Electron microscopy facility.
Cells  were  fixed  in  4%  (v/v)  glutaraldehyde  for  lh,  before  being  processed  for 
routine araldite processing and sectioning by the Electron microscopy unit of Cancer 
Research  UK.  Sections were placed on  200  mesh nickel  grids  and post stained in 
lead citrate and uranyl acetate. For negative staining 20pl concentrated supernatants 
were fixed with 20pl  8% (v/v) glutaraldehyde.  lOpl of this mixture was spread on 
glow  discharged carbon/formvar 400  mesh  nickel  grids  and  allowed to  settle  in  a 
moist chamber for a few minutes.  Grids were washed twice  in distilled water and 
stained with  1   drop aqueous  1% uranyl acetate.  Specimens were examined using a 
JEOL 1010 (JEOL Ltd., Tokyo, Japan) electron microscope.
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2.9.  In vivo applications
2.9.1.  Immunisation 
Immunisation with LV
Mice  were  immunised  with  concentrated  OVA-expressing  lentivirus  or  egg  white 
equivalent to  250pg  ovalbumin  supplemented  with  PBS,  CpG  (25pg)  or  poly-I:C 
(50pg). A total volume of 200jil was injected into each mouse.
Immunisation with TVS
Mice  were  immunised  intraperitoneally  with  egg  white  equivalent  to  250pg 
ovalbumin, in PBS alone, mixed with 320pl VSV-G-TVS, mixed with CpG (25pg) 
or mixed with poly-I:C (50pg).
2.9.2.  Staining for tetramer positive T-cells
A tetramer assay is used to detect the presence of antigen specific T-cells. A tetramer 
consisting of 4 MHC molecules with its bound peptide will only bind the T-cells that 
bear the T-cell receptor specific for the particular tetramer.
1  week  after  immunisation,  blood  was  analysed  for  the  presence  of OVA/H2-Kb 
tetramer positive T-cells.  For that,  100-300pl blood was obtained from the tail vein 
and  collected  into  a  tube  containing  heparin,  which  prevents  coagulation.  Whole 
blood was then stained for 30min with PE conjugated SIINFEKL-tetramer (lOjxl per 
sample) and a TC conjugated CD8 antibody. Thereafter, cells were washed in FACS 
buffer and data was acquired in a FACS Calibur cytometer.
2.9.3.  In vivo killing assay
Activation of adaptive immune responses can be monitored by assessing the ability 
of cytotoxic T-lymphocytes (CTL) to specifically eliminate target cells that present a 
peptide  of  the  immunogen  on  their  class  I  MHC.  In  case  of  TVS  and  LV 
immunisation,  10-12  days  after  immunisation  an  in  vivo  target  killing  assay  was 
performed  to  test  the  induction  of  OVA  specific  immune  responses.  Briefly,
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splenocytes  from  mice  carrying  a  congenic  marker  (C57BL/6SJL-CD45.1)  were 
isolated  and  incubated  with  different  amounts  (0,  20  and  200nM)  of SIINFEKL 
peptide (Cancer Research UK peptide  synthesis  service)  in RPMI  1640 medium at 
37°C for lh. Cells were then washed twice in PBS and then resuspended in 2ml PBS 
supplemented with different amounts of Carboxyflourescein (CFSE) (2.5pM CFSE, 
unloaded  cells;  0.25pM  CFSE,  200nM  peptide  loaded  cells  and  0.025pM  CFSE, 
20nM  peptide)  and  incubated  for  lOmin  in  a  water  bath  at  37°C. Aliquots  were
washed  three  times  in  PBS,  pooled  and  passed  through  a  40pm  strainer  (Becton
Dickinson, Oxford, UK). 200pl cell suspension (containing approximately 10  cells) 
was  injected  intravenously  into  each  mouse.  24h  later  the  mice  were  sacrificed, 
splenocytes and blood collected.
For the in vivo killing assay l/20th of every spleen was used to stain with a Tri-colour 
conjugated anti-CD8 AB (1:100) and incubated for 30min on ice. Cells were washed 
in FACS buffer and data acquired with a FACS Calibur cytometer.
2.9.4.  In vitro re-stimulation of T-cells
For CD4 T-cell responses,  isolated splenocytes were incubated over night in RPMI 
1640 medium in the presence or absence of 10% (v/v) FCS. Brefeldin A was added 
for the last 3 hours and cells stained for intracellular IFN-y as described above.
2.9.5.  Serum isolation and antibody responses
Whole  blood  isolated  from  10-12  days  immunised  mice  was  incubated  at  room 
temperature for 2 hours, which resulted in blood coagulation. Blood was then spun at 
max  speed  in  an  eppendorf  benchtop  centrifuge  for  2min  and  serum  that 
accumulated in the top  layer was  carefully removed.  ELISA  for  serum  antibodies 
was performed as described above.
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CHAPTER 3:  Lentiviral vector preparations
activate dendritic cells via Toll-like receptor 9
3.1.  Introduction
3.1.1.  Virus infection routes
Viruses are intracellular parasites and rely on living cells in order to replicate. Each 
virus only has a single chance to infect a cell, and, consequently, the virus particle 
has  to  enter  the  living  cell  at  the  first  contact.  Whether  or  not  this  infection  is 
successful relies on proteins present on the virus surface. In fact, there are two basic 
mechanisms that guarantee a virus to infect the right target:
Some viruses bear surface proteins that have to co-engage multiple receptors on the 
host cell in order to be activated. Upon receptor binding, fusogenic domains of these 
surface proteins  are exposed,  leading to  penetration of the host plasma membrane 
and  delivery  of the virus  core  into  the  cytoplasm.  Examples  of viruses  using  this 
route  are  members  of the  retro-  and  paramyxovirus  family  (Smith  and  Helenius, 
2004; Stein et al.,  1987). The best-understood and most prominent example for this 
kind  of infection  is the  human  immunodeficiency  virus  -1  (HIV-1).  HIV-1  has  a 
surface protein named gpl20 that co-engages  CD4  and the  co-receptor CCR5  and 
CXCR4, respectively. Only binding of receptor and co-receptor leads to release of a 
fusion protein gp41  that inserts into the plasma membrane of the cell and mediates 
delivery  of the  virus  capsid  into  the  cellular  cytoplasm  (Colman  and  Lawrence,
2003). However, most viruses infect cells by a different mechanism, i.e. through the 
endocytic  pathway.  Endosomal  acidification  activates  virus  surface  proteins  and 
leads to delivery of the virus core into the cytoplasm (Colman and Lawrence, 2003). 
This  mechanism  guarantees  infection  of  a  metabolically  active  cell.  The  pH- 
dependent fusogenic properties of the virus surface proteins can easily be tested in 
vitro  by  using  weak bases  that  inhibit  acidification  of the  endosome  and  thereby 
virus delivery into the cytoplasm (Smith and Helenius, 2004).
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3.1.2.  TLRs sense nucleic acid in the endosome
TLR3, -7,  -8 and -9 are activated by viral nucleic acid and therefore came into focus 
of virologists and immunologists (Akira et al., 2006; Bowie, 2007). These TLRs are 
present  in  endosomal  compartments  of  immune  cells  and  have  the  ability  to 
recognise nucleic acid delivered into this cellular compartment.
Single  stranded RNA and DNA viruses  that  infect  cells  via  the  endosome  trigger 
TLR7  and  -9,  respectively.  This  leads  to  IFN-a  production  in  plasmacytoid  DC 
(pDC). It is believed that incoming viruses activate endosomal TLRs. However, how 
the vims entry route affects activation of TLR7 and -9 is not entirely understood (Fig 
3.1.1).  Direct comparison between vimses can be complicated as some viruses may 
differ  in  their  stimulatory  activity,  regardless  of their  entry  route  and  others  may 
actively suppress TLR activation or signalling. The HIV-1  surface protein gpl20, for 
instance,  can  selectively  inhibit  TLR9  dependent  responses  through  an  unknown 
mechanism  (Martinelli  et  al.,  2007).  Hepatitis  C  virus  NS3/4A  protease  cleaves 
TRIF  (Li  et  al.,  2005)  and  therefore  potentially  interferes  with  TLR3  dependent 
responses. Finally, the porcine circovirus can inhibit activation of TLR9 (Vincent et 
al.,  2007).  Therefore,  more  standardised  models  are  required  to  understand  the 
relationship  between  vims  entry  and  TLR  activation.  One  way  to  proceed  is  to 
compare very similar vims particles that only differ in their entry routes.
3.1.3.  Lentiviral vectors as tools for innate immunity
Lentiviral vectors (LVs) are promising agents for genetic therapy of human diseases 
(Cockrell and Kafri, 2003; Galimi and Verma, 2002; Wiznerowicz and Trono, 2005). 
They  have  several  advantages  over  other  vims-based  vectors,  which  include 
integration of the transgene into the genome and the lack of pre-existing immunity 
against the viral vector.
Remarkably,  little  is known  about  innate  immune  responses  to  recombinant  LVs. 
Recombinant LVs are replication-incompetent and intracellular sensing mechanisms 
by  means  of  dsRNA  helicases  are  therefore  unlikely  to  contribute  to  their 
immunogenic  potential.  The  most  likely  stimuli  for  inducing  innate  and  adaptive 
immunity to LVs are the nucleic acids carried by the virions,  including the ssRNA 
viral  genome  or  short DNA  transcripts  that  are  produced  after  maturation  of the
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virion  (Trono,  1992).  It  has  been  reported  that  HIV-1  can  stimulate  IFN-a 
production in human pDC most probably by triggering TLR7 (Beignon et al., 2005; 
Fonteneau et al., 2004; Schmidt et al., 2005; Yonezawa et al., 2003).
Recombinant  lentiviruses  are  produced  by  transient  transfection  of producer  cells 
with a plasmid coding for the viral RNA genome (bearing the transgene), as well as 
additional  plasmids  that  provide  in  trans  the  necessary  components  for  virus 
assembly and budding (Gag,  Pol,  Rev and Env proteins)  (Fig 3.1.3)  (Wiznerowicz 
and  Trono,  2005).  This  transient  transfection  method  is  the  basis  for  simple 
manipulation of LVs: The envelope protein, being responsible for the infection route, 
can be  replaced with  other surface  proteins  and viral  entry can thereby be  altered 
easily. Furthermore, this technique provides a standardised system, as the rest of the 
lentiviral particle is not affected by exchanging the envelope protein.
3.1.4.  Aim of this Chapter
I wanted to investigate whether LV can induce an innate immune response and how 
the  virus  entry  route  influences  this.  On  the  one  hand,  studying  the  interaction 
between  LVs  and  cells  of the  innate  immune  system  might  suggest  strategies  to 
minimise LV immunogenicity and maximise therapeutic use in gene delivery. On the 
other hand,  further insight could tell us how to increase immune responses against 
HIV-1.
This  study  was  designed  to  gain  knowledge  of the  importance  of the  virus  entry 
route  in  regard  of TLR  activation.  I  hypothesized  that  the  entry  route  of virus 
particles contributes to the activation of the innate immune system: LV entering the 
cell  via the  endosome  may  give  a stronger  innate  immune  response  than particles 
entering  the  cell  via  fusion  at  the  plasma  membrane  (Fig  3.1.4).  I  further 
hypothesized  that  incubation  of  virus  particles  with  antibodies  or  complement 
components  could  enhance  innate  sensing  of LVs  as  opsonisation  increases  their 
uptake via the endosomal pathway. If this were the case it would emphasize the role 
for antibodies and the complement system as ‘adjuvant’ of innate immunity.
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3.2.  Results
3.2.1.  LV  preparations simulate IFN-a from BM-pDC
In  order  to  establish  whether  LV  induce  innate  immune  responses  I  examined 
whether  exposure  of LV  to  leucocytes  induces  IFN-a,  one  of the  earliest  innate 
responses  to  invading  viruses.  For  that  purpose  I  incubated  total  murine  bone 
marrow  (BM)  cells  isolated  from  C57B1/6  mice  with  graded  doses  of  LV 
preparations and measured IFN-a in the supernatant after over night culture.  CpG- 
containing  DNA  oligonucleotides  that  stimulate  TLR9  in  pDC  and  lead  to 
production of high amounts of IFN-a were used as positive control. As shown in Fig
3.2.1 A,  standard  LV  preparations  are  very  potent  IFN-a  inducers  in  BM.  LV 
preparations were comparable or superior to CpG used at an optimal concentration 
(Fig  3.2.IB).  Concentration  of  the  LV-containing  supernatant  also  increased  its 
ability  to  induce  IFN-a  and  resulted  in  a  bell-shaped  dose  response  courve  (Fig
3.2.1 A), a feature that is commonly seen for TLR agonists or agonists of cytoplasmic 
PRRs.  I  cannot  exclude  the  possibility,  however,  that  high  concentrations  of LV 
induce  cell  death  and  that  this  results  in  loss  of  IFN-a  induction.  In  order  to 
investigate which cells were responsible, I stimulated BM cells with LV and stained 
for  intracellular  IFN-a.  Although  all  nucleated  cells  can  produce  IFN-a/13  only  a 
small  subset of cells produced IFN-a  in  these  experiments (Fig  3.2.1C).  The cells 
responsible  for  this  were  CD llclow,  B220positlve  and  Ly6cposmve,  a  phenotype 
indicative of pDC  (Liu, 2005)  (Fig 3.2.1C).  To  confirm this I  enriched pDC  from 
BM of RAG2-deficient mice on the basis of B220 expression by magnetic activated 
cell sorting (MACS) (Fig 3.2.ID). The only cell type expressing B220 in BM from 
rag2'A mice are pDC (Shinkai et al.,  1992).  Only cultures containing B220-positive 
cells produced significant levels IFN-a in response to LV preparations and CpG (Fig 
3.2.IE). Similarly, LV elicited IFN-a from BM cultured in the presence of Fms-like 
tyrosine kinase 3 ligand (Flt3L), which is a standard method to generate pDC in vitro 
(Fig 3.2.IF).
I concluded that LV preparations stimulate pDC to produce IFN-a.
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3.2.2.  LV  that  infect  cells  via  the  endosome  do  not 
necessarily induce IFN-a
Standard LV preparations bear the glycoprotein of vesicular stomatitis virus (VSV- 
G)  on  the  surface,  a  protein  that  mediates  uptake  via  endocytosis.  This  uptake 
mechanism  may  deliver  the  virus  genome  into  endosomes  to  trigger  a  TLR- 
dependent response. To investigate whether endocytic uptake is necessary for IFN-a 
production,  I  generated virus particles  carrying  four different surface proteins that 
mediate infection via different routes. In vitro, virus infection through the endocytic 
route  can  be  blocked  by  weak  bases  (Smith  and  Helenius,  2004).  Treatment  of 
293FT cells with ammonium chloride (NH4CL) did not affect GFP expression after 
infection with LV bearing the amphotropic murine leukaemia virus envelope protein 
(MLV-A)  (Fig  3.2.2A),  consistent  with  the  notion  that  MLV-A  mediates  pH- 
independent fusion at the plasma membrane (Hernandez et al.,  1996; McClure et al., 
1990). In contrast, the same treatment reduced GFP expression in cells infected with 
LV equipped with VSV-G (Fig 3.2.2A),  as expected (McClure et al.,  1990;  Puri et 
al.,  1988).  Infection  of  LV  pseudotyped  with  the  hitherto  uncharacterised 
Thogotovirus glycoprotein (THOV-G) could also be blocked by treatment with weak 
bases (Fig 3.2.2A), indicative for endosomal uptake. Lymphochoriomeningitis virus 
glycoprotein (LCMV-G)  is reported to deliver the virus particle into an  endosomal 
compartment (Borrow and Oldstone, 1994).
To assess their innate stimulatory activity, pseudo typed viruses were normalised for 
virus  titre  on  293T  cells  and  added  to  BM  at  a  MOI  of  1.  Surprisingly,  only 
preparations  containing  VSV-G  pseudotyped  virus  generated  detectable  IFN-a  in 
BM after over night treatment (Fig 3.2.2B).  Thus, only LV preparations containing 
VSV-G stimulate IFN-a production from BM pDC.  This was surprising as VSV-G 
was  not  unique  in  mediating  endocytic  uptake  (Fig  3.2.2A,  and  (Borrow  and 
Oldstone,  1994)). However, this result may be explained by the fact that VSV-G has 
a remarkable host range and for that reason VSV-G pseudotyped LV could be the 
only virus  allowing  successful  infection  of pDC.  Testing  this  hypothesis  was  not 
possible  as GFP  expression  was  not  detectable  in  the  short-term  assays  necessary 
when using primary pDC.
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3.2.3.  IFN-a  induction  is  independent  of viral RNA  but 
depends on VSV-G
I hypothesised that the virus genome present in virus particles acted as the agonist in 
the  observed  IFN-a  response.  However,  virus  particles  lacking  virus  RNA 
(LVAvRNA)  induced high amounts of IFN-a  (Fig  3.2.3A).  As  expected,  omitting 
the VSV-G (LVAenv) plasmid or transfecting the viral  RNA only (vRNA) did not 
result in preparations with the capacity to induce IFN-a (Fig 3.2.3A). Unexpectedly, 
however, transfection of VSV-G and Rev alone (VSV-G) was sufficient to render the 
cell supernatant stimulatory (Fig 3.2.3A).
I  next  investigated  whether  functional  VSV-G  is  necessary  for  IFN-a  induction. 
Inactivation  of VSV-G  LV preparations  by  treatment  with  acidic  medium  or heat 
diminished the IFN-a response in BM (Fig 3.2.3B). Furthermore, pre-incubation of 
VSV-G  containing  preparations  with  a  neutralising  anti-VSV  antibody  abrogated 
IFN-a  induction  but  the  same  treatment  had  no  effect  when  using  the  control 
stimulus CpG (Fig 3.2.3C).
I concluded that VSV-LV preparations induce IFN-a in the absence of viral RNA. 
Transient  transfection  of  VSV-G,  renders  the  supernatant  stimulatory  and  this 
depends on functionally active VSV-G.
3.2.4.  VSV-G transfection leads to accumulation of VSV-G-
bearing  tubulo-vesicular  structures  in  the  extracellular 
milieu
The  standard  production  of  LV  involves  an  ultracentrifugation  step  in  order  to 
concentrate  virus particles.  This  concentration  step  also  increased IFN-a  inducing 
activity of LV containing supernatants (Fig 3.2.1 A), which suggests the presence of 
a  particulate  stimulus.  I  therefore  examined  the  transfected  cells  and  cell 
supernatants by electron microscopy for the presence of particles that are associated 
with  VSV-G  expression.  293T  cells  were  transfected  with  three  combinations  of 
plasmids, supernatants and cells harvested 48h later and processed for imaging in an 
electron  microscope.  Cells  transfected  with  the  four  plasmids  used  for  virus 
production  (LV)  showed  abundant  tubulo-vesicular  structures  (TVS)  in  the
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extracellular  space  (Fig  3.2.4A,  iv,  black  arrow).  These  structures  could  also  be 
found in LV preparations (Fig 3.2.4A,  i)  and greatly outnumbered the actual virus 
particles (Fig 3.2.4A,  iv, white arrow). Transfection of plasmids coding for vRNA, 
Gag-Pol and Rev (LVAenv) was not sufficient to trigger formation of TVS but led to 
generation of virus particles (Fig 3.2.4A,  iii and vi, white arrows). In contrast, TVS 
could be found when cells were transfected with the VSV-G plasmid alone (VSV-G) 
(Fig 3.2.4A, ii and v, black arrows).
TVS  were  also  detectable  by  flow  cytometry  of cell  supernatants  as  a population 
with distinct scatter properties (Fig 3.2.4B), which stained positive with an antibody 
against VSV-G  (Fig  3.2.4C)  indicating that this protein  is  associated with  TVS.  I 
confirmed this by western blot analysis (Fig 3.2.4D). Notably, LV and VSV-G but 
not control preparations of LVAenv contained VSV-G and other proteins, like GFP 
and P-actin, present in cells originally used for transfection (Fig 3.2.4D).  However, 
as  expected,  the  LV  capsid  protein  (HIV-p24),  which  is  the  main  structural 
component of lentiviral particles, was present in LV and LVAenv preparations (Fig 
3.2.4D).
Thus,  VSV-G pseudotyped LV preparations,  as  well  as  supernatants  from VSV-G 
transfected cells, contain large amounts of TVS that are associated with VSV-G and 
other proteins present in cells used for virus production.
3.2.5.  Separation  of TVS from  LV suggests  minor  innate 
immune response to virus particles
I speculated whether the virus particles and TVS synergised in IFN-a induction from 
LV preparations. Membrane vesicles have a lower density than lentiviruses (1.08 vs. 
1.16-1.18g/ml) (Goff, 2001). Therefore I fractionated LV preparations by continuous 
sucrose gradient ultracentrifugation and tested each fraction for interferon inducing 
activity on  BM  cells  and the presence  of virus by  infecting  293T  cells.  Further,  I 
analysed the presence of VSV-G and HIV-p24 by western blot. IFN-a induction was 
found  in  distinct  fractions,  mainly  fractions  5  and  6  (Fig  3.2.5).  These  fractions 
contained virus  and the  majority  of the  VSV-G protein  indicating  the presence  of 
TVS.  However,  fraction  8  did  not  contain  detectable  VSV-G  and  did  not  induce
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detectable  IFN-a,  yet  contained  comparable  amounts  of  infectious  particles  and 
HIV-p24  capsid  protein  (Fig  3.2.5).  These  results  suggest  that  the  actual  virus 
particle has  little interferon inducing activity and defines TVS  as the major IFN-a 
stimulus in LV preparations. The VSV-G protein itself, however, was probably not 
responsible for IFN-a induction as the protein was detectable in fraction 3  that did 
not activate IFN-a production (Fig 3.2.5).  Only minute amounts of VSV-G may be 
necessary to confer infectivity to a lentiviral particle (fraction 8).
I concluded that TVS rather than virions or the VSV-G protein constitute the main 
stimulus for IFN production upon treatment of BM with LV preparations.
3.2.6.  TLR9  is  the  main  receptor  responsible for  IFN-a
production after L V treatment of BM
In order to investigate which  PRR is involved in IFN-a induction from  LV I used 
BM cells from MyD88-deficient mice that are devoid of TLR7 and TLR9 signalling. 
Electroporation  of  poly-I:C,  which  is  recognised  by  the  intracellular  pattern 
recognition receptor MDA5 (Kato et al., 2006), triggered similar amounts of IFN-a 
in wild-type and myd8Sf' BM.  In contrast, the response to LV was completely lost, 
arguing  for  involvement  of  TLR  signalling  in  the  recognition  process  of  LV 
preparations in BM (Fig 3.2.6A). As LV carry a RNA genome I investigated whether 
TLR7  would  be  the  major receptor  involved.  Surprisingly,  treatment  of BM  from 
wild-type and from tlrTf' mice showed no differences  in terms of IFN-a  induction 
when  exposed  to  LV  preparations  whereas  the  response  to  the  TLR7-dependent 
control stimulus R848 was decreased in tlr f' BM (Fig 3.2.6B).  In contrast, TLR9- 
deflcient BM  cells had  a more than  100-fold reduced ability to produce  IFN-a in 
response  to  LV  preparations  or  the  TLR9-dependent  stimulus  CpG  whereas  the 
response to Loxoribine, a TLR7 stimulus, was equal in both cell types (Fig 3.2.6C). 
Similarly, IFN-a triggered by supernatants from VSV-G transfected cells was also 
dependent on TLR9 (Fig 3.2.6C).
From  these  data  I  concluded  that  TLR9  is  the  main  pattern  recognition  receptor 
mediating IFN-a production from BM cells treated with preparations containing LV 
and TVS.
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3.2.7.  Plasmid DNA is present in TVS
The  TLR9  requirement  for  IFN-a  induction  suggested  the  presence  of DNA.  To 
investigate this I stained cell supernatants with YOYO-I, a dye that intercalates into 
nucleic  acid  and  thereby  gains  fluorescence  activity  that  can  be  detected  by  flow 
cytometry.  LV  and  TVS  but  not  control  preparations  contained  YOYO-I  positive 
populations bearing the scatter properties of TVS (Fig 3.2.7A).
RT-PCR and PCR analysis of nucleic acids extracted from LV and TVS preparations 
confirmed the presence  of RNA and DNA,  corresponding to each  of the plasmids 
that  had  been  transfected  into  the  producer  cells  (Fig  3.2.7B,  C).  Furthermore,  I 
could detect DNA for (3-actin, presumably derived from the genome of the producer 
cells (Fig 3.2.7B). In contrast, preparations containing LV but no TVS (LVAenv) did 
not generate amplicons for plasmid or (3-actin DNA by PCR analysis (Fig 3.2.7B, C). 
However, RNA coding for the virus genome (GFP) and (3-actin could be amplified, 
consistent with the fact that lentiviral particles can package viral and cellular RNA 
(Muriaux et al., 2001).
To  confirm  the  presence  of  intact  plasmids,  I  transformed  bacteria  with  DNA 
extracted  from  LV  preparations.  DNA  corresponding  to  1ml  of  LV  preparation 
generated five times as many antibiotic resistant bacterial colonies than  lOpg of the 
control  plasmid pUC19  (Fig  3.2.7D).  In contrast,  no  plasmids  could be  recovered 
from preparations of LVAenv (Fig 3.2.7D).  To exclude  a possible  contamination I 
isolated  DNAs  from  individual  bacteria  colonies  and  compared  their  restriction 
pattern with that of the plasmids. The results indicate that each of the plasmids used 
for virus generation could be recovered from the transformants (Fig 3.2.7E, F).
I  concluded  that  DNA  of plasmid  and  cellular  origin  is  present  in  LV  and  TVS 
preparations and this DNA may constitute the main IFN-a trigger in BM.
3.2.8.  Transfer  of plasmid  DNA  and/or  cellular  contents 
within TVS
The  presence  of DNA  within  TVS  suggests  that  TVS  might have  the potential  to 
transfer intact plasmids into target cells. To test this, I transfected 293T cells with a 
GFP  expression plasmid together with or without a VSV-G plasmid and 48h  later
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transferred  the  supernatant  to  fresh  293T  cells  (Fig  3.2.8A).  Cells  exposed  to 
supernatant of GFP transfected cells remained GFP negative (Fig 3.2.8B), whereas a 
portion  of cells  exposed  to  supernatants  from  GFP  and  VSV-G  transfected  cells 
contained GFP (Fig 3.2.8B) suggesting either carry over of intact GFP and/or nucleic 
acid resulting in new generation of GFP.
3.2.9'.  Generation of LV in cells exposed to TVS
Transfer of plasmids used for generation of LV could potentially convert target cells 
into virus producers. Indeed, supernatant of 293T cells exposed to high doses of LV 
contained  small  amounts  of infectious  LV  at  120h  after infection  and  after  seven 
washes with PBS  (Fig 3.2.9A).  As I  could not entirely exclude the possibility that 
remaining input virus is detected in this assay, I resorted to an alternative strategy to 
convincingly  show  that  new  virus  was  generated.  A  preparation  of  VSV-G 
pseudotyped  LV  lacking  the  viral  genome  (LVAvRNA)  was  used  to  infect  293T 
cells containing a stably integrated lentiviral genome encoding GFP but none of the 
genes encoding viral  structural proteins (293HV cells)  (see  scheme  in  Fig  3.2.9B). 
Only TVS-mediated transfer of nucleic acid expressing viral structural proteins can 
result in generation of new virus that contains a GFP genome (Fig 3.2.9B).  Indeed, 
small amounts  of indicator 293T cells  could be  transduced with  a GFP expressing 
virus  present  in  293HV  supernatant  that  was  exposed  to  LVAvRNA  preparations 
(Fig  3.2.9C).  FACS  sorting  and  expansion  of GFP  positive  cells  for  six  weeks 
resulted in a population containing more than 30% GFP positive cells (Fig 3.2.9D). 
Amplification  of a DNA  fragment within the  LTR that is  only present  in  infected 
cells confirmed that GFP-positive cells were infected with a lentivirus (Fig 3.2.9E). 
Taken  together,  these  experiments  indicate  that  VSV-G  pseudo  typed  LV 
preparations generated by transient transfection contain TVS that carry DNA, which 
may provide the major stimulus for triggering TLR9.  Furthermore,  TVS can act as 
gene delivery vehicles  in  a VSV-G  dependent manner,  resulting  in  transfection  of 
cells with residual plasmid DNA that potentially lead to the generation of new virus 
particles.
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3.2.10.  Avoiding  transient  transfection  of producer  cells 
decreases the innate stimulatory potential of  LV  preparations
Plasmid derived DNA is present in LV preparations and may be the major stimulus 
for innate immune responses. To test whether the stimulatory potential of LV can be 
decreased by nuclease digestion I exposed LV or a control plasmid (pMSCV-eGFP) 
to  benzonase.  The  virus  titre  was  not  affected  by  benzonase  treatment  (data  not 
shown),  consistent with the notion that virus  genomes are protected from nuclease 
activity  by  the  membranous  envelope  and  capsid  proteins.  Similarly,  benzonase 
treatment  of  LV  did  not  change  the  ability  to  induce  IFN-a  in  BM,  whereas 
treatment of a control plasmid abrogated IFN induction (Fig 3.2.10A). This suggests 
that  immunostimulatory  nucleic  acid  within  LV  preparations  is  not  accessible  to 
nucleases,  probably  due  to  localisation  within  a  membranous  compartment.  Virus 
particles present in the same preparations could be responsible for IFN-a production 
in BM exposed to benzonase-treated LV.  However,  this  is unlikely as  an previous 
experiment  (see  section  3.2.5)  suggested  minor  innate  immune  stimulation  from 
virus particles.
To evaluate whether plasmids associated with LV are the actual source  of IFN-a I 
resorted to  an alternative  strategy to  generate LV.  I  made use  of STAR-HV  cells, 
which contain a HIV-based packaging vector encoding GFP and stably express HIV 
Gag, Pol and Rev proteins, needing only an exogenously-provided Env gene in order 
to  secrete  infectious  LVs  encoding GFP  (Ikeda et  al.,  2003).  I  introduced VSV-G 
Env  into  these  cells  by  transduction  with  a  retrovirus  and  compared  this  to  the 
plasmid transfection method used previously. STAR-HV cells transduced with VSV- 
G  encoding  retrovirus  are  not  exposed  to  plasmids  and  only  produce  limiting 
amounts of VSV-G (Fig 3.2.10B) probably resulting in less TVS. For both reasons, 
LV  preparations  generated  by  this  method  should  display  a  markedly  diminished 
ability to activate pDC.  VSV-G gene introduction by either plasmid transfection or 
retroviral transduction allowed LV production by STAR-HV cells as determined by 
titration on 293T cells (data not shown). The titre of LV produced through retroviral 
infection  was  significantly  reduced  when  compared  to  LV  produced  through 
transient transfection.  The preparations were normalised for viral  titre and used to
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stimulate  BM  cells.  LV  preparations  produced  by  regular  plasmid  transfection 
induced IFN-a, as expected (Fig 3.2.10B). In contrast, LV preparations generated by 
retroviral transduction did not elicit IFN-a from BM cells (Fig 3.2.1 OB).
Therefore, I concluded that the interferon inducing ability of LV preparations clearly 
depends on the method of virus generation and not on the viral particles themselves.
3.2.11.  L V can induce adaptive immune responses
Adaptive  immune  responses  are  initiated  through  delivery  of an  antigen  together 
with  an  innate  immune  stimulus.  An  adaptive  immune  response  against  a  viral 
pathogen is characterised by induction of cytotoxic CD8+ T-cells that can recognise 
and  kill  cells  displaying  peptide-bound  MHC-I  and  by  antibody  production  that 
requires  help  from  CD4+  T-cells.  Activated  CD8+  and  CD4+  T-cells  can  be  re­
stimulated in vitro to produce IFN-y. LV have been described to give rise to adaptive 
immune  responses  against  the  encoded  antigen.  However,  it  is  unclear  what  the 
innate  stimulus  promoting  this  immune  response  results  from.  I  wanted  to  test 
whether  successful  vaccination  with  LV  requires  TLR  signalling,  which  could 
suggest a role for TVS in this process. To investigate this, I immunised mice lacking 
the  signalling molecule MyD88  with an ovalbumin  (OVA)  expressing  LV or egg- 
white (as an adjuvant-free source of OVA protein) together with PBS, CpG or poly- 
I:C.  10  days  after  immunisation  mice  were  injected  with  splenocytes  pulsed  with 
OVA or not and in vivo killing tested 48h later. In my hands, CpG that should have 
served  as  control  for  a  TLR9  dependent  adjuvant  response  did  not  act  as  potent 
adjuvant. In vivo killing of OVA loaded splenocytes was marginally detectable in wt 
mice  and  reduced  in  myd8&A  mice  (Fig  3.2.11C,  D).  As  expected,  killing  and 
expansion of tetramer positive CD8+ T-cells was comparable in wt and myd88'A mice 
when poly-I:C was used as adjuvant (Fig 3.2.11). Unexpectedly, when LV was used 
for  immunisation,  myd88'A  mice  mounted  an  efficient  adaptive  immune  response 
against  OVA.  Expansion  of tetramer  positive  CD8+  T-cells  and  killing  of OVA 
loaded target cells was comparable in wt and myd88'A mice immunised with OVA 
expressing LV (Fig 3.2.11C, D).
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This  suggests  that  activation  of the  adaptive  immune  system  in  response  to  LV 
immunisation  does  not  rely  on  MyD88  signalling.  However,  MyD88-dependent 
responses may be present but masked by alternative innate stimuli.
3.2.12.  TVS act as adjuvant in vivo
Given  that  LV  preparations  can  act  as  immunogens  but  their  innate  stimulatory 
properties in vitro appear highly dependent on the presence of TVS contaminants, I 
wondered  to  what  extent  TVS  modulate  adaptive  immune  responses  in  vivo.  I 
therefore  intraperitoneally immunised wt and TLR9-deficient mice with  egg  white 
together  with  TVS,  CpG  or  poly-I:C  and  tested  for  CD8+  T-cell  responses  by 
monitoring expansion of OVA-specific tetramer positive T-cells and in  vivo killing 
of  OVA-pulsed  splenocytes.  In  vivo  killing  of  OVA-loaded  splenocytes  and 
expansion of tetramer positive CD8+ T-cells was reduced in tlr9'f' mice  immunised 
with  CpG  (Fig  3.2.12A-D)  whereas  poly-I:C  immunisation  resulted  in  a  TLR9 
independent immune response  (Fig 3.2.12A-D).  Control mice immunised with  egg 
white  alone  did  only  show  background  levels  of tetramer  stain  and  no  killing  of 
OVA-pulsed splenocytes  (Fig 3.2.12A-D).  Surprisingly,  however,  when TVS  were 
used as adjuvant, expansion of tetramer positive CD8+ T-cells and in vivo killing of 
OVA-loaded splenocytes was similar in wt and tlr9'f' mice (Fig 3.2.12A-D).
In vitro re-stimulation of splenocytes with OVA did not result in any detectable IFN- 
y  production  by  T-cells  (data  not  shown).  However,  FCS  re-stimulation  of 
splenocytes  from  OVA-TVS  immunised  mice  triggered  CD4+  T-cells  to  produce 
IFN-y (Fig 3.2.12E).  Furthermore,  I could detect antibodies against OVA and FCS 
(Fig  3.2.12F)  suggesting  that  immunisation  elicits  both,  a  B-  and  T-cell  response 
against TVS-associated proteins.
In  conclusion,  TVS  clearly  have  adjuvant  activity  in  vivo.  However,  this  effect  is 
TLR9-independent,  suggesting  the  presence  of  additional  innate  stimuli  in  TVS 
preparations.  These additional stimuli make  TLR9 activation in  vivo  redundant for 
activating adaptive immune responses.
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3.2.13.  Supernatant of VSV infected cells  does  not contain
TVS
Finally,  I  considered  the  possibility  that  TVS-like  structures  are  produced  during 
infection  with  VSV.  VSV  particles  have  a  diameter  of about  70nm,  a  length  of 
approximately  170nm and bear an electron-dense core protein.  As shown in Figure 
3.2.4A, TVS, in contrast, only show a diameter of 35-45nm, are up to 2pm long and 
do not show electron-dense structures of particular order. Therefore, it is feasible to 
discriminate  TVS  from  virus  particles  by  electron  microscopy.  Yasu  Takeuchi 
(UCL,  Windeyer Institute of Virology) infected 293T cells with VSV (strain:  New 
Jersey) at an MOI of 10 and we harvested the cells 24 hours after infection to assess 
the presence of TVS in the electron microscope.  The majority of cells showed vast 
amounts of virus that was in the process of budding off the plasma membrane.  An 
example  is  shown  in  Fig  3.2.13A.  Although  particles  were  present  in  great 
abundance, especially in the intercellular space (Fig 3.2.13B, white arrows), I could 
not  detect  structures  that  were  reminiscent  of TVS.  In  fact,  most  particles  were 
viruses  as judged by diameter,  length and electron density  (examples  given  in Fig 
3.2.13C, D).
This  suggests  that  the  virus  coordinates  expression  of its  structural  proteins.  This 
regulation  might  partly  have  evolved  to  avoid  formation  of TVS  that  potentially 
could alert the immune system.
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3.3.  Discussion
Gene transfer for therapeutic purposes should, if possible, be immunologically silent 
or provoke immunological tolerance. Paradoxically, lentiviral vectors have also been 
used as tools for immunisation and shown to elicit powerful cytotoxic T-cell (CTL) 
responses against transgene-encoded proteins (Dullaers et al., 2004; Esslinger et al., 
2003; Firat et al., 2002; He et al., 2005; Iglesias et al., 2007; Palmowski et al., 2004; 
Rowe  et  al.,  2006).  Similarly,  HIV-1,  from  which  most  recombinant  LVs  are 
derived, elicits potent cell and antibody-mediated responses in humans (McMichael 
and  Phillips,  1997).  This  indicates  that  lentiviruses  and  recombinant  LV  are 
intrinsically immunogenic,  suggesting that they have the capacity to activate innate 
viral sensing pathways, which subsequently couple to adaptive immunity. 
Recombinant LVs  are used  extensively  to transduce  non-dividing  cells  and  are  an 
attractive  vehicle  for  gene  delivery.  LVs  are  less  immunogenic  than  other  viral 
vectors (Bessis et al.,  2004;  Chen et al.,  2003), but induce  an immune response  in 
vivo,  which  limits  their  application  for  gene  therapy  (Kafri,  2001).  This 
immunogenicity  has  been  linked  to  their  ability  to  transduce  dendritic  cells 
(Esslinger et al., 2003) although it is elusive why this should be sufficient as antigen 
targeting  to  DC  in  the  absence  of  innate  stimuli  induces  tolerance  rather  than 
immunity (Iwasaki and Medzhitov, 2004; Steinman and Hemmi, 2006). Therefore, it 
seems likely that the ability of LVs to prime immune responses reflects their ability 
to deliver both antigen and innate stimuli for DC activation. However, the ability of 
recombinant  LVs  to  stimulate  conventional  DC  is  unclear  and  their  capacity  to 
stimulate pDC is ill defined despite the importance of this cell type in inducing anti­
viral immune responses.
In this chapter I show that standard VSV-G-pseudotyped LVs prepared by transient 
transfection methods activate pDC, which results in high levels of IFN-a production 
in BM (Fig 3.2.1). Most of this activity appears to be contained in tubulo-vesicular 
structures (TVS) that outnumber the virus particles in standard LV preparations (Fig 
3.2.4).  TVS  carry  DNA  (Fig  3.2.7)  and  activate  TLR9  (Fig  3.2.6),  a  receptor 
implicated in innate immune responses against DNA viruses.  Purified TVS can act
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as potent adjuvant for co-administered antigens in vivo (Fig 3.2.12).  TLR9, that is 
required  for  production  of IFN-a  in  vitro,  is  not  required  for  initiating  adaptive 
immune  responses  against  TVS  (Fig  3.2.12)  and  LV  (Fig  3.2.11).  This  could  be 
attributable  to  alternative  stimuli  present  in  the  supernatant  of VSV-G  transfected 
cells. Indeed, it has been proposed recently that the VSV-G protein has the ability to 
activate  TLR4  (Georgel  et  al.,  2007).  However,  additional  stimuli  might  well  be 
present in TVS preparations as TLR7/9 and TLR4 responses are reduced in myd88" /_  
mice (Akira et al., 2006; Kawai and Akira, 2007), yet wt and myd88'f' mice mount a 
similarly strong immune response when immunised with TVS (Fig 3.2.11).
TVS may be similar to micro  vesicles found within HIV preparations, which appear 
to be the actual source of many cellular proteins previously thought to be associated 
with the virus envelope (Bess  et al.,  1997;  Gluschankof et al.,  1997;  Trubey et al.,
2003).  Like  those  microvesicles,  TVS  carry  proteins  of  producer  cell  origin, 
including proteins encoded by plasmids (Fig 3.2.4D) and proteins derived from the 
culture  medium  (FCS  components;  Fig  3.2.12C,  D).  Notably,  TVS  may  mediate 
transfer of several  of these  proteins  (e.g.  GFP)  into  target cells  (Fig  3.2.8),  likely 
explaining the phenomenon of “pseudo-transduction” observed with LV preparations 
(Nash  and  Lever,  2004).  The  actual  origin  of TVS  and  micro  vesicles  is  unclear 
although  the  presence  of  cell-derived  vesicular  structures  within  supernatants  of 
cultured cells is a long-established phenomenon (Dalton,  1975). TVS are unlikely to 
be  apoptotic  bodies  because  preliminary  experiments  suggested  that  deliberate 
induction of apoptosis in cells transfected with MLV-A, THOV-G or LCMV-G Env 
genes does not generate supernatants capable to stimulate cytokine production from 
BM cells (data not shown). Similarly, TVS are unlikely to be exosomes, which have 
a different EM appearance (Fevrier and Raposo, 2004).  I favour the possibility that 
TVS  are distinct structures,  which are actively induced by VSV-G  overexpression. 
This is supported by the fact that VSV-G is known to promote budding of vesicular 
stomatitis  virus  (Brown  and  Lyles,  2003b).  Furthermore,  an  alphavirus  replicon 
encoding  for  VSV-G  but  not  for  viral  capsid  proteins  spontaneously  generates 
infectious  virus-like  particles  (Rolls  et  al.,  1994).  VSV-G  is  not  the  only 
glycoprotein  with  budding  activity.  In  fact,  virus  surface  proteins  expressed  by 
Ebola-,  Respiratory  syncytial  virus  and  Rift  valley  fever  virus  are  important  for
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efficient budding of virus particles (Jasenosky and Kawaoka, 2004; Techaarpomkul 
et al., 2001)(and Friedemann Weber, personal communication). Bearing that in mind 
could be of importance when using these proteins to generate recombinant viruses 
for means of gene therapy or immunisation (Kobinger et al.,  2001;  Swenson et al., 
2005) as TVS-like structures could be present in these virus preparations.
VSV-G  is  expressed in  cells  that are  infected with  VSV.  However,  this  abundant 
presence does not result in TVS accumulation, as seen when transfecting the VSV-G 
plasmid (Fig 3.2.13).  TVS could potentially alert the immune system and the virus 
might therefore carefully balance the expression of VSV-G. The matrix (M) protein 
is  mainly  responsible  for  budding  of  VSV  (Mebatsion  et  al.,  1999).  VSV-G 
accumulates in foci on the plasma membrane and facilitates the budding process of 
preformed virus particles that are localising underneath the cell surface. It is believed 
that  the  virus  ensures  efficient  coating  of the  virus  particles  with  VSV-G  by  this 
mechanism  (Brown  and  Lyles,  2003a,  b).  It may be  that this  budding  mechanism 
minimises formation of TVS-like structures.
Functional  VSV-G  is  involved  in  TVS  formation  (Fig  3.2.4)  and  necessary  for 
induction of IFN-a from pDC (Fig 3.2.3).  This, together with the fact that VSV-G 
was unique in promoting innate stimulation, prompted me to speculate that the VSV- 
G  itself may  promote  IFN-a  production.  Fractionation  experiments,  resulting  in 
VSV-G containing fractions that do not activate an antiviral response, argue against 
this  hypothesis:  Fraction  3  and  4  in  Fig  3.2.5  contain  immunodetectable  VSV-G 
protein but elicit no or little IFN-a.  Furthermore, the TLR9 dependency for IFN-a 
induction  (Fig  3.2.6C)  suggests  that  TVS-associated  DNA  rather than  the  VSV-G 
protein is the actual stimulus.
The  VSV-G  protein  most  likely  promotes  delivery  of  TVS  into  endosomal 
compartments  of pDC  where  DNA  coming  from  the  producer  cell  is  sensed  by 
TLR9.  LVs  pseudotyped  with  other  glycoproteins  like  THOV-G,  LCMV-G  and 
MLV-A  do  not  act  as  strong  activators  of  BM  (Fig  3.2.2),  underlining  the 
importance  of the  VSV-G  protein  for  the  described  phenomenon.  LCMV-G  and 
THOV-G promote virus entry via the endosomal route (Borrow and Oldstone,  1994) 
(Fig 3.2.2A) but may not promote formation of DNA-containing TVS.
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It is surprising that murine pDC do not produce IFN-a in response to LV particles 
(Fig 3.2.2), which is in contrast to human pDC that produce IFN-a and mature in a 
TLR-dependent manner when exposed to HIV-I (Beignon et al.,  2005; Francis and 
Meltzer,  1993). It may reflect intrinsic differences between murine and human pDC 
in response  to  lentivirus  particles.  For instance,  murine pDC  could be  different in 
handling endosomal cargo, or, alternatively, HIV could be recognised by TLR8 that 
is thought to be non-functional in mice (Heil et al., 2004; Jurk et al., 2002). A simple 
explanation could be insufficient uptake of virus particles by pDC  although this is 
unlikely  as  VSV-G  allows  uptake  of  TVS,  which  results  in  a  TLR9  response. 
However,  in  comparison  to  other  stimuli  like  influenza,  VSV  or  HSV-2,  which 
trigger  IFN-a  responses  via  TLR7  and  TLR9,  respectively,  HIV-I  is  only  poorly 
stimulatory in human pDC (Beignon et al., 2005; Diebold et al., 2004; Fonteneau et 
al., 2004; Lund et al., 2004; Schmidt et al., 2005; Yonezawa et al., 2003).
A provocative possibility could be that replication-competent HIV-I  is only poorly 
recognised upon uptake of virus particles, but that lentiviral particles are delivered 
into an endocytic compartment later during the virus  life cycle.  HIV is believed to 
leave  the  cell  through  a  process  called  inward  budding.  This  process  involves 
delivery of virus particles into the endosome followed by exocytosis (Kramer et al., 
2005).  One could speculate that, newly generated HIV particles contribute to TLR7 
or -8  mediated interferon responses  in human pDC.  This hypothesis  can easily be 
tested  as  reverse  transcriptase  inhibitors  like  AZT  should  not  influence  TLR 
activation  if  the  virus  is  solely  activated  through  incoming  viruses.  If  virus 
replication  and  budding  is  necessary  for  efficient  TLR  activation  AZT  treatment 
should reduce TLR activation. If inward budding was involved in lentivirus sensing, 
expression of the HIV gag protein in pDC should result in a TLR7-dependent IFN-a 
response.  Alternatively,  BM  from transgenic  mice  bearing receptors  for successful 
entry  of HIV (Schule  et al.,  2006) could be  infected with wt HIV  and this  should 
give  a  TLR7-dependent  IFN  response.  Further,  if the  virus  is  recognised  during 
entry,  TLR  activation  should  be  possible  in  cells  lacking  a  functional  ESCRT 
system,  which  is  critically  involved  in  budding  of HIV  particles  (Stuchell  et  al.,
2004).  Sensing of viruses budding into the  endosome would add another aspect to
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TLR recognition and would underline the notion that the TLR system may also have 
evolved to as a means to ensure self-control in pDC (Lee et al., 2007).
In vitro, human pDC produce little IFN-a when exposed to HIV-I but this may be 
different  in  vivo,  as  the  virus  could  be  opsonised  and  thereby  would  be  better 
endocytosed by  pDC  (Palmer et al.,  2000).  In that regard,  it has  been  shown  that 
antibodies  present  in  the  serum  of  HIV  infected  patients  can  enhance  IFN-a 
production  if  added  together  with  HIV-1  to  peripheral  blood  mononuclear  cells 
(Green  et  al.,  2002),  an  effect  likely  explained by  increased  Fc-receptor mediated 
internalisation of HIV particles into pDC endosomes and recognition via TLR7.
I found that LV preparations can induce efficient CTL priming in MyD88-deficient 
mice  (Fig  3.2.11).  Thus,  in  vivo,  LVs  contain  immunostimulatory  properties  that 
cannot be  attributed to  TLR4  or TLR7/9  stimulation as those  receptors  signal  -  at 
least in part - via MyD88. A source of this activity could be DNA that is delivered 
into the cytoplasm of cells and then would activate cytoplasmic receptors for DNA, 
like the recently identified DAI  (Takaoka et  al.,  2007)  and others,  that  signal  in  a 
MyD88  independent  way.  How  does  DNA  that  is  present  in  LVs  enter  the  cell? 
Reagents such as DOTAP or PEI are routinely used to transfect cells but have also 
been exploited experimentally to deliver nucleic acids to endosomes for recognition 
by TLR7, -8 and -9 (Diebold et al., 2004; Heil et al., 2004).  Similarly, just like they 
deliver  DNA  for  innate  sensing  in  endosomes,  VSV-G-coated  TVS  also  act  as 
transfecting particles and deliver DNA directly into cells (Fig 3.2.8  and Fig 3.2.9). 
The ability of VSV-G to act as a transfection agent when added to plasmid DNA or 
to  retroviruses  lacking  envelope  proteins  has  been  noted  previously  (Abe  et  al., 
1998; Okimoto et al., 2001) and, given that cytosolic delivery of DNA activates anti­
viral responses (Ishii et al., 2006;  Stetson and Medzhitov, 2006a), this ability could 
account for TLR-independent innate stimulatory activity of TVS in vivo.
The notion that DNA can be present in LV preparations  is not new  (Sastry  et al.,
2004).  DNA delivery raises the possibility that TVS within LV preparations might 
transfer plasmids used for virus production  into  target cells.  Indeed,  I  could  show 
that  cells  exposed to  VSV-G-pseudotyped  LV  preparations  can  be  converted  into 
virus producing cells (Fig 3.2.9). Recombinant LVs have been tested extensively for 
potential clinical use (Fuller and Anson, 2004) and it is unlikely that plasmid transfer
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could ever constitute a risk in gene therapy protocols, especially as I detect only low 
titres  of newly  generated  infectious  virus  (Fig  3.2.9).  Nevertheless,  it  may  be  of 
value to assess LV preparations for the presence of TVS as this may further enhance 
their safety profile.
My  results  on  the  innate  stimulatory potential  of LV  preparations  have  important 
practical  implications  for  the  use  of recombinant  LVs  in  gene  therapy.  There  are 
many examples in which innate responses to vectors have adverse effects (Bessis et 
al.,  2004;  Chen  et  al.,  2003).  For  adenovirus  vectors  it  has  been  noticed  that 
induction of cytokines limits high expression of delivered genes (Bessis et al., 2004). 
Similarly,  interferons reduce gene  expression  from retroviral  vectors,  which  might 
contribute to the relatively poor performance of such vectors in vivo (Ghazizadeh et 
al.,  1997).  In mice,  intracranial delivery of VSV-G-pseudotyped LVs induces local 
inflammation  and  a  systemic  immune  response  which  can  limit  transduction 
efficiency (Baekelandt et al., 2003). Therefore, gene therapy approaches,  as well as 
in  vitro transduction of immune  cells,  would likely benefit  from  having  LVs with 
low innate stimulatory potential. In this regard, my results suggest that pseudotyping 
with  THOV-G,  LCMV-G  or  MLV-A  may  be  preferable to  the  more  widely  used 
VSV-G.  This  needs  to  be  weighed  against  the  fact  that  THOV-G,  LCMV-G  or 
MLV-A  also  result  in production  of LV preparations  containing  lower  virus  titres 
than those obtained by VSV-G-pseudotyping (references (Cockrell and Kafri, 2003; 
Verhoeyen and Cosset, 2004) and data not shown). If VSV-G cannot be avoided, my 
results suggest that either careful purification of virus particles or generation of virus 
in  stable  producer  cell  lines  by  retroviral  transduction  (Fig  3.2.10B)  or  inducible 
VSV-G  expression  (Ory  et  al.,  1996)  might  help  to  decrease  their  immunogenic 
potential.  However,  I  was  unable  to  purify  large  enough  quantities  of  virus  by 
gradient fractionation and yet would have to generate a stable LV producer cell line 
expressing  a  suitable antigen to  set up  in  vivo  experiments to  address  this.  In this 
line, it has been reported by others that sucrose gradient fractionation decreases LV 
immunogenicity  (Baekelandt  et  al.,  2003).  More  work will  be  needed  to  see  how 
different virus generation and purification methods impact on contamination by TVS 
and on immune responses.
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3.4.  Figures 
Figure 3.1.3
pMDLg/pRRE
pVSV-G
pLLCG
pRSV-REV
transfection
93T
I
concentration
Lentivirus preparation
Figure 3.1.3: Generation of recombinant lentiviruses
Transfection of 293T cells with four plasmids coding for the lentiviral capsid protein 
(pMDLg/pRRE),  an  envelope  protein  (pVSV-G),  the  lentiviral  genome  (pLLCG) 
and a helper plasmid (pRSV-REV) results in production of replication incompetent 
lentiviral particles that are released into the cell supernatant. The standard procedure 
of LV production involves ultracentrifugation as a means to increase the virus titre.
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Figure  3.1.4
it
T
RNA
TLR7
I
]MyD88|
1
IFN-a
Figure  3.1.4:  What  is  the  influence  of the  virus  infection  route  on 
TLR activation?
Recombinant lentiviruses (LV) can infect the cell via two routes (green arrows). Left 
arrow:  Virus  entry  through  the  endosome  should  theoretically  deliver  ssRNA  that 
activates TLR7, resulting in MyD88 dependent downstream signalling.  In pDC this 
would result in expression of IFN-a. Right arrow: Changing the envelope protein of 
the  virus  should  mediate  fusion  of  the  virus  particle  at  the  plasma  membrane. 
Therefore such a virus is not delivered into the endocytic compartment.
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Figure 3.2.1
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Figure 3.2.1: LV preparations induce IFNa production by pDC
(A)  1*106 BM cells were stimulated with VSV-G-pseudotyped LVs at the indicated 
MOI  or with  CpG  (0.5pg/ml;  positive  control)  or with  100-fold  concentrated  cell 
supernatant of untransfected cells (SN; negative control). Shown is the concentration 
of IFN-a in the supernatant as measured by ELISA  16h after treatment. (B) BM was 
treated with graded doses of CpG and IFN-a measured by ELISA after over night 
stimulation. (C) Intracellular staining for IFN-a in BM cells stimulated with LVs at a 
MOI  of 0.2  for  6h.  Left  panel:  IFN-a  vs.  CD 11c.  Right  panel:  Ly6C  and  B220 
expression  on  IFN-a  positive  cells  gated  as  indicated  in  the  left  panel.  Numbers 
represent the percentages of cells  in each gate.  (D,  E)  IFN-a  secretion  from B220 
MACS-enriched and B220 MACS-depleted BM cells isolated from rag2';  mice. (D) 
Panels show FACS blots of cells from B220 enriched and B220 depleted fractions. 
Numbers represent percentage  of cells  in  the  indicated  gate.  (E)  Accumulation  of 
IFN-a in supernatant of cells from (D) treated over night with VSV-G-pseudotyped 
LVs (MOI 0.2) or CpG (0.5pg/ml). (F) 2*105  Flt-3L derived BM-DC (approx 30% 
pDC)  were  treated  with  LV  (MOI  1)  and  IFN-a  measured  after  over  night 
incubation. One representative experiment of two (B), three (C, D, E, F) or more (A) 
experiments is shown.
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Figure 3.2.2
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Figure 3.2.2: LV entering the endosome do not necessarily stimulate 
IFN-a
(A)  293FT  cells  were  treated  with  medium  containing  the  indicated  amount  of 
ammonium chloride (NH4C1) for lh. Cells were then washed with PBS and infected 
for 1  h with the indicated viruses. Medium containing ammonium chloride was again 
added  for  over  night  incubation.  At  24h  cells  were  analysed  by  flow  cytometry. 
FACS  blots  show  cells  gated  on  sideward  and  forward  scatter.  SSC:  sideward 
scatter.  Numbers  indicate  percentage  of cells  in  the  indicated  gate.  (B)  BM  cells 
were stimulated with preparations containing LV bearing the indicated glycoproteins 
(MOI  1); IFN-a was measured by ELISA after over night culture, n.d., not detected. 
One of three (A) or more (B) experiments with similar results is shown.
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Figure 3.2.3: VSV-G expression is required for the IFN-a  response 
to LVs
(A) Treatment of BM with concentrated supernatants from 293FT cells transfected 
with  the  indicated  combinations  of plasmids  to  generate  preparations  of VSV-G- 
pseudotyped  LV  (LV),  LV  lacking  viral  RNA  (LVAvRNA)  or  LV  lacking  the 
envelope  protein  (LVAenv).  Concentrated  supernatants  (dilution  1:20)  from 
untransfected cells  (SN)  or  from  cells  transfected with plasmids  encoding  REV  + 
VSV-G  (VSV-G)  or  REV  +  viral  RNA  (vRNA)  were  tested  as  controls.  Where 
applicable,  stimuli  were  normalised  for  HIV  p24  content  (data  not  shown).  (B) 
Concentrated supernatant from VSV-G transfected cells (VSV-G) was pretreated as 
indicated for 30min and used to stimulate BM. (C) VSV-G supernatant (VSV-G) and 
CpG  (0.5pg/ml)  were  pre-incubated with  a neutralizing  anti-VSV-G  or unspecific 
msIgG (control  mAb)  before adding to BM cells.  (A-C) IFNa  in supernatants  was 
measured  by  ELISA  16h  after  stimulation,  n.d.,  not  detected.  One  representative 
experiment of three (B, C) or more (A) is shown.
Page 110Chapter 3 LV preparations activate TLR9
Figure  3.2.4 
A
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Figure  3.2.4:  VSV-G  transfection  induces  formation  of  tubulo- 
vesicular structures (TVS) that carry proteins of cellular origin
(A) Electron micrographs of supernatants (upper panels) and transfected cells (lower 
panels) producing VSV-G-pseudotyped LV,  VSV-G only or LV without envelope 
protein  (LVAenv).  Bars  represent  200nm  (upper  panels)  and  1pm  (lower  panels) 
respectively.  Black  arrows  indicate  TVS,  white  arrows  show  virus  particles.  * 
indicates the cell cytoplasm. (B) FACS blots of concentrated supernatant of cells that 
were left untransfected (control) or transfected to produce LV and VSV-G. Numbers 
show  percentage  of  particles  in  indicated  gates.  (C)  Histogram  of  concentrated 
supernatant  from  VSV-G  transfected  cells  stained  with  a  VSV-G  antibody  or  an 
isotype control. The panel shows particles of the indicated gate in (B).  (D) Western 
blots  of 20pl  concentrated  supernatant  of the  indicated  preparations  were  stained 
with the indicated antibodies. Experiments were repeated two (C) or three (A, B, D) 
times.
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Figure  3.2.5
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Figure  3.2.5:  TVS  constitute  the  main  pDC  stimulus  in  VSV-G- 
containing LV preparations
VSV-G-LV preparations were fractionated on  a continuous  sucrose  gradient.  Each 
fraction was assessed for IFN-a induction in BM cells (dilution 1:20, solid line) and 
for virus titre in 293T cells (dashed line). Western blots (20pl of each fraction) show 
the  relative  amount  of VSV-G  and  the  viral  capsid  protein  (HIV  p24)  in  each 
fraction. Fraction 8 represents the bottom of the gradient (dense fraction).
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Figure  3.2.6
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Figure  3.2.6:  IFN-a  induction  by  LV  preparations  and  TVS  is 
dependent on TLR9
(A) BM cells from C57BL/6 or m y d 8 mice were cultured in medium alone (No 
stim), with LV (MOI 0.1) or were electroporated with poly-I:C (0.5pg).  IFN-a was 
measured by ELISA after over night incubation. (B) IFN-a from tlrTA or wild type 
BM cells after stimulation with LV (MOI 0.1), R848 (lpg/ml) or CpG (0.5pg/ml). 
(C) BM cells from wild type or tlr9'' mice were stimulated with LV (MOI 0.1  and 
0.01), TVS (dilution  1:20 and 1:200), Loxoribine (20mM) or CpG (0.5pg/ml). IFN- 
a  was  measured  after over night culture,  n.d.,  not detected.  All  experiments  were 
repeated more than three times, representative experiments are shown.
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Figure 3.2.7: TVS and LV preparations contain plasmid DNA
(A)  Paraformaldehyde  fixed preparations of LV, TVS  and control transfected cells 
(pLLCG)  were  stained  with  the  nucleic  acid  stain  YOYO-1  (dilution  1:1000); 
histograms  show  YOYO-1  staining  of ungated  particles.  Dot  blots  show  particles 
gated on YOYO-1  as indicated in the histogram.  (B,  C)  RT-PCR and PCR for the 
indicated genes on RNA and DNA isolated from preparations of LV, LV lacking the 
envelope  protein  (LVAenv),  or  TVS  (concentrated  supernatant  from  VSV-G 
transfected  cells).  Expression  plasmids  for  VSV-G  and  GFP  or  cDNA  from  cells 
served  as  positive  controls  (pos  Ctrl)  (B).  In  (C)  the  indicated  serial  dilutions  of 
template were used for PCR and RT-PCR.  Starting concentration:  1/10th of nucleic 
acid  isolated  from  35p,l  concentrated  supernatant.  (D-F)  DNA  extracted  from  LV 
preparations  was  used  to  transform  bacteria.  (D)  The  table  shows  the  number  of 
ampicillin-resistant colonies after transforming bacteria with DNA isolated from 1ml 
LV or 1ml LVAenv.  lOng pUC19 plasmid was used as control. The average of three 
experiments  (±  SD)  is  shown.  (E)  Ampicillin-resistant  individual  colonies  were 
picked,  the plasmid DNA  extracted and analysed by restriction  double-digest with 
EcoRI and Hindlll for 3h. Lanes show the restriction pattern of a random sample of 
26 colonies and the pattern of the plasmids that were used for generation of LV as a 
control.  The first and last lanes  show molecular weight markers.  (F)  Frequency of 
bacterial  colonies  containing  each  plasmid  (average  ±  SD  from  3  independent 
experiments analysing a total of more than 150 colonies).
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Figure 3.2.8
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Figure 3.2.8: TVS transfer protein and/or nucleic acid
(A)  Schematic  drawing  of  the  experiment.  293FT  cells  were  transfected  with 
plasmids coding for GFP (peGFP-Nl) and VSV-G (pVSV-G) or the GFP expression 
plasmid  only.  48h  later  cell  supernatant  was  filtered  and  transferred  to  indicator 
cells.  (B)  FACS  blots  of  indicator  cells  48h  after  exposure  to  supernatant  of 
transfected  cells.  The  numbers  indicate  percentage  of cells  in  the  indicated  gates. 
SSC: sideward scatter.
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Figure 3.2.9:  LV preparations can transfer plasmid DNA to  target 
cells leading to production of new LV particles
(A)  293T cells were  infected with LV containing 2*108  gfu LV.  The medium was 
changed at the  indicated time points  (arrows)  and tested  for the presence of GFP- 
transducing virus. (B) Schematic outline of the experiment shown in (C): cells were 
transfected with 3 plasmids coding for the lentiviral capsid protein (pMDLg/pRRE), 
VSV-G  (pVSV-G)  and  REV  (pREV).  Concentrated  supernatant  from  these  cells, 
containing  both  TVS  and  LV  lacking  viral  genome  (LVAvRNA),  was  transferred 
onto 293HV cells that carry an integrated lentiviral genome coding for GFP. Newly 
generated  eGFP  expressing  virus  was  assayed  by  monitoring  GFP  expression  in 
293FT indicator cells. (C) Supernatant of 293HV cells only (293HV) or 293HV cells 
exposed  to  LVARNA  (293HV  LVARNA)  was  added  to  293T  cells  and  GFP 
expression was assayed 72h later by flow cytometry. (D, E) GFP positive cells from 
(C) were sorted, expanded for 6 weeks and analysed by flow cytometry (D) or used 
to isolate genomic DNA to test the presence of integrated virus and (3-actin by PCR 
(E). Untransduced and LV-infected 293FT cells were used as negative and positive 
controls,  respectively  (E).  All  experiments  were  repeated  three  times,  one 
representative experiment is shown.
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Figure  3.2.10
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Figure  3.2.10:  Avoiding  transient  transfection  reduces  IFN-a 
stimulatory activity of LV
(A)  IFN-a production in  BM after stimulation for  16h with LV,  a control plasmid 
(pMSCFeGFP,  control)  or  CpG  (0.5pg/ml).  Where  indicated,  LV  and  the  control 
plasmid were pretreated with benzonase for 2h at 37°C (B) VSV-G was introduced 
into  STAR-HV  cells  by  transient  transfection  or  by  retroviral  transduction. 
Supernatant containing VSV-G pseudotyped LV (MOI 0.1) was added to BM cells 
or used  for western blot analysis.  IFN-a was measured by  ELISA  16  hours  after 
treatment. CpG (0.5pg/ml) was used as a positive control, n.d., not detected. One of 
three experiments with similar results is shown.
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Figure 3.2.11
PBS + OVA  OVA-LV  CpG + OVA  PIC + OVA
co 0.1
s 0.1 0.5
Q
0.1
0.1 1.6
e
B
4
■   C57BL/6 
□   myd88 3
a
2
1
0
PBS+ LV CpG+  PIC+
OVA OVA  OVA
CD8
PBS + OVA  OVA-LV  CpG + OVA  PIC + OVA
8 1
V
_
\
v  v l
•■ =   60
J ID
C57BL/6
[J myd88
PBS+  LV  CpG+  PIC+
OVA  OVA  OVA
CFSE
Figure 3.2.11: LV induce adaptive immune responses in the absence 
of MyD88
C57BL/6  and myd88'1   mice  were  immunised  intravenously with  OVA  expressing 
LV (n = 4) or egg white in PBS (n = 2), CpG (n = 2) or poly-I:C (PIC; n = 2). (A) 
Contour plots  show Thyl.2+  cells  in blood of representative  mice  one  week  after 
immunisation.  Numbers  indicate  the  percentage  of OVA/H-2Kb  tetramer  positive 
cells, as gated. The graph in (B) shows the average ± SD frequency of OVA/H2-Kb  
tetramer positive Thyl.2+ cells for all mice. (C, D)  10 days after immunization mice 
were challenged with congenic CD45.1  splenocytes loaded with 20nM (CFSE low), 
200nM (CFSE intermediate) or OnM (CFSE high) of OVA peptide (SIINFEKL). (C) 
Histograms  show  the  CFSE  profile  of  target  cells  (gated  on  CD45.1)  from 
representative mice 48h after injection. (D) The graph shows the amount of specific 
killing  of  200nM  OVA  peptide  loaded  splenocytes  as  compared  to  splenocytes 
without OVA peptide. The average of all mice ± SD is shown.
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Figure 3.2.12: TVS act as adjuvant for adaptive immune responses
C57BL/6 and tlr9'f  mice were immunised intraperitoneally with egg white in PBS (n 
= 2) or with added TVS (n = 4), CpG (n = 2) or poly-I:C (PIC; n = 2). (A) Contour 
plots  show  Thyl.2+  cells  in  blood  of  representative  mice  one  week  after 
immunisation.  The  numbers  represent  the  percentage  of  OVA/H-2Kb  tetramer 
positive  cells,  as  gated.  The  graph  in  (B)  shows  the  average  ±  SD  frequency  of 
OVA/H2-Kb  tetramer  positive  Thyl.2+  cells  for  all  mice.  (C,  D)  10  days  after 
immunization mice were challenged with congenic CD45.1  splenocytes loaded with 
20nM  (CFSE  low),  200nM  (CFSE  intermediate)  or  OnM  (CFSE  high)  of  OVA 
peptide (SIINFEKL). (C) Histograms show the CFSE profile of target cells (gated on 
CD45.1)  from  representative  mice  48h  after  injection.  (D)  The  graph  shows  the 
amount of specific killing of 200nM SIINFEKL-loaded splenocytes as compared to 
splenocytes not loaded with OVA.  Shown is the average of all mice ±  SD.  (E)  12 
days after immunization splenocytes of wt mice were isolated, cultured over night in 
the  absence  or presence  of FCS  and  stained  for intracellular IFN-y.  Contour plots 
show  cells  gated  on  Thy 1.2.  The  numbers  indicate  frequency  of IFN-y  positive 
Thyl.2+  CD4+cells,  as  gated  (average  ±  SD  of  all  mice).  (F)  12  days  after 
immunization  serum  of wt mice was tested for the presence  of specific  antibodies 
against  OVA  and  FCS.  Data  are  displayed  as  titration  curves  from  individual 
representative mice.
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Figure 3.2.13: VSV does not generate detectable TVS
Representative electron micrographs of 293T cells infected with VSV for 24h.  (A, 
B) low magnification. (A) budding of virus off the plasma membrane. Insert shows a 
further  2-fold  magnification.  (B)  virus  accumulates  in  intrercellular  gaps.  (C,  D) 
Most particles have size and electron density characteristic for VSV. No TVS could 
be  detected  in  VSV  infected cells.  Bars  represent  the  indicated  length.  Arrows  in 
(A), (B) and (D) point to virus particles.
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Figure 3.3.1
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Figure 3.3.1: Model of IFN-a induction by LV preparations
293T  cell  transfection with plasmids commonly  used for LV production  results  in 
generation of virus particles (LV) and tubulo-vesicular structures (TVS).  The latter 
carry VSV-G on their surface and are delivered into the endosome of pDC. Plasmids 
(blue) present in TVS can activate TLR9 and this results in production of IFN-a.
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b
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CHAPTER 4:  RIG-I  is  activated  by  viral  RNA
bearing 5’ triphosphates
4.1.  Introduction
dsRNA  is believed to  be  the  main vims  associated pathogen  associated molecular 
pattern recognised within infected cells (Akira et al., 2006). Intracellular delivery of 
dsRNA by lipofection or electroporation rapidly stimulates high amounts of IFN-a/(3 
and other cytokines that are critical for inducing antiviral immunity (Diebold et al., 
2003). Recently, RIG-I and MDA5 have been defined as critical pattem-recognition 
receptors (PRRs) for RNA vimses (Gitlin et al., 2006; Kato et al., 2005; Kato et al., 
2006; Yoneyama et al., 2005; Yoneyama et al., 2004). Both proteins are capable of 
binding to poly-I:C but display distinct specificities for certain vimses. RIG-I senses 
vimses  like  NDV,  VSV,  Flu  and  SeV  whereas  MDA5  is  activated  by  the 
picomavimses  EMCV  and  Theiler's  vims  (Gitlin  et  al.,  2006;  Kato  et  al.,  2006). 
Likewise, RIG-I is necessary for inducing IFN-a/p in response to in vitro transcribed 
dsRNA  whereas  MDA5  is  indispensable  for  recognition  of poly-I:C  (Gitlin  et  al., 
2006;  Kato  et  al.,  2006).  The  reason  for  this  discrepancy  between  both  RNA- 
helicases was not known.
CD8+  DC,  a  DC  subset  with  special  abilities  to  phagocytose  apoptotic  material, 
produce IFN-p and IL6 when co-cultured with cells that were infected with EMCV 
or SFV or pulsed with poly-I:C (Schulz et al., 2005). TLR3 present in endosomes of 
CD8+  DC  recognises  dsRNA,  which  is  thought  to be  commonly  generated  during 
vims replication.  However, when Oliver Schulz in my laboratory co-cultured CD8+  
DC with Flu infected Vero-cells no IL6 production could be seen (Pichlmair et al., 
2006).  We  hypothesised  that  this  could  be  due  to  the  influenza  vims  interferon 
antagonist  NS1  as  this  protein  is  supposed  to  exert  its  function  by  sequestering 
dsRNA.  However,  cells  infected  with  a  mutant  vims,  lacking  a  functional  NS1 
protein (FluANSl) were still not able to activate  CD8+  DC  although all  Vero cells
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were  expressing  Influenza  virus  nucleoprotein  suggesting  that  the  cells  were 
homogenously infected (Pichlmair et al., 2006).
Possible explanations  for the  lack of TLR3  activation could be that dsRNA  is  not 
accessible in Flu infected Vero-cells or that replication of the Flu genome does not 
result in accumulation of dsRNA. To test the latter hypothesis, Oliver infected Vero 
cells and measured the content of intracellular dsRNA by ELISA (Pichlmair et al, 
2006) and intracellular FACS  (Fig 4.1.1 A).  As expected, EMCV and SFV infected 
Vero cells contained substantial amounts of dsRNA  (Fig 4.1.1 A and (Pichlmair et 
al.,  2006)).  Surprisingly,  however,  Flu  and  FluANSl  infected  cells  did  not 
accumulate detectable amounts of dsRNA (Fig 4.1.1 A and (Pichlmair et al., 2006)), 
despite the fact that they were uniformly infected (Fig 4.1.IB). This result is in line 
with  a  recent  report  from  Friedemann  Weber,  stating  that  negative  strand  RNA 
viruses like Influenza or SeV do not generate detectable amounts of dsRNA (Weber 
et al., 2006). The lack of dsRNA production was not dependent on the infected cell 
line  as  this  phenomenon  was  conserved  in  monkey  fibroblasts  (Vero),  human 
fibroblasts (HEK293) murine  fibroblasts  (NIH3T3),  and murine  BM-DC  (personal 
communication Oliver Schulz). We concluded that influenza virus infection appears 
to generate no or only marginal amounts of dsRNA during its infectious life cycle.
As dsRNA was considered to be  the  main  stimulus for intracellular PRRs  and we 
could not detect dsRNA  in influenza virus  infected cells,  I  set  out to  test whether 
ssRNA can elicit an IFN-a/p response.
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4.2.  Results
4.2.1.  Influenza virus lacking a functional NS1 protein is a 
potent IFN inducer
dsRNA  is  reported  to  be  critically  involved  in  IFN-a/p  production  by  the 
cytoplasmic  PRRs  RIG-I  and MDA5  (Kato  et al.,  2006).  As there  was no  or little 
detectable dsRNA in cells infected with FluANSl  I tested whether this virus induces 
IFN-a/p. I  co-transfected  HEK293  cells  with  a  reporter  plasmid  that  carried  the 
firefly-luciferase gene under control of the IFN-P promoter and a plasmid coding for 
renilla-luciferase  under  the  control  of a  constitutive  promoter,  which  served  as  a 
transfection control.  24h  later the  cells were  infected with  FluANSl,  SeV,  EMCV 
and SFV at a comparable MOI. As reported previously (Garcia-Sastre et al.,  1998), 
FluANSl  and SeV strongly activated the IFN-P promoter, whereas EMCV and SFV 
were less strong inducers of the IFN-P promoter (Fig 4.2.1). Oliver Schulz obtained 
similar results when he stimulated BM-DC: compared to EMCV and SFV, FluANSl 
was always superior in inducing IFN-a from BM-DC (Pichlmair et al., 2006).  The 
superiority of FluANSl  and  SeV  over EMCV  and  SFV  could be  explained by the 
fact that the latter viruses are wild-type strains that are very often bad inducers of 
IFN-a/p.  However,  I  concluded  that  IFN-a/p  production  does  not  require 
accumulation of detectable amounts of dsRNA.
4.2.2.  The NS1 protein  inhibits IFN-a/p production from
some but not  from all viruses
As discussed in the introduction, the NS1  protein suppresses IFN-a/p production in 
virally  infected  cells  and  is  important  for  efficient  influenza  virus  replication  in 
interferon competent systems (Diebold et al., 2003; Garcia-Sastre et al.,  1998).  The 
most  accepted  belief is  that  the  RNA  binding  site  of the  NS1  protein  sequesters 
dsRNA  and thereby  prevents  induction  of IFN-a/p  (Diebold  et  al.,  2003;  Garcia- 
Sastre et al.,  1998). As no dsRNA could be detected in Flu infected cells (Fig 4.1.1 
and (Weber et al., 2006)), I analysed how the NS1 protein might function.
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I  asked  whether  NS1  has  the  ability  to  sequester  dsRNA  produced  during  an 
infection  with  EMCV  and  SFV  and  thereby  suppresses  IFN  induction  elicited  by 
those viruses.  As shown previously by others,  transfection of a NS1  (derived from 
influenza  strain  A/PR8/34)  expressing  plasmid  into  HEK293  cells  actively 
suppressed IFN-p luciferase production in FluANSl and SeV infected cells (Hayman 
et  al.,  2007;  Kochs  et  al.,  2007;  Talon  et  al.,  2000),  whereas  an  empty  control 
plasmid  was  not  able  to  do  so  (Fig  4.2.2).  Surprisingly,  however,  NS1  showed 
remarkable  specificity,  as  it  appeared  not  to  influence  IFN-P  promoter  activation 
from EMCV or SFV (Fig 4.2.2). Notably, the former two viruses produce minimal 
amounts of dsRNA but strongly activated the IFN-P promoter whereas EMCV and 
SFV generate high levels of dsRNA but lower levels of IFN-p luciferase (Fig 4.1.1, 
Fig 4.2.1  and (Pichlmair et al.,  2006;  Weber et al.,  2006)).  Oliver Schulz obtained 
similar data by showing that a recombinant SFV expressing either the NS1 protein or 
an irrelevant protein induce similar amounts of IFN-a in BM-DC (Pichlmair et al., 
2006).
Collectively,  these  data  indicate  that  neither  IFN-a/p  induction  nor  the  inhibitory 
effect of NS1 correlate with levels of dsRNA.
4.2.3.  Flu NS1 co-localises and co-precipitates with RIG-I
Interestingly,  recent  studies  have  demonstrated  that  both  SeV  and  FluANSl  are 
recognised  via  RIG-I  whereas  EMCV  elicits  responses  via  MDA5.  I  therefore 
investigated whether the virus-specific  effects of NS1  correlated with its  ability to 
interact  with  RIG-I.  Consistent  with  this  possibility,  the  NS1  protein  co- 
immunoprecipitated with an eGFP tagged version of RIG-I when both proteins were 
expressed  in  293T  cells  (Fig  4.2.3A).  Similarly,  NS1  and  eGFP-RIG-I  co- 
immunoprecipitated when influenza virus  infection was used to  introduce the NS1 
protein  into  eGFP-RIG-I  expressing  293T  cells  (Fig  4.2.3A).  In  addition, 
immunofluorescence staining revealed that in influenza virus infected 293T cells the 
cytoplasmic fraction of NS1 co-localised with transfected GFP-RIG-I (Fig 4.2.3B). 
As  NS1  was  not  able  to  block  activation  of the  IFN-P  promoter  when  a  MDA5 
dependent virus (EMCV) was used for stimulation, I investigated the possibility that 
NS1  specifically interacts with RIG-I but not with MDA5.  Therefore I  transfected
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293T cells with HA tagged versions of RIG-I and MDA5 and subsequently infected 
those cells with Flu.  As expected, HA-RIG-I could be co-immunoprecipitated with 
anti-NSl  antibody  after  influenza virus  infection  (Fig 4.2.3C).  In  contrast,  MDA5 
did not co-precipitate with NS1 (Fig 4.2.3C).
These results suggest that NS1  specifically targets RIG-I during Flu infection.
4.2.4.  The ssRNA genome of Flu induces IFN-a and IL6
I considered how infection with Influenza virus might lead to RIG-I activation in the 
absence  of  detectable  dsRNA  and  how  NS1  interferes  with  this  process.  TLR- 
mediated  virus  recognition  process  evolved  to  recognise  virus  genomes  delivered 
into endosomes and I speculated that the cytoplasmic recognition system might have 
evolved ways to sense cytoplasmic presence of virus genomes.  Furthermore,  RIG-I 
binds RNA, and I considered the possibility that RIG-I might recognise the influenza 
single-stranded  RNA  genome  directly.  Consistent  with  this  hypothesis,  BM-DC 
transfected with genomic RNA  isolated from influenza virus particles (Flu vRNA) 
produced high amounts of IFN-a and IL6, comparable or superior to those elicited 
by poly-I:C  (Fig  4.2.4A).  Flu  vRNA  was  unique  in  terms  of IFN-a  induction  as 
other transfected RNAs like spleen mRNA, total bovine RNA, bovine t-RNA or E. 
coli tRNA did not elicit IFN-a above background (Fig 4.2.4B).
Cytoplasmic  virus recognition is believed to critically depend on  virus replication. 
However, genomes of negative strand RNA viruses are not infective and transfection 
cannot result in replication or production of progeny virus (Lamb and Krug, 2001). 
Consistent  with  this  notion,  293HEK  cells  transfected  with  Flu  vRNA  did  not 
produce  Flu  specific  proteins  (Fig  4.2.4C)  as  tested  by  western  blot.  Further, 
supernatant  of the  same  cells  did  not  contain  cytopathic  activity  on  Vero  cells, 
suggesting the  absence  of a cytolytic  virus  like  influenza  (Fig  4.2.4D).  Dominant 
interfering particles of the ssRNA virus VSV can contain dsRNA, which is believed 
to  act  as  potent  IFN-a/p  inducer  (Marcus  and  Sekellick,  1977).  To  exclude  a 
possible dsRNA contamination of Flu vRNA I used acridine orange staining of Flu 
vRNA separated on an agarose gel, a method that has been used extensively in the 
past to easily discriminate between single- and double stranded nucleic acid (Lauretti 
et al., 2003). Acridine orange is a metachromatic stain resulting in green colour for
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ds nucleic acid (dsRNA and dsDNA) whereas ss nucleic acid (ssRNA and ssDNA) 
appears  flame-red  when  excited  with  UV  light  at  254  nm.  In  contrast  to  RNA 
preparations  containing  a  dsRNA-genome  of the  bacteriophage  (BRL  5907),  Flu 
vRNA  preparations  appeared  not  to  contain  detectable  amounts  of  dsRNA  (Fig 
4.2.4E).
I concluded that ssRNA from Influenza virus particles is sufficient to stimulate IFN- 
a/p.  This IFN production does not require dsRNA or virus replication as generally 
assumed for activation of cytoplasmic PRRs.
4.2,5.  IFN induction by Flu vRNA is blocked by NS1
As shown in Fig 4.2.2 the NS1 protein blocks IFN-a/p induction from Flu and SeV. 
I tested whether the IFN-a/p response to  single-stranded Flu vRNA is  sensitive to 
NS1. Compared to an appropriate control, expression of NS1  in 293T cells markedly 
reduced activation of the IFN-p promoter triggered by Flu vRNA transfection (Fig 
4.2.5).  A mutant NS1  (NS1  R38A K41A),  which bears two point mutations in the 
dsRNA binding domain, loses its ability to bind dsRNA (Donelan et al., 2003; Min 
and Krug, 2006) and a recombinant influenza virus bearing the same point mutations 
in its NS1 has been reported to induce higher levels of IFN-a/p than a corresponding 
virus with an intact NS1  (Donelan et al., 2003). I considered the possibility that the 
NS1 protein may exert its activity by interacting with single stranded RNA and that 
this  may  require  a  functional  dsRNA-binding  domain.  Consistent  with  this 
hypothesis  wt NS1  was  much  more  potent  in blocking  IFN-p  promoter activation 
after Flu vRNA transfection than a mutant NS1  (NS1  R38A K41A) (Fig 4.2.5). The 
expression of wt and mutant NS1  was similar (Fig 4.2.5), excluding the possibility 
that the observed effect was simply due to differences in expression levels.  Choon- 
Ping Tan in our laboratory found that wt NS1  but not the mutant NS1  was able to 
bind to beads coated with ssRNA (Pichlmair et al.,  2006),  demonstrating that NS1 
can interact with ssRNA.
Collectively  these  data  suggest  that  NS1  can  bind  to  ssRNA  and  block  IFN-a/p 
induction triggered by the ssRNA genome of influenza virus and both effects depend 
on the integrity of the dsRNA binding site.
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4.2.6.  RIG-I is the cytoplasmic sensor for Flu vRNA
NS1  binds  to  RIG-I  and  specifically  blocks  IFN-a/p  triggered  by  the  RIG-I 
dependent viruses Flu and SeV, which may suggest that responses blocked by NS1 
are RIG-I dependent. Consistent with this, activation of the IFN-P promoter by Flu 
vRNA was inhibited by expression of a dominant negative RIG-I-helicase construct 
when  compared  to  an  empty  control  plasmid  (Fig  4.2.6A).  Also,  reducing 
intracellular levels of RIG-I by means of siRNA in human 293HEK or mouse 3T3 
cells reduced activation of the IFN-P promoter by Flu vRNA to comparable levels as 
the control SeV (Fig 4.2.6B). IFN-p triggered by EMCV, in contrast, was unchanged 
in  cells  that  received  siRNA  for  RIG-I,  consistent  with  the  notion  that  EMCV 
induces  IFN-a/p  via  MDA5  (Fig  4.2.6B).  SiRNAs  were  designed  to  be  species 
specific; therefore hRIG-I siRNA served as unspecific control for mRIG-I siRNA in 
murine  cells  and vice  versa  in  cells  of human  origin.  Unspecific  effects  mediated 
through siRNA transfection could be excluded,  as cells receiving unspecific siRNA 
were similarly responsive as cells not receiving siRNA (Fig 4.2.6C).
I concluded that RIG-I is responsible for sensing Flu vRNA.
4.2.7.  Similar  to  Flu  vRNA,  in  vitro  transcribed  RNA 
induces IFN-a/fi
Flu vRNA is uncapped and contains phosphorylated 5’  ends (5’PPP),  a remnant of 
the transcription process. Notably, phosphorylated 5’  termini in siRNA and ssRNA 
generated  by  viral  RNA  polymerases  in  vitro  have  been  reported  to  induce  IFN- 
a/p responses when transfected into cells (Kim et al., 2004). I confirmed that in vitro 
transcribed RNA elicits an IFN-a response when transfected into murine BM-DC or 
NIH3T3 cells (Fig 4.2.7A, B) and activates the IFN-p promoter in NIH3T3 cells and 
human HEK293 cells (Fig 4.2.7C, D). As reported, treatment of in vitro transcribed 
RNA  with  Calf intestinal  phosphatase  (CIP),  which  removes  the  5’  triphosphate 
group, completely abolished activation of the IFN-P promoter (Fig 4.2.7C, D). Long 
dsRNA  generated  by  annealing  of in  vitro  synthesised  sense  and  anti sense  GFP- 
RNA induced IFN-a in NIH3T3  cells, as reported (Kato et al., 2006) (Fig 4.2.7E).
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Surprisingly, IFN-a induction by dsGFP-RNA was highly sensitive to CIP treatment 
(Fig 4.2.7E).
From these experiments I concluded that, unlike any other RNA tested (Fig 4.2.4B), 
Flu  vRNA  and  in  vitro  transcribed  RNA  are  both  inducing  IFN-a/p  when 
transfected  into  cells.  In  vitro  transcribed  ssRNA  and  in  vitro  generated  dsRNA 
require the presence of a 5’triphosphate group to induce IFN-a/p.
4.2.8.  59  phosphates present  on  Flu  vRNA  are  critically
involved in IFN-a/p induction
I proceeded to test whether Flu vRNA recognition also depends on the presence of 
phosphorylated 5’  ends. Treatment of Flu vRNA with CIP completely abrogated its 
stimulatory properties, whether tested in an IFN-P reporter assay (Fig 4.2.8A) or by 
IFN-a  and  IL6  induction  in  BM-DC  (Fig  4.2.8B).  To  exclude  that  CIP  was 
contaminated or has  an unspecific effect on the  RNA,  I  incubated Flu vRNA with 
CIP  in  the  absence  or  presence  of increasing  amounts  of inorganic  phosphate  or 
EDTA,  which  both  act  as  phosphatase  inhibitors.  As  expected,  inhibiting  CIP 
restored the  stimulatory  activity  of Flu  vRNA  to  levels  seen  without  phosphatase 
treatment (Fig 4.2.8C).  CIP did not affect the ability of vRNA to  stimulate TLR7- 
dependent IFN-a production from BM, which contains pDC (Fig 4.2.8D), showing 
that CIP treatment does not unspecifically degrade the RNA.  Further,  this suggests 
that 5’ phosphorylation is not required for TLR7 activation.
Choon-Ping Tan in our laboratory could show that RIG-I has higher binding affinity 
to  beads  coupled  to  5’  triphosphorylated  RNA  as  compared  to  beads  bearing 
unphosphorylated version of the  same RNA (Pichlmair et al.,  2006), which  further 
suggests that RIG-I binds and senses 5’ phosphates.
In  conclusion,  the  RIG-I  agonist  Flu  vRNA  induces  cytokine  responses  in  a 
5’phosphate dependent manner.
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4.2.9.  RIG-I activating virus genomes  induce IFN-a  in  a
5’PPP dependent manner
Many other ssRNA viruses belonging to the family of negative strand RNA viruses 
have  uncapped  genomes  (Ball,  2001;  Lamb  and  Krug,  2001),  including  vesicular 
stomatitis virus (VSV) (Rose and Whitt, 2001) that is recognised via RIG-I (Kato et 
al., 2005; Kato et al., 2006).  Similar to Flu vRNA, transfection of vRNA from VSV 
activated the IFN-P promoter in HEK293 cells (Fig 4.2.9A) and elicited IFN-a from 
BM-DC  (Fig  4.2.9B),  which  was  completely  abrogated  by  CIP  treatment  (Fig 
4.2.9A,  B).  Picomavirus  genomes  like  the  one  of EMCV  do  not  have  a  5’  tri­
phosphate but a covalently bound protein at the 5’ terminus (Ball, 2001; Racaniello, 
2001).  Consistent with the lack of 5’  phosphates,  EMCV is recognised via MDA5 
instead of RIG-I (Gitlin et al., 2006; Kato et al., 2006) and EMCV vRNA failed to 
induce a response when transfected into cells at amounts comparable to Flu or VSV 
vRNA (Fig 4.2.9A). At high doses, however, transfection of EMCV vRNA elicited 
IFN-a in NIH3T3 cells (Fig 4.2.9C), as might be expected from the fact that vRNA 
from positive strand RNA viruses is infectious (Ball, 2001; Racaniello, 2001).
These  data  suggest  that  cells  use  RIG-I  to  recognise  phosphorylated  5’  ends  of 
uncapped  ssRNA  viral  genomes  and  that  RNAs  not  recognised  by  RIG-I  bear 
5’modifications or lack a 5’ triphosphate.
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4.3.  Discussion
The ability to sense viral presence is critical to initiate innate- and adaptive immunity 
to viral infection (Akira et al.,  2006;  Iwasaki and Medzhitov,  2004;  Pichlmair and 
Reis e  Sousa,  2007).  dsRNA produced during viral replication and transcription or 
present in the genome of dsRNA viruses is thought to constitute the major target of 
the RIG-I and MDA5 RNA helicases involved in cytosolic viral sensing (Kawai and 
Akira, 2006; Meylan et al., 2006). The ability to produce dsRNA after virus infection 
was  already  recognised  in  the  70’s  when  a  couple  of publications  suggested  the 
presence  of dsRNA  after infection with various  viruses  (Merigan,  1970).  Notably, 
there are no reports of dsRNA production from negative strand RNA viruses like Flu 
and SeV. Indeed, when compared to some positive strand RNA vimses like SFV and 
EMCV, the negative strand RNA vimses influenza A and SeV generate undetectable 
amounts  of dsRNA  in infected cells,  if any  (Fig 4.1.1  and (Pichlmair et al.,  2006; 
Weber  et  al.,  2006)).  As  experiments  done  by  Oliver  Schulz  (Fig  4.1.1  and 
(Pichlmair  et  al.,  2006))  and  by  Friedemann  Weber  (Weber  et  al.,  2006)  are 
essentially based on the same technique using monoclonal antibodies raised against 
dsRNA  one  cannot  exclude  that  the  antibody  is  selectively  binding  to  products 
generated  by  positive  strand  RNA  vimses.  However,  the  absence  of 
immunodetectable  dsRNA  in  influenza  vims  infected  cells  correlates  with  the 
inability to stimulate TLR3  in CD8+ DC (Pichlmair et al.,  2006),  strengthening the 
point  that  influenza  vims  infected  cells  only  contain  little  amounts  of  dsRNA. 
Despite the apparent absence of dsRNA, however,  influenza vims can elicit a very 
potent  innate  immune  response  involving  production  of IFN-a/p  (Fig  4.2.1)  by 
activating the cytoplasmic sensor protein RIG-I (Kato et al., 2006).
In this chapter, I describe dsRNA independent activation of a cytoplasmic PRR that 
leads to production of IFN-a/p and could constitute a major innate stimulus in cells 
infected  with  influenza  vims:  When  transfected  into  cells,  the  uncapped  single 
stranded  RNA  genome  isolated  from  influenza  vims  particles  (vRNA)  acts  as  a 
powerful stimulator of IFN-a/p and IL6 (Fig 4.2.4).  Dominant interfering particles
Page 135Chapter 4 RIG-I and 5’PPP-RNA
of VSV are known to be strong inducers of the IFN system, a phenomenon originally 
explained by the presence  of dsRNA  in these preparations  (Marcus  and  Sekellick, 
1977).  However,  Flu  vRNA  did  not  contain  detectable  dsRNA  when  tested  by 
acridine orange staining (Fig 4.2.4E). I could exclude new generation of dsRNA as 
transfection of genomes derived from negative strand RNA viruses does not result in 
expression  of  detectable  virus  proteins  and  accumulation  of  progeny  virus  (Fig 
4.2.4D, E), consistent with the conception that negative strand RNA is not infectious 
(Ball,  2001;  Lamb  and Krug,  2001).  Further,  transfection of ssRNA  generated by 
viral polymerases in vitro resulted in a similar IFN-a/p induction (Fig 4.2.7). 
Expression  of  a  dominant  negative  protein  and  siRNA  knockdown  experiments 
suggest that  RIG-I  is  involved  in  sensing  Flu vRNA  (Fig 4.2.6).  I  cannot  entirely 
exclude the possibility that other proteins are involved, as cells receiving siRNA for 
RIG-I  were  still  able  to  activate  the  IFN-P  promoter  albeit  to  lesser  extent  (Fig 
4.2.6B, C). This is likely to be explained by insufficient reduction of the endogenous 
protein level. Testing this proved to be difficult as commercially available antibodies 
did not detect endogenous RIG-I (data not shown). It would be possible to clarify the 
requirement for RIG-I by using cells from mice genetically engineered to lack RIG-I 
(Kato et al., 2005).
I demonstrate that vRNA from influenza virus is not unique in its ability to activate 
RIG-I  as  vRNA  from  VSV,  another  RIG-I-dependent  ssRNA  virus,  behaves  in  a 
similar manner (Fig 4.2.9B, C). Notably, the response to both vRNAs is abrogated 
by  dephosphorylation  with  CIP,  suggesting  that  RIG-I  recognises  viral  5’ 
phosphorylated ssRNAs (Fig 4.2.8 and Fig 4.2.9B, C). I excluded the possibility that 
unspecific  effects  of  the  dephosphorylation  process  could  influence  IFN-a/p 
induction as CIP treated RNA was still able to stimulate TLR7 responses in BM (Fig 
4.2.8D)  and  blocking  CIP  by  phosphatase  inhibitors  preserved  the  stimulatory 
potential of vRNA (Fig 4.2.8C).
Transcription  of  5’  triphosphorylated  RNA  is  not  uncommon  as  all  cellular 
polymerases transcribe RNA bearing  5’  triphosphates.  The  absence  of RIG-I  from 
the nucleus (Fig 4.2.3B) and the requirement of signalling molecules partly tethered 
to mitochondria may explain why IFN responses  are not initiated.  Intriguingly, the 
5’PPP  is  very  often  lost  during  processing  and  modification  of  cellular  RNA.
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Messenger RNA (mRNA), for instance, is transcribed by the cellular polymerase-II 
(pol-II) and enzymes that are part of the pol-II transcription complex mediate ‘RNA- 
capping’,  a  process  that  results  in  covalent  binding  of  a  7-mehtyl  guanosine 
nucleotide  (Cap)  at the  5’  end of the  RNA, therefore masking the  5’  triphosphate 
group  (Alberts  et  al.,  2002).  A nuclear protein,  CRM1  (also  called  exportin  1),  is 
involved in exporting large RNA fragments but this only happens in the presence of 
a Cap (Alberts et al., 2002).  It is feasible to speculate that the nuclear RNA export 
machinery does not allow potential  stimulatory  RNA  (bearing  5’  triphosphates)  to 
enter  the  cytoplasm  and  therefore  contributes  to  avoid  recognition  of  self-RNA. 
Transfer  RNA  (tRNA)  is  processed  from  a  larger  precursor  tRNA  that  must  be 
trimmed and covalently altered before allowed to exit from the nucleus (Alberts et 
al., 2002; Xiao et al., 2002). Therefore tRNA only bears a 5’ monophoshate and this 
has been shown not to be sufficient to activate RIG-I (Homung et al., 2006). Similar 
to tRNA, ribosomal RNA (rRNA), that represents the most abundant RNA species in 
the  cell,  undergoes  a  processing  step  before  leaving  the  nucleus.  Most  rRNA 
subunits are transcribed as a single 13 kilo Bases precursor RNA that is cleaved and 
subject to  extensive  chemical  modifications before  leaving  the  nucleus  (Alberts  et 
al.,  2002).  Such chemical modifications  include methylation of the 2’OH positions 
on  nucleotide  sugars  and  isomerization  of uridine  to  pseudouridine  nucleotides. 
Functions of these modifications  are not understood but are thought to  aid folding 
and assembly of the final rRNAs (Ferre-D'Amare, 2003).  However, Homung et al. 
and others (Homung et al., 2006; Kariko et al., 2005) showed very elegantly that the 
presence of pseudouridine and other nucleotide modifications found in mammalian 
RNA abolishes IFN induction despite the presence of a 5’ triphosphate. Notably, the 
5S rRNA found in the cytoplasm carries a methyl group on the y-phosphate of the 5’ 
RNA  terminus  and  I  would  expect  that this  kind  of RNA  might  not  allow  RIG-I 
activation.  Clearly,  chemical  modification  of  cellular  RNA  within  the  nucleus 
contributes to avoid initiation of antiviral processes elicited by cellular RNA. 
Interestingly,  in  my  hands,  GFP-tagged  RIG-I  appears  to  reside  in  the  cytoplasm 
(Fig 4.2.3B), which could be of importance to ignore newly transcribed 5’PPP-RNA 
generated  in  the  nucleus.  One  could  even  speculate  that  orthomyxoviruses  like 
influenza  exploit  this  ‘ignorance’  by  replicating  in  the  nucleus  (Lamb  and  Krug,
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2001), although this may also have other reasons like the use of the cellular splicing 
machinery in order to process viral RNA (Lamb and Krug, 2001).
In  vitro  studies  suggest  that  virus  delivery  into  cells  can  induce  IFN-a/p  in  the 
absence  of virus  replication  and  independent  of TLR  recognition  (Collins  et  al., 
2004;  Hidmark et al.,  2005;  Isaacs and Lindenmann,  1957).  Remarkably,  IFN was 
originally discovered as a factor that is produced from chorio-allantois membranes 
infected  with  heat  inactivated  influenza  virus  (Isaacs  and  Lindenmann,  1957).  As 
heat  inactivated  influenza  virus  cannot  replicate  I  would  suspect  that  the  virus 
genome was the  initiator for IFN production.  Entry of virus particles therefore can 
deliver stimulatory nucleic acid that can be sensed by cytoplasmic PRRs.  However, 
it  is  questionable  whether  the  amount  of  virus  entering  a  cell  during  a  natural 
infection  is  sufficient  to  activate  an  IFN  response  and  I  would  rather  expect  that 
virus replication is necessary to amplify the agonist.
Orthomyxoviruses  such  as  influenza  generate  two  types  of RNA.  Viral  mRNA  is 
capped  at  the  5’  end  because  the  viral  polymerase  actively  scavenges  host  cell 
mRNA caps  to use  as primers  for mRNA  synthesis  (Krug  et al.,  1979;  Lamb  and 
Krug,  2001).  At  later  stages  of the  infectious  cycle,  the  polymerase  switches  to 
making primer-independent full-length transcripts of template RNA which are then 
replicated  into  vRNA,  again  in  a  primer-independent  manner  (Lamb  and  Krug, 
2001).  This  primer-independent  replication  process  results  in  5’  triphosphorylated 
genomic RNA (Ball, 2001; van Dijk et al., 2004) and other RNA species of shorter 
length (personal communication George Brownlee). However, influenza virus RNA 
requires  accessory  viral  proteins  to  exit  the  nucleus:  The  nucleoprotein  (NP)  of 
influenza virus binds  to  virus  RNA  and at  the  same  time  can  interact  specifically 
with CRM1, the nuclear export factor that is needed for mRNA transport through the 
nuclear  pore  (Elton  et  al.,  2001).  Thus,  through  direct  interaction  with  cellular 
proteins involved in nuclear export, the triphosphorylated virus genome and possibly 
other viral RNA  species gain access to the  cytoplasm.  However,  whether the viral 
RNA  genome  or  other  viral  RNA  species  are  recognised  by  RIG-I  is  currently 
unknown. In fact, the virus polymerase complex is still attached to the 5’ end of the 
virus’  genomic segments and may potentially protect the genomic viral RNA from 
being recognised by RIG-I (Basler and Garcia-Sastre,  2007).  In that regard,  it was
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shown  that  viral  transcripts  are produced early in  the  replication  cycle  of measles 
virus and these may be sensed via RIG-I (Plumet et al, 2007).
For influenza virus,  the  viral  RNA  (i.e.  the viral genome  and possibly  other RNA 
species)  exported  from  the  nucleus,  contains  uncapped  5’  ends  bearing  tri­
phosphorylated ribonucleotides (Lamb and Krug, 2001). My data would indicate that 
this type of RNA can be recognised by cytosolic  RIG-I unless this is prevented by 
the NS1 protein (Fig 4.2.2). Others and myself found that the NS1  protein binds and 
inhibits  RIG-I  dependent  interferon  responses  (Fig  4.2.2)(Guo  et  al.,  2007; 
Mibayashi et al., 2007). The dsRNA-binding site of NS1  appears to be important to 
exert this activity as a dsRNA binding mutant (NS1  R38A K41A) partly looses  its 
interferon  antagonistic  function  (Pichlmair  et  al.,  2006).  Interestingly,  Choon-Ping 
Tan  could  show  that  association  of NS1  with  ssRNA  also  requires  a  functional 
dsRNA-binding domain (Pichlmair et al., 2006). It is feasible to speculate that NS1 
may be recruited to nascent viral RNA molecules present within the nucleus and the 
NS1  protein could accompany the viral RNA  into the cytosol.  This model  may be 
supported by  the  fact  that  NS1  is  found  predominantly  in  the  nucleus  and  in  the 
cytosol  of  infected  cells  (Fig  4.2.3  B)  and  that  a  dsRNA-binding  mutant  NS1 
(A/WSN/33) has cytoplasmic rather than nuclear localisation when expressed in the 
context of a virus infection. Although the mechanism by which NS1  inhibits RIG-I 
activation is not known, the two proteins can be found in a complex (Fig 4.2.3A, C) 
and  it  is  therefore  possible  that  NS1  prevents  RIG-I  from  accessing  the  5’ 
triphosphate. Although expression of RIG-I and NS1  is sufficient to form a complex 
(Fig  4.2.3A),  the  presence  of  5’PPP  RNA  significantly  enhances  its  stability 
(Pichlmair et al.,  2006).  The co-immunoprecipitation results could be  explained by 
various  models:  (i)  As  NS1  and  RIG-I  can  bind  ssRNA  the  reason  for  them  co- 
immunoprecipitating could simply be based on both proteins binding the same RNA 
molecule.  This  is  an  unlikely  scenario,  as  it  would  not  explain  why NS1  inhibits 
RIG-I  responses (Fig 4.2.2).  Alternatively,  (ii)  the NS1  protein could bind first to 
triphosphorylated  RNA  and  thereby  prevent  RIG-I  activation,  (iii)  NS1  could  be 
recruited  to  a  complex  of RIG-I  and  5’PPP  RNA  in  a  dsRNA  binding  domain 
dependent manner and thereby disturb the function of RIG-I. (iv) RIG-I changes its 
conformation and exposes the CARD after binding to its ligand (Saito et al., 2007). It
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is  possible  that  the  NS1  is  recruited  to  the  exposed  CARD  and  thereby  prevents 
activation of the downstream signalling molecule IPS-1. The latter hypothesis would 
also  be  supported  by  the  fact  that  NS1  can  block  IFN  induction  elicited  by 
expression of the  RIG-I  CARD domain (Mibayashi  et al.,  2007).  Collectively,  my 
data and published observations suggest that the binding of RIG-I and NS1 can occur 
in a steady state (Fig 4.2.2 and (Mibayashi et al., 2007)) but that the presence of a 
RIG-I  agonist  can  facilitate  this  association  (Pichlmair  et  al.,  2006).  I  want  to 
emphasise at this stage that all my experiments were done with the NS1  protein of 
the PR8 strain of influenza virus (A/PR8/34) and that strain specific differences may 
occur (Kochs et al., 2007).  Like many other IFN inhibitors (Andrejeva et al., 2004; 
Garcia et al., 2007; Kim et al., 2003; Smith et al., 2001), the NS1  protein definitely 
has multiple functions.
The  presence  of  5’  triphosphates  on  virus  genomes  is  a  remnant  of  the  virus 
replication process.  Viruses  that replicate  and transcribe their genome  in a primer- 
independent manner bear 5’PPP (van Dijk et al.,  2004).  In contrast, picomaviruses 
such as EMCV, use a  small protein primer that covalently binds the  5’  end of the 
vRNA  via  a  0 4(5’-uridylyl)  tyrosine  linkage  and thereby  protect the  uncapped  5’ 
uridylic acid (Ball, 2001; Racaniello, 2001).  The unavailability of a phosphorylated 
5’  end may explain why the vRNA of picomaviruses such as EMCV only elicits a 
minimal response when transfected into cells (Fig 4.2.9A, C) and, therefore, why the 
vims cannot be recognised via RIG-I (Gitlin et al.,  2006;  Kato  et al., 2006).  Other 
vimses  like  some  members  of the  bunyaviridae  and  bomaviridae  use  a  different 
replication  strategy  that  results  in  a  genome  bearing  only  monophosphates 
(Kolakofsky and Hacker,  1991;  Schneider et al., 2007) and these vims genomes do 
not  activate  RIG-I  (personal  communication  Friedemann  Weber).  The  replication 
mechanisms  used  by  these  vimses  may  constitute  a  way  to  subvert  the  IFN-a/p 
response  and could be  of eminent importance  for vimses  that  do  not have  known 
interferon  antagonistic  proteins.  It may  be  that  some  persisting  vimses  like  Boma 
disease vims evolved this mechanism to remain undetected from the innate immune 
surveillance (Schneider et al., 2007).
One  might  wonder  why  NS1-containing  influenza  vims,  which  blocks  RIG-I 
activation,  does not  engage  the  MDA5  pathway  like EMCV?  As  shown  here  and
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elsewhere,  the  answer  could  lie  in  the  differential  ability  of the  two  vimses  to 
generate dsRNA (Fig 4.1.1  and (Pichlmair et al., 2006; Weber et al., 2006)). MDA5 
mediates  responses  to  poly-I:C  (Gitlin  et  al.,  2006;  Kato  et  al.,  2006)  and  may 
therefore act as a dsRNA sensor, which would mean that it can only be activated by 
dsRNA-generating vimses such as EMCV. This notion is complicated by the lack of 
IFN  induction  from  de-phosphorylated  in  vitro  transcribed  dsRNA  (Fig  4.2.7E), 
which  suggests  that  MDA5  may  recognise  dsRNA  in  the  context  of another,  yet 
undefined vims specific structure that may also be found in poly-I:C. Notably, RIG-I 
does not mediate IFN-a/p responses to poly-I:C in vivo (Gitlin et al., 2006; Kato et 
al., 2006; Rothenfusser et al., 2005; Yoneyama et al., 2005; Yoneyama et al., 2004) 
and its reported ability to recognise in vitro synthesised dsRNA (Kato et al., 2006) is 
probably  due  to  the  presence  of triphosphates  at  the  5’  terminus  rather  than  the 
double  stranded  nature  of the  stimulus  (Fig  4.2.7E).  It  is  therefore  tempting  to 
speculate  that  MDA5  recognises  virally  produced  dsRNA  whereas  RIG-I  acts 
primarily  as  a  ssRNA  sensor  (Fig  4.3.1).  However,  further  work  is  needed  to 
elucidate the role dsRNA structures for RIG-I activation.
The entry of ssRNA vimses into cells can trigger innate responses in the absence of 
vims replication (Collins et al., 2004; Hidmark et al., 2005; Isaacs and Lindenmann, 
1957) and synthetic  ssRNA has long been know to induce IFN (Baron et al.,  1969; 
Billiau et al.,  1969).  Yet, the role of ssRNA in activating cytosolic PRRs has been 
largely  ignored  until  a  recent  report  highlighted  the  IFN-inducing  potential  of 
synthetic RNAs bearing 5’ phosphates (Kim et al., 2004).  Here I propose that vims 
recognition in the cytoplasm can be accomplished by RIG-I sensing of ssRNA with 
5’  phosphorylated  termini  (Fig  4.3.1).  Of  course,  it  remains  possible  that  the 
activation of RIG-I by ssRNA is potentiated by local double stranded regions, such 
as the panhandle secondary structures found at the ends of the influenza genome and 
local dsRNA formation of the non-translated region of HCV (Lamb and Krug, 2001; 
Saito et al.,  2007).  Likewise,  even though NS1  can bind ssRNA,  I do not exclude 
that local dsRNA formation contributes to its inhibitory activity (Wang et al.,  1999). 
Nevertheless, my results argue for an ability of the innate immune system to sense 
uncapped ssRNA in the cytoplasm. Added to the recent discovery of mechanisms for 
sensing cytoplasmic DNA (Ishii et al., 2006; Stetson and Medzhitov, 2006a; Yasuda
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et al., 2005) via DAI and possibly other proteins (Takaoka et al., 2007), this finding 
extends  our  understanding  of  the  repertoire  of  antiviral  defense  strategies  and 
suggests  a remarkable  parallel between cytosolic  and endosomal  viral recognition, 
with  MDA5,  RIG-I  and  the  cytosolic  DNA  PRRs  constituting  functional 
homologues of TLR3, -7/8 and -9.
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4.4.  Figures 
Figure 4.1.1
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Figure 4.1.1: Virus infection does not necessarily generate dsRNA
Vero cells were left uninfected or infected with influenza virus (Flu), influenza virus 
lacking the NS1  protein (FluANSl) or EMCV for six hours. Cells were then stained 
for dsRNA (A) or Flu nucleoprotein (NP) (B). This Figure was kindly provided by 
Oliver Schulz.
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Figure 4.2.1
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Figure 4.2.1: Activation of the IFN-p  promoter by various viruses
HEK293 cells were co-transfected with an IFN-p firefly luciferase reporter plasmid 
and  a  control  plasmid  encoding  renilla  luciferase  under  control  of a  constitutive 
promoter (see material and methods for details). 24h later cells were left uninfected 
or infected with the indicated viruses at a MOI of 1   and luciferase activity analysed 
16h  later.  All  reporter  assays  in  this  thesis  show  the  fold  induction  of the  ratio 
between firefly- and renilla luciferase from stimulated cells as compared to the ratio 
of uninfected or untreated cells. One representative of three independent experiments 
is shown.
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Figure 4.2.2:  Flu NS1  inhibits activation of the IFN-P  promoter in  a 
virus specific manner
HEK293  cells  co-transfected  with  IFN-p reporter  plasmids  together  with  NS1- 
encoding plasmid or control empty vector, as indicated. 24h later cells were infected 
with the indicated viruses at an MOI of 1   and luciferase activity analysed  16h later. 
Shown  is the  fold  induction  of the  ratio  between  firefly-  and  renilla  luciferase  as 
compared  to  the  ratio  of uninfected  cells.  One  representative  of four  independent 
experiments is shown.
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Figure 4.2.3
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Figure 4.2.3: Flu NS1 associates with RIG-I
293T cells were transiently transfected with pGFP-RIG-I (A) or with pHA-RIG-I or 
pHA-MDA5  (C)  and  12h  later  infected  or  not  with  influenza  virus  (MOI  1),  as 
indicated.  At  24h,  cells  were  lysed  and  lysates  subjected  to  immunoprecipitation 
with an anti-NSl antibody. (A) and (C) show western blots (WB) for the presence of 
NS1  and  GFP (A)  or NS1  and  HA (C)  in total  cell  lysates  (lower panels)  or after 
immunoprecipitation  (IP)  with  anti-NSl  antibody  (upper  panels).  All  detected 
proteins  had  the  expected  molecular  size.  (B)  Confocal  analysis  of  293T  cells 
transfected with pGFP-RIG-I for  16h and infected with influenza virus (MOI 2) for 
another 24h.  Cells were fixed and stained for NS1.  Panels show GFP-RIG-I (green, 
left panel), NS1 (red, middle panel) and the merged image (yellow, right panel).
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Figure  4.2.4:  The  ssRNA  genome  of influenza  virus  induces  IFN- 
a/p  and IL6
(A,  B)  BM-DC  were mock treated or transfected with Flu vRNA (lpg and 0.2pg) 
and poly-I:C  (0.5pg),  respectively,  (A)  or with  0.2pg  of the  indicated  RNAs  (B). 
IFN-a (A, B)  and  IL6  (A)  were  measured  by  ELISA  after  over  night  incubation, 
n.d.,  not  detectable.  (C,  D)  293HEK  cells  were  transfected  with  0.2pg  of  the 
indicated RNA or infected with influenza virus (MOI  1).  16h later supernatant was 
collected  for  (D)  and  cells  lysed  for  western  blot  to  detect  viral  proteins  using  a 
polyclonal antibody raised against influenza virus (C). (D) Supernatant of transfected 
cells  (mock,  Flu vRNA)  or control  influenza virus  (Flu virus)  was  serially  diluted 
and used to treat Vero cells. Shown are cells stained with giemsa 48h after treatment. 
(E) Acridine orange staining of the indicated nucleic acid separated on a  1  % agarose 
gel.  The  blue  channel  has  been  removed  by  Adobe  Photoshop.  All  shown 
experiments have been repeated for three or more times.
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Figure 4.2.5
o
o
E
>
c o
’ « M
o
3
■o c
o
LL
1000
100
Control
mutNSI
Flu vRNA WB:
NS1
Tubulin
Figure 4.2.5: NS1 inhibits IFN-a/p  induction elicited by Flu vRNA
Induction  of IFN-(3  luciferase  activity  in  HEK293  cells  co-transfected with  IFN-p 
reporter plasmids and NS1  expression plasmids (NS1  or mutNSI)  or empty vector 
(control).  24h  later,  cells were  transfected with  flu vRNA  (0.2,  0.04  or  0.008pg). 
Cell  lysates  were  prepared  at  38h  and  used  to  measure  luciferase  activity  and 
perform western blot for NS1  and a loading control (Tubulin).  The experiment was 
done three times, one representative experiment is shown.
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Figure  4.2.6
A)
B)
C)
25
■  Control 
□  DN RIG-1
1   20
15
10
5
L L
0
100
o
o
E
C O
>
•5£  10 
o
3
T3
C
2
o
u.
■  hu siRNA 
□ m u  siRNA 
Ino siRNA
Flu vRNA
HEK293 NIH3T3
HEK293 NIH3T3
1000
■  hu siRNA 
□  mu siRNA
■  hu siRNA 
□  mu siRNA
100
> > > >
Flu vRNA Flu vRNA
LU UJ
Page 150Chapter 4 RIG-I and 5’PPP-RNA
Figure  4.2.6:  Inhibition  of RIG-I  reduces  the  IFN  response  to  Flu 
vRNA
(A)  Inhibition of IFN-p reporter activation by Flu vRNA through transfection of a 
dominant negative version of RIG-I.  HEK293 cells were co-transfected with IFN-p 
reporter plasmids and a plasmid encoding dominant negative RIG-I (DN RIG-I) or 
an empty vector control (control). 48h later cells were transfected with 0.5, 0.1  and 
0.02pg  Flu  vRNA  and  luciferase  activity  was  tested  16h  later.  Shown  is  the  fold 
induction of the ratio  between  firefly and renilla luciferase  compared to  untreated 
control cells.  One of three repeat experiments with similar results is  shown.  (B, C) 
Human HEK293  cells and mouse NIH3T3 were co-transfected with IFN-P reporter 
plasmids and siRNAs specific for mouse (mu siRNA) or human RIG-I (hu siRNA) 
(B,  C),  or the IFN-p  reporter plasmids only (no  siRNA)  (C).  72h later,  cells were 
transfected with Flu vRNA (B:  0.2 or 0.04pg and C: 0.04pg) or were infected with 
SeV or EMCV (both MOI  1) where indicated.  Luciferase activity was measured at 
86h. The graphs show induction of IFN-P reporter activity compared to unstimulated 
control  cells.  siRNA  experiments  were  repeated  4  times,  two  representative 
experiments are shown.
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Figure 4.2.7
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Figure  4.2.7:  IFN  responses  to  in vitro  transcribed  RNA  in  human 
and mouse cells
(A)  BM-DC  or  (B)  NIH3T3  cells  were  transfected  with  varying  doses  of GFP 
ssRNA  (A:  5,  1,  0.2,  0.04pg  and  B:  1,  0.2pg)  or  infected  with  SeV  as  positive 
control (A). IFN-a in over night culture supernatants was measured by ELISA.  (C, 
D) NIH3T3 (C) or HEK293 (D) cells were transfected with IFN-p reporter plasmids. 
24h later cells were transfected with RNA transcribed by T7 polymerase (GFP(T7)) 
(0.2pg) (C)  or  SP6 polymerase  (7SK-as(SP6))  (0.5  and 0.16pg)  (D)  that had been 
either  mock  treated  (NoCIP)  or  treated  with  calf  intestinal  phosphatase  (CIP). 
Luciferase  activity  was  measured  at  38h.  Graphs  show  fold  activation  of IFN-P 
promoter as compared to untreated control cells. (E) NIH3T3 cells were transfected 
with 1 and 0.2pg in vitro transcribed dsRNA (GFP(T3/T7)) and IFN-a accumulation 
after over night stimulation was measured by ELISA. One representative experiment 
of three (C, E) to five (A, B, D) is shown.
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Figure  4.2.8
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Figure 4.2.8
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Figure  4.2.8:  Flu  vRNA  induces  IFN  in  a  5’phosphate  dependent 
manner
HEK293  transfected  with  IFN-P reporter  plasmids  (A)  or  BM-DC  (B)  were 
transfected with different amounts (0.6, 0.2, 0.06.  0.02pg) of mouse spleen mRNA 
or the same amount of Flu vRNA (A, B) or poly-I:C (2,  1, 0.5pg) (A).  RNAs were 
pre-treated (CIP) or not (NoCIP) with calf intestinal phosphatase. Luciferase activity 
(A) or IFN-a and IL6 (B) were measured after over night culture. (C) HEK293 cells 
were  transfected  with  IFN-p  reporter  plasmids  and  stimulated  24h  later  with  Flu 
vRNA  that  had  been  either  mock  treated  or  treated  with  CIP  in  the  absence  or 
presence  of  pyrophosphate  (50,  10,  2,  0.4mM)  or  EDTA  (250,  50,  10,  2mM). 
Luciferase  activity was measured at  38h.  (D)  Total  bone  marrow  cells  (lxlO6  per 
cavity 96-well plate) from C57BL/6 (wt) or tlrTf' mice were treated with complexes 
of lipofectamine2000 and 0.2pg of Flu vRNA  and  lpg of poly-U,  respectively,  or 
with  CpG  (0.5pg/ml).  IFN-a  accumulation  in  over night  culture  supernatants  was 
measured by ELISA.  One  of four (A,  B)  or two  (C,  D)  experiments  with  similar 
results is shown.
Page 155Chapter 4 RIG-I and 5’PPP-RNA
Figure 4.2.9
A)
NoCIP
mock  VSV  EMCV 
vRNA  vRNA
B)
4000
■  NoCIP
|p   3000
□  CIP
D
2  2000
i 1 1000
0
< 30 J=L l III
o  VSV vRNA Flu vRNA
C)
5000
4000
E
2.3000
Z   2000  u.
1000
mmm^rnrn  Flu
EMCV vRNA  vRNA
Figure  4.2.9:  IFN-a/p  induction  by  genomic  RNA  from  other 
viruses
(A)  HEK293  transfected  with  IFN-p reporter  plasmids  for  24h  were  treated  with 
0.2pg EMCV vRNA or vRNA  from  8xl07 pfu VSV that was not (NoCIP)  or was 
treated with  CIP.  At  38h cells were  lysed and  luciferase expression analysed.  The 
graph  shows induction of IFN-P luciferase  as  compared to  mock treated cells.  (B) 
IFN-a production in BM-DC transfected with vRNA from VSV and Flu that was not 
(NoCIP) or was treated with CIP. Cells received vRNA corresponding to 8x107 pfu 
VSV and 5-fold serial dilutions thereof and 0.6,  0.2, 0.06 or 0.02pg of Flu vRNA, 
respectively.  IFN-a  accumulation in the  cell  supernatant was measured by ELISA 
after over night incubation.  In panel (C) BMDC were treated with various doses of 
EMCV vRNA (5,  1, 0.2, 0.04pg) or Flu vRNA (0.2pg) and IFN-a in the supernatant 
was  measured  by  ELISA  after  over  night  incubation.  The  bracket  indicates 
transfections with similar amounts of vRNA.  Experiments were repeated twice (A, 
B) or four times (C).
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Figure 4.3.1
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Figure 4.3.1: Proposed model for IFN induction through activation 
of cytoplasmic PRRs
Virus infection delivers agonists for MDA5 and RIG-I. The replication process may 
be necessary to generate  sufficient amount of agonist although virus entry may be 
sufficient.  RIG-I  is activated by triphosphorylated RNA  and this activation can be 
inhibited by the influenza NS1  protein.  MDA5  may or may not recognise dsRNA. 
RIG-I and MDA5 signal via IPS-1   and the canonical interferon induction pathway to 
modulate transcription of IFN genes.
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CHAPTER 5:  Final Discussion and Concluding
Remarks
Antiviral  programs  are  mainly  initiated  through  recognition  of  virus-associated 
nucleic  acid that can be  distinguished  from  cellular nucleic  acid by  two  criteria:  a 
specific signature present on nucleic acid and/or atypical localisation within the cell 
(Basler and Garcia-Sastre, 2007; Bowie and Fitzgerald,  2007;  Pichlmair and Reis e 
Sousa,  2007;  Yoneyama  and  Fujita,  2007).  TLRs  recognise  nucleic  acid  that  is 
delivered into the endosomal compartment during the viral life cycle.  Similarly, the 
cytoplasmic  presence  of  DNA,  which  exclusively  localises  in  the  nucleus  under 
normal conditions, can be sensed by DNA recognition receptors.  Specific structural 
features  on  viral  RNA  that  include  long  double-strandedness  and  the  presence  of 
5’phosphates mark viral RNA as foreign and initiates an innate antiviral response. 
Here I  discuss the current knowledge and  ‘unknowns’  in viral recognition and also 
present some further thoughts.
5.1.  TLR recognition of recombinant lentiviruses
TLRs3, -7, -8, and -9 recognise nucleic acid in the endosome (Fig 5.1.1). Normally, 
nucleic acid is not present in the endosome but degraded by nucleases, either within 
the  cell  or in  the  extracellular milieu  (Barton  et  al.,  2006).  However,  nucleic  acid 
present  in  virus  particles  is  highly  resistant  to  nucleases  (e.g.  Fig  3.2.10A)  and 
endosomal  uptake  of  the  virus  particle  is  believed  to  deliver  nucleic  acid  to  a 
compartment that allows sensing via TLRs (Bowie, 2007; Kawai and Akira, 2006). 
Consequently, the infection route  should be critical  for TLR-  mediated recognition 
of viruses. Indeed, in murine pDC, viruses that infect the cell via the endosome like 
influenza,  VSV  and  HSV-1  are  strong  activators  of TLR7  and  -9  (Diebold  et  al., 
2004;  Lund et  al.,  2003;  Lund et  al.,  2004).  Also,  TLR7  responses  are  reduced  if 
VSV is genetically engineered to bear the RSV-F protein that mediates fusion at the 
plasma membrane (Lund et al., 2004). If TLR9 is genetically engineered to localise
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at the plasma membrane antiviral responses to HSV-1  are abolished (Barton et al.,
2006), clearly demonstrating that TLR9 senses viruses in the endosome.
The  ability  of pDC  to  produce  IFN-a  was  associated  with  their  unique  ability  to 
retain CpG in the early endosome and cDC  express IFN-a when treated with CpG 
that is experimentally formulated to be delivered into early endosomes (Honda et al., 
2005a).  Hence,  IFN-a production through TLR9 activation requires  localisation of 
the agonist in early endosomes. pDC and cDC are apparently intrinsically different 
in handling endosomal cargo and this difference can lead to cell type-specific innate 
immune responses  after treatment with TLR9  ligands.  It  still remains to be  shown 
whether this also applies to TLR7 and whether the unique ability of pDC to produce 
high  amounts  of IFN-a  after virus  infection  is  based  on  similar  mechanisms,  i.e. 
whether the viral genomic nucleic acid is localising in early endosomes of pDC but 
not in early endosomes of cDC.
As mentioned above, viral genomes are tightly packaged and thereby protected from 
degradation.  Sensing  viral  genomic  nucleic  acid by  TLRs  would require  releasing 
the virus’  genomic material by degrading the virus particle,  something that is only 
happening  in  late  endosomes.  Currently  it  is  not  clear how  TLR7,  -8  and  -9  gain 
access to virus genomic material after virus uptake.
Viruses entering the cell via endosomes remain in this compartment for varying time 
(Smith and Helenius,  2004):  Influenza virus,  for instance,  requires an  acidification 
step  at  low pH  to  enter the  cytoplasm  (Sieczkarski  and  Whittaker,  2002)  and this 
only  takes  place  in  late  endosomes.  Therefore,  Influenza  virus  particles  could 
theoretically interact with TLRs that are thought to be activated in early endosomes. 
Adenoviruses  (AdV),  in  contrast,  transverse  the  endocytic  compartment  very 
transiently; they leave the early endosome before endosomal maturation (Smith and 
Helenius, 2004). It is surprising, that AdV can be sensed by the TLR system, as an 
entering virus particle would leave the endosome at a very early stage of endosomal 
maturation and one may question whether the current model of TLR activation can 
accommodate this aspect of virus biology.  Even more puzzling  is the situation  for 
viruses belonging to the paramyxo- (e.g.  SeV) and retrovirus family.  These viruses 
mainly fuse at the plasma membrane when infecting the cell. One could hypothesise 
that this route of infection may have  evolved as  a mechanism to  circumvent TLR
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signalling.  Surprisingly,  pDC  stimulated  with  SeV  can  mount  an  efficient  innate 
immune  response  and  this  clearly  depends  on  endosomal  acidification  and  TLR7 
(Lee et al., 2007).
I aimed to evaluate the importance of the virus infection route by using standardised 
virus particles that only differ in their glycoproteins which mediate  fusion of virus 
particles at the plasma membrane or virus entry through endosomes, respectively. In 
my hands,  LV  particles  did not  lead to  detectable  activation  of the  TLR pathway 
regardless  of the  surface  protein  present  on  the  surface  of the  virus  particle  (Fig 
3.2.2,  3.2.5 and 3.2.10).  This was surprising;  especially in the light of publications 
suggesting TLR activation by wild type HIV-I (Beignon et al.,  2005; Fonteneau et 
al., 2004; Francis and Meltzer,  1993; Schmidt et al., 2005; Yonezawa et al., 2003). A 
more  recent  publication  by  Lee  et  al.  may  help  to  find  an  explanation  for  this 
apparent discrepancy.  Lee  et  al  showed  that  for some  viruses  like  VSV  and  SeV, 
induction of IFN-a from pDC depends on the presence of TLR7 and the ability of 
the virus to replicate. Unlike UV-treated Influenza virus, UV-treated VSV and SeV 
are  not  stimulating  IFN-a  from  pDC.  The  authors  therefore  hypothesised  that 
replication  is necessary for efficient recognition of VSV in pDC.  Surprisingly,  this 
still  depended  on  TLR7  that  senses  endosomal  nucleic  acid.  One  way  to  deliver 
cytoplasmic  contents  into  the  endosome  is  autophagy  (self-ingestion),  a  cellular 
process that is known to be important to recycle catabolic substances. By using PI3K 
inhibitors that block autophagy (and many other cellular processes)  and pDC  from 
mice  deficient  in  ATG5,  that  is  required  for  autophagy,  the  authors  showed  that 
autophagy could be involved in TLR7 recognition of VSV.  Although this model is 
very appealing,  it is not  entirely clear how the  cell might distinguish viral  nucleic 
acid  from  cellular  nucleic  acid,  as  cellular  contents  including  cytoplasmic  RNA 
would also be delivered into the auophagosome. However, this work highlights the 
existence  of remarkable  cross-talk  between  the  cytoplasmic  and  the  endosomal 
compartment.
Might a similar phenomenon explain differences  between my results and  the ones 
obtained  by  Beignon  and  colleagues?  Replication-competent  lentivirus  may  be 
delivered into endosomes during the virus  life cycle but not necessarily during the 
entry process.  Indeed, HIV-I particles can be found in endosomes of infected cells
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and  the  HIV  envelope  contains  proteins  found  exclusively  in  the  endosomal 
compartment.  Further,  the  ‘Late-domain’  (PPPY  motif)  of  the  HIV  gag  protein 
interacts  with  the  ESCRT-I  system,  which  is  implicated  in  inward  budding  into 
endosome-like vesicles and formation of multivesicuar bodies. Multivesicular bodies 
and  HIV  particles  are  released  through  exocytosis  or  can  re-enter  the  endocytic 
machinery  (Morita  and  Sundquist,  2004;  Williams  and  Urbe,  2007).  Intriguingly, 
Rhabdoviruses  like  VSV  may  also  interact  with  the  cellular  ESCRT-I  system 
through  interaction  with  a  similar  L-domain  on  its  matrix  protein  (Craven  et  al., 
1999;  Morita  and  Sundquist,  2004;  Williams  and  Urbe,  2007).  It  would  be 
interesting  to  understand whether inward budding  is  involved  in  delivery  of virus 
particles from the  cytoplasm into endosomes and therefore facilitate recognition of 
Retro-  and Rhabdoviruses.  I  would speculate  that this  endosomal  delivery method 
would be virus specific (possibly requiring a Late-domain) and could therefore serve 
to distinguish cellular from virus-derived nucleic acid.
It  is  feasible  to  speculate that the  TLR system has  evolved to  recognise viruses at 
different  stages  of their  life-cycle:  viruses  entering  the  cell  are  recognised  in  the 
endocytic compartment, viruses replicating in the cytoplasm may be sensed through 
autophagy  and,  additionally,  viruses  could  possibly  be  detected when  leaving  the 
cell.
5.2.  Cytoplasmic recognition of influenza virus
Virus entry and replication deliver molecules into the cytoplasm that can be sensed 
by cytoplasmic PRRs, which leads to initiation of an antiviral state. Per definition, a 
PRR recognises  a PAMP  that must be  necessarily  expressed by the pathogen  and 
must not be present or not accessible  in uninfected cells.  dsRNA present  in  some 
virally infected cells serves this purpose as it is expected that dsRNA is not present 
in uninfected cells.  However,  the notion that dsRNA is capable to induce antiviral 
responses seems surprising when considering the fact that about 98% of transcribed 
RNA  in  mammals  is  non-coding  and  wide-spread  expression  of  sense-  and 
corresponding antisense RNA species has clearly been shown (Lavorgna et al., 2004; 
Mattick  and  Makunin,  2005;  Yelin  et  al.,  2003).  However,  upon  transcription,
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nuclear  dsRNA  would  quickly  be  hyperedited by  nuclear  Adenosine  deamination 
processes  and  edited  RNA  is  selectively  retained  in  the  nucleus  (Zhang  and 
Carmichael,  2001)  or  degraded by  a  promiscuous  nuclear  endonuclease  (Scadden 
and Smith,  2001).  The presence of dsRNA in the nucleus and the  lack of IFN-a/|3 
induction at the same time implies that the cell either cannot respond to this kind of 
dsRNA  and/or  that  the  nucleus  forms  a  specialised  compartment  not  allowing 
initiation of IFN responses.  The former point is  supported by the  fact that dsRNA 
not bearing 5’PPP does not stimulate activation of the IFN-p promoter (Fig 4.2.7E). 
Further,  annealing  polyriboadenylic  :  polyribouridylic  acid  (poly-A  and  poly-U) 
homopolymers  to  form  poly-A.TJ  appears  not  to  result  in  RNA  with  stimulatory 
potential  (Okahira  et  al.,  2005)  (and  data  not  shown).  This  suggests  that  double 
stranded-ness  is  not  sufficient  to  activate  cytoplasmic  PRRs  and  that  special 
properties associated with poly-I:C are necessary to do so. dsRNA generated during 
virus  replication  may  have  properties  of  poly-I:C  and  not  constitute  perfectly 
matched dsRNA.  That viral polymerases can generate products that are recognised 
by the antiviral defence system of the cell was demonstrated by Kim and colleagues 
who described that siRNA generated in vitro by phage polymerases can induce IFN 
when transfected into cells (Kim et al., 2004). Interestingly, in vitro transcription of 
RNA  resembles  generation  of virus-derived  RNA  during  an  infection:  Similar  to 
phage polymerases, polymerases of some viruses infecting mammalian cells produce 
RNA bearing  a  triphospate  group  on  the  5’  terminus  (Ball,  2001;  van  Dijk  et  al., 
2004). Others and myself could show that this kind of RNA stimulates RIG-I in the 
cytoplasm (Homung et al., 2006).
It  would  be  interesting  to  investigate  whether  replicative  products  from  MDA5- 
activating  viruses  like  EMCV  also  bear  a  specific  signature  and  have  special 
potential to activate the innate immune system.
5.3.  Redundancy in virus recognition
Most viruses may not be specific for a single PRR but activate a panoply of PRRs at 
the time:  The “RIG-I  dependent viruses”  VSV and NDV tested in RIG-I deficient
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cells elicit basal levels of IFN-a and JEV and SeV are decreased to a variable extent 
by MDA5 deficiency suggesting that some viruses may be recognized by more than 
one PRR (Kato et al., 2006).  Influenza virus is thought to be a specific agonist for 
TLR7  that  senses  ssRNA  and  RIG-I  that  is  activated  through  single-stranded 
triphosphorylated Flu vRNA  (Diebold et al.,  2006)(and results presented here).  At 
the same time Flu infection leads to activation of the dsRNA activated proteins PKR 
(Bergmann  et  al.,  2000;  Lu  et  al.,  1995)  and  TLR3,  resulting  in  inflammatory 
reactions in the lung and immunopathology (Le Goffic et al., 2006; Le Goffic et al.,
2007).  Therefore,  viruses  preferentially  activate  a  certain  class  of  PRRs  but 
activation of additional pathways may happen. It may well be, however, that dsRNA 
binding  proteins  are  activated  indirectly  through  other  proteins  as  it  has  been 
demonstrated for PKR that can be positively regulated by the dsRNA binding protein 
PACT  and melanoma  differentiation  associated  gene  -7  (MDA7)  or  negatively by 
p58IPK, TAR RNA binding protein (TRBP), nucleophosmin and Heat shock protein 
90 and -70 (Garcia et al., 2007).
5.4.  A mirror image of TLRs and RLRs?
Endosomal  TLRs  and  cytoplasmic  RLRs  discriminate  between  viral  and  cellular 
nucleic acid. Startling similarities between both recognition systems begin to unravel 
(Fig 5.1.1): Downstream signal transduction in both, the TLR and the RLR system, 
for  instance,  relies  on  the  same  or  very  similar  signalling  molecules  (Bowie  and 
Fitzgerald, 2007; Kawai and Akira, 2007; Uematsu and Akira, 2007; Yoneyama and 
Fujita, 2007). TLR3 is activated by the dsRNA analog poly-I:C and dsRNA derived 
from ReoV and is thought to be a receptor for dsRNA (Alexopoulou et al.,  2001). 
Likewise,  based  on  similar  experiments  (i.e.  IFN-a/p  induction  through  poly-I:C 
transfection)  cytoplasmic proteins were believed to  sense  dsRNA that is produced 
during virus replication (Field et al.,  1967b; Merigan,  1970). However, some viruses 
do not produce substantial amounts of dsRNA and 5’PPP ssRNA can activate RIG-I. 
Therefore RIG-I may constitute a cytoplasmic analogue for TLR7 that senses ssRNA 
in the endosome (Diebold et al., 2004; Heil et al., 2004). The difference mainly lies 
in  the  mechanism  both  proteins  utilise  to  discriminate  between  self  from  viral
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ssRNA:  Whereas  RIG-I  senses  a structure present on viral RNA in the  cytoplasm, 
TLR7 discriminates cellular from viral RNA on the basis of localisation within the 
endosome.  Similarly,  DAI  is  a  cytoplasmic  receptor  that  detects  the  presence  of 
DNA in the cytoplasm (Takaoka et al., 2007) and therefore  functionally resembles 
TLR9 that is sensing DNA in the endosome (Lund et al., 2003). Poly-I:C activates 
innate immune responses through MDA5 in the cytoplasm (Gitlin et al., 2006; Kato 
et al., 2006) or TLR3 in the endosome (Alexopoulou et al., 2001). Although little is 
known about the real agonist for both proteins, it is suspected that dsRNA present in 
poly-I:C  preparations  is  recognised.  This  is  supported  by  binding  experiments 
showing  that  TLR3  and  MDA5  can  bind  to  dsRNA  in  vitro  (Bell  et  al.,  2006; 
Rothenfusser  et  al.,  2005;  Yoneyama  et  al.,  2005).  TLR3  recognises  exogenously 
added poly-I:C and isolated ReoV dsRNA, but is only weakly activated by perfectly 
matched synthetic dsRNA (Okahira et al., 2005). A recent report by Marshall-Clarke 
and colleagues  clearly  shows  that TLR3  can be  activated by  polyinosinic  (poly-I) 
homopolymers (Marshall-Clarke et al., 2007), highlighting the possibility of ssRNA 
recognition  through  TLR3.  It  would  be  interesting  to  understand  whether  the 
similarities  between  TLR3  and  MDA5  in  terms  of  ligand  requirements  can  be 
extended beyond the recognition of poly-I:C.
5.5.  Future directions and concluding remarks
A  lot  of work has been  done  in the  past  50  years to  elucidate principles  of virus 
recognition leading to induction of IFN-a/p. The discovery TLRs and RLRs as viral 
sensors opened a new avenue in the field of viral innate immune recognition. 
Phosphate-bearing  RNA  binding  and  activating  RIG-I  is  currently  the  only  well- 
defined  PAMP  activating  the  cytoplasmic  pathway.  However,  it  still  needs  to  be 
shown  whether  virus  genomes  or  by-products  of  virus  replication  bearing 
5’phosphates are sensed by RIG-I. The characterisation of the ligand(s) for MDA5 
and the  search  for  DAI-like  receptors  that  sense  cytoplasmic  DNA will  be  in  the 
centre of future research.  It will be interesting to understand the interplay between 
cytoplasmic virus PRRs and whether viruses produce several PAMPs activating a set 
of cytoplasmic PRRs at a time.
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TLRs  and  RLRs  sense  viral  nucleic  acid  within  distinct  cellular  compartments. 
These compartments can feed into each other, i.e. virus nucleic acid can be delivered 
from the endosome into the cytoplasm and vice versa. It is important to understand 
the cross talk between the cytoplasmic and the endosomal compartment in order to 
understand  how  PRRs  get  in  contact  with  stimulatory  nucleic  acid  (Schmid  and 
Munz,  2007).  In  fact,  this  cross  talk  is  reminiscent  to  the  MHC  system  where 
cytoplasmic  content  is  commonly  presented  on  MHC-I  and  endosomal  contents 
MHC-II.  However,  endosomal contents can also be presented on MHC-I through a 
process named cross-presentation.  Integrating cell biological aspects in innate virus 
recognition mechanisms may play  a central role to  eventually understand antiviral 
responses to virus infections.
Clearly, much more work is needed to understand mechanistic details of host-virus 
interactions. Every piece that is added to the puzzle of innate immune recognition of 
viruses raises  new questions  and  shows  the remarkable  sophistication  of the  host- 
pathogen interplay.
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between cytosolic  and endosomal  viral  recog­
nition,  with  MDA5,  RIG-I,  and  the  cytosolic 
DNA receptor constituting functional homologs 
of TLR3, TLR7, TLR8, and TLR9. Similar to 
virologists,  the  innate  immune  system  may 
therefore have learned to classify viruses by their 
genomes.
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